Thyroid hormone receptor beta agonist compounds

ABSTRACT

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No.62/745,195, filed Oct. 12, 2018, the disclosure of which is herebyincorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

This invention relates to compounds, preferably thyroid hormone receptorbeta (THR beta) agonist compounds, compositions thereof, and methods oftheir preparation, and methods of agonizing THR beta and methods fortreating disorders benefiting from THR beta agonism.

BACKGROUND OF THE INVENTION

The beneficial effects arising from treating hyperthyroid or hypothyroidpatients with T3/T4 endogenous ligands or early analogs of theseendogenous ligands have been described in the literature (RichardsonHill Jr., S. et al. J. Clin. Invest. 1960, 39, 523-533). These earlystudies, as well as similar follow-up studies, established the heart asa major organ for the manifestation of side effects of bothhyperthyroidism and hypothyroidism (Klein, I. et al. Circulation, 2007,1725-1735). In particular, tachycardia, hypertrophism, atrialdysrhythmias, and atrial fibrillation are serious concerns. In addition,increased bone turn-over leading to decreased bone mineral density hasalso been noted. Negative effects at both sites, heart and bone, havebeen linked to the agonism of the THR alpha isoform, whereas thebeneficial effects of THR agonism in the liver are largely linked to theTHR beta isoform (Sinha, R. A. et al. Nat. Rev. Endocrinology 2018, 14,259-269).

Diseases or disorders associated with THR beta include non-alcoholicsteatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD),metabolic syndrome, dyslipidemia, hypertriglyceridemia, andhypercholesterolemia. There is a need to develop new thyroid hormoneanalogs that are selective agonists for THR beta, and preferably thosethat avoid the undesirable effects associated with agonism of THR alpha,and maintain the beneficial effects of thyroid hormones, e.g., for thetreatment for patients with non-alcoholic steatohepatitis (NASH),non-alcoholic fatty liver disease (NAFLD), metabolic syndrome,dyslipidemia, hypertriglyceridemia, or hypercholesterolemia.

BRIEF SUMMARY OF THE INVENTION

In one aspect, provided herein is a compound of formula (I):

wherein:

-   R₁ is substituted or unsubstituted C₁-C₆ alkyl, substituted or    unsubstituted C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈), —N(R₉)C(O)(R₁₀), or    halo;-   R₂ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;-   R₃ is H or halo;-   R₄ is H, or substituted or unsubstituted linear C₁-C₃ alkyl;-   L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—;    R₅ and R₆ are independently H, halo, —CN, or substituted or    unsubstituted C₁-C₆ alkyl, or R₅ and R₆ are taken together with the    carbon atom to which they are attached to form a substituted or    unsubstituted C₃-C₆ cycloalkyl;    R₇ and R₈ are independently H, or substituted or unsubstituted C₁-C₆    alkyl, or R₇ and R₈ are taken together with the nitrogen atom to    which they are attached to form a substituted or unsubstituted 3- to    7-membered heterocycloalkyl;-   R₉ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;-   R₁₀ is substituted or unsubstituted C₁-C₆ alkyl, substituted or    unsubstituted C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁);-   R₁₁ is substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;    M₁ and M₂ are independently halo, or substituted or unsubstituted    C₁-C₆ alkyl; and    M₃ is H, halo, or substituted or unsubstituted C₁-C₆ alkyl, or M₃ is    taken together with M₂ and the carbon atoms to which they are    attached to form a 5- to 7-membered ring containing 0, 1, or 2    heteroatoms selected from the group consisting of N, O, and S, or a    pharmaceutically acceptable salt thereof.

In some embodiments, provided herein is a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein:

-   R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈),    —N(R₉)C(O)(R₁₀), or halo, wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl    are optionally substituted by 1-5 substituents selected from the    group consisting of —OH, oxo, —CN, and halo;-   R₂ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and    C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents    selected from the group consisting of —OH, —CN, and halo;-   R₃ is H or halo;-   R₄ is H or linear C₁-C₃ alkyl optionally substituted by 1-5    substituents selected from the group consisting of —OH, oxo, —CN,    halo, and —O(C₁-C₂ alkyl);-   L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—;    R₅ and R₆ are independently H, halo, —CN, or C₁-C₆ alkyl, or R₅ and    R₆ are taken together with the carbon atom to which they are    attached to form a C₃-C₆ cycloalkyl, wherein each C₁-C₆ alkyl or    C₃-C₆ cycloalkyl is optionally independently substituted by 1-5    substituents selected from the group consisting of —OH, —CN, and    halo;    R₇ and R₈ are independently H or C₁-C₆ alkyl, or R₇ and R₈ are taken    together with the nitrogen atom to which they are attached to form a    3- to 7-membered heterocycloalkyl, wherein each C₁-C₆ alkyl or 3- to    7-membered heterocycloalkyl is optionally independently substituted    by 1-5 substituents selected from the group consisting of —OH, —CN,    and halo;-   R₉ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and    C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents    selected from the group consisting of —OH, —CN, and halo;-   R₁₀ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁),    wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted    by 1-5 substituents selected from the group consisting of —OH, —CN,    and halo;-   R₁₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each of which is optionally    substituted by 1-5 substituents selected from the group consisting    of —OH, —CN, and halo;    M₁ and M₂ are independently halo or C₁-C₆ alkyl optionally    substituted by 1-5 substituents selected from the group consisting    of —OH, —CN, and halo; and    M₃ is H, halo, or C₁-C₆ alkyl optionally substituted by 1-5    substituents selected from the group consisting of —OH, —CN, and    halo, or M₃ is taken together with M₂ and the carbon atoms to which    they are attached to form a 5- to 7-membered ring containing 0, 1,    or 2 heteroatoms selected from the group consisting of N, O, and S.

In some embodiments, R₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each ofwhich is optionally substituted by 1-5 substituents selected from thegroup consisting of —OH, oxo, —CN, and halo. In some embodiments, R₁ iscyclopropyl, isopropyl, ethyl, —CH(CH₂CH₃)₂, —CH(CH₃)(CH₂OH),—CH(OH)(CH₂CH₃), —CH(OH)(CH₃), —CH(CH₃)(CH₂CH₃), or —C(O)(CH₃).

In some embodiments, R₂ is H or C₁-C₆ alkyl optionally substituted by1-5 substituents selected from the group consisting of —OH, —CN, andhalo. In some embodiments, R₂ is H or methyl.

In some embodiments, R₃ is H.

In some embodiments, R₄ is H or linear C₁-C₃ alkyl optionallysubstituted by 1-3 substituents selected from the group consisting of—OH, oxo, —CN, halo, and —O(C₁-C₂ alkyl). In some embodiments, R₄ is H,methyl, ethyl, —CH₂C(O)O(CH₂CH₃), —CH₂CF₃, —CH₂CN, or —CH₂CHF₂.

In some embodiments, L is —O—, —C(O)—, or —CH₂—.

In some embodiments, M₁ and M₂ are independently halo or C₁-C₃ alkyloptionally substituted by 1-3 substituents selected from the groupconsisting of —OH, —CN, and halo. In some embodiments, M₁ and M₂ areindependently halo or methyl. In some embodiments, M₁ and M₂ are eachchloro. In some embodiments, M₁ and M₂ are each methyl.

In some embodiments, M₃ is H, halo, or C₁-C₃ alkyl optionallysubstituted by 1-3 substituents selected from the group consisting of—OH, —CN, and halo. In some embodiments, M₃ is H, F, or methyl.

In some embodiments, provided herein is a compound selected fromCompounds 1-3 and 5-35, or a pharmaceutically acceptable salt thereof.

Further provided is a pharmaceutical composition comprising a compounddescribed herein, or a pharmaceutically acceptable salt thereof, and apharmaceutically acceptable excipient.

In another aspect, provided herein is a method of agonizing thyroidhormone receptor beta (THR beta) comprising contacting an effectiveamount of a compound described herein, or a pharmaceutically acceptablesalt thereof, or an effective amount of the pharmaceutical compositioncomprising a compound described herein, with the THR beta.

In another aspect, provided herein is a method of treating a disorderwhich is mediated by THR beta in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound described herein, or a pharmaceutically acceptable saltthereof, or a therapeutically effective amount of the pharmaceuticalcomposition comprising a compound described herein. In some embodiments,the disorder is non-alcoholic steatohepatitis (NASH).

DETAILED DESCRIPTION OF THE INVENTION Definitions

As used herein, the following definitions shall apply unless otherwiseindicated. Further, if any term or symbol used herein is not defined asset forth below, it shall have its ordinary meaning in the art.

“Comprising” is intended to mean that the compositions and methodsinclude the recited elements, but not excluding others. “Consistingessentially of” when used to define compositions and methods, shall meanexcluding other elements of any essential significance to thecombination. For example, a composition consisting essentially of theelements as defined herein would not exclude other elements that do notmaterially affect the basic and novel characteristic(s) of the claimedinvention. “Consisting of” shall mean excluding more than trace amountof, e.g., other ingredients and substantial method steps recited.Embodiments defined by each of these transition terms are within thescope of this invention. Thus, it is understood that aspects andembodiments described herein as “comprising” include “consisting of” and“consisting essentially of” embodiments.

“Effective amount” or dose of a compound or a composition, refers tothat amount of the compound, or a pharmaceutically acceptable saltthereof, or the composition that results in an intended result asdesired based on the disclosure herein. Effective amounts can bedetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, e.g., and without limitation, by determining theLD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dosetherapeutically effective in 50% of the population).

The term “excipient” as used herein means an inert or inactive substancethat may be used in the production of a drug or pharmaceutical, such asa tablet containing a compound of the invention as an active ingredient.Various substances may be embraced by the term excipient, includingwithout limitation any substance used as a binder, disintegrant,coating, compression/encapsulation aid, cream or lotion, lubricant,solutions for parenteral administration, materials for chewable tablets,sweetener or flavoring, suspending/gelling agent, or wet granulationagent. Binders include, e.g., carbomers, povidone, xanthan gum, etc.;coatings include, e.g., cellulose acetate phthalate, ethylcellulose,gellan gum, maltodextrin, enteric coatings, etc.;compression/encapsulation aids include, e.g., calcium carbonate,dextrose, fructose dc (dc=“directly compressible”), honey dc, lactose(anhydrate or monohydrate; optionally in combination with aspartame,cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.;disintegrants include, e.g., croscarmellose sodium, gellan gum, sodiumstarch glycolate, etc.; creams or lotions include, e.g., maltodextrin,carrageenans, etc.; lubricants include, e.g., magnesium stearate,stearic acid, sodium stearyl fumarate, etc.; materials for chewabletablets include, e.g., dextrose, fructose dc, lactose (monohydrate,optionally in combination with aspartame or cellulose), etc.;suspending/gelling agents include, e.g., carrageenan, sodium starchglycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame,dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulationagents include, e.g., calcium carbonate, maltodextrin, microcrystallinecellulose, etc.

“Patient” refers to mammals and includes humans and non-human mammals.Examples of patients include, but are not limited to mice, rats,hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows,and humans. In some embodiments, patient refers to a human.

“Pharmaceutically acceptable” refers to safe and non-toxic, preferablyfor in vivo, more preferably, for human administration.

“Pharmaceutically acceptable salt” refers to a salt that ispharmaceutically acceptable. A compound described herein may beadministered as a pharmaceutically acceptable salt.

“Prodrug” refers to a compound that, after administration, ismetabolized or otherwise converted to a biologically active or moreactive compound (or drug) with respect to at least one property. Aprodrug, relative to the drug, is modified chemically in a manner thatrenders it, relative to the drug, less active or inactive, but thechemical modification is such that the corresponding drug is generatedby metabolic or other biological processes after the prodrug isadministered. A prodrug may have, relative to the active drug, alteredmetabolic stability or transport characteristics, fewer side effects orlower toxicity, or improved flavor (for example, see the referenceNogrady, 1985, Medicinal Chemistry A Biochemical Approach, OxfordUniversity Press, New York, pages 388-392, incorporated herein byreference). A prodrug may be synthesized using reactants other thanemploying the corresponding drug. For illustration and withoutlimitation, prodrugs include, carboxy esters, linear and cyclicphosphate esters and phosphoramide and phosphoramidates, carbamates,preferably phenolic carbamates (i.e., carbamates where the hydroxy groupis part of an aryl or heteroaryl moiety, where the aryl and heteroarylmay be optionally substituted), and the likes.

“Salt” refers to an ionic compound formed between an acid and a base.When the compound provided herein contains an acidic functionality, suchsalts include, without limitation, alkali metal, alkaline earth metal,and ammonium salts. As used herein, ammonium salts include, saltscontaining protonated nitrogen bases and alkylated nitrogen bases.Exemplary and non-limiting cations useful in pharmaceutically acceptablesalts include Na, K, Rb, Cs, NH₄, Ca, Ba, imidazolium, and ammoniumcations based on naturally occurring amino acids. When the compoundsutilized herein contain basic functionality, such salts include, withoutlimitation, salts of organic acids, such as carboxylic acids andsulfonic acids, and mineral acids, such as hydrogen halides, sulfuricacid, phosphoric acid, and the likes. Exemplary and non-limiting anionsuseful in pharmaceutically acceptable salts include oxalate, maleate,acetate, propionate, succinate, tartrate, chloride, sulfate, bisulfate,mono-, di-, and tribasic phosphate, mesylate, tosylate, and the likes.

“Therapeutically effective amount” or dose of a compound or acomposition refers to that amount of the compound or the compositionthat results in reduction or inhibition of symptoms or a prolongation ofsurvival in a patient. The results may require multiple doses of thecompound or the composition.

As used herein, “treatment” or “treating” is an approach for obtainingbeneficial or desired results including clinical results. For purposesof this invention, beneficial or desired results include, but are notlimited to, one or more of the following: decreasing one more symptomsresulting from the disease or disorder, diminishing the extent of thedisease or disorder, stabilizing the disease or disorder (e.g.,preventing or delaying the worsening of the disease or disorder),delaying the occurrence or recurrence of the disease or disorder, delayor slowing the progression of the disease or disorder, ameliorating thedisease or disorder state, providing a remission (whether partial ortotal) of the disease or disorder, decreasing the dose of one or moreother medications required to treat the disease or disorder, enhancingthe effect of another medication used to treat the disease or disorder,delaying the progression of the disease or disorder, increasing thequality of life, and/or prolonging survival of a patient. Alsoencompassed by “treatment” is a reduction of pathological consequence ofthe disease or disorder. The methods of the invention contemplate anyone or more of these aspects of treatment.

An “isotopomer” of a compound is a compound in which one or more atomsof the compound have been replaced with isotopes of those same atoms.For example, where H has been replaced by D or T, or ¹²C has beenreplaced by ¹¹C or ¹⁴N has been replaced by ¹⁵N. For example, andwithout limitation, replacement of with D can in some instances lead toreduced rates of metabolism and therefore longer half-lives. Replacementof H with T can provide radioligands potentially useful in bindingstudies. Replacement of ¹²C with the short-lived isotope ¹¹C can provideligands useful in Positron Emission Tomography (PET) scanning.Replacement of ¹⁴N with ¹⁵N provides compounds that can bedetected/monitored by ¹⁵N NMR spectroscopy. For example, an isotopomerof a compound containing —CH₂CH₃ is that compound but containing —CD₂CD₃instead of the —CH₂CH₃.

“Stereoisomer” or “stereoisomers” refer to compounds that differ in thestereogenicity of the constituent atoms such as, without limitation, inthe chirality of one or more stereocenters or related to the cis ortrans configuration of a carbon-carbon or carbon-nitrogen double bond.Stereoisomers include enantiomers and diastereomers.

“Tautomer” refer to alternate forms of a compound that differ in theposition of a proton, such as enol-keto and imine-enamine tautomers, orthe tautomeric forms of heteroaryl groups containing a ring atomattached to both a ring —NH— moiety and a ring ═N— moiety such aspyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.

“Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groupshaving from 1 to 12 carbon atoms, preferably from 1 to 10 carbon atoms,and more preferably from 1 to 6 carbon atoms. This term includes, by wayof example, linear and branched hydrocarbyl groups such as methyl(CH₃—), ethyl (CH₃CH₂—), n-propyl (CH₃CH₂CH₂—), isopropyl ((CH₃)₂CH—),n-butyl (CH₃CH₂CH₂CH₂—), isobutyl ((CH₃)₂CHCH₂—), sec-butyl((CH₃)(CH₃CH₂)CH—), t-butyl ((CH₃)₃C—), n-pentyl (CH₃CH₂CH₂CH₂CH₂—), andneopentyl ((CH₃)₃CCH₂—). C_(x) alkyl refers to an alkyl group having xnumber of carbon atoms.

“Alkenyl” refers to straight or branched monovalent hydrocarbyl groupshaving from 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms andhaving at least 1 and preferably from 1 to 2 sites of vinyl (>C═CC)unsaturation. Such groups are exemplified, for example, by vinyl, allyl,and but-3-en-1-yl. Included within this term are the cis and transisomers or mixtures of these isomers. C_(x) alkenyl refers to an alkenylgroup having x number of carbon atoms.

“Alkynyl” refers to straight or branched monovalent hydrocarbyl groupshaving from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms andhaving at least 1 and preferably from 1 to 2 sites of acetylenic (—C≡C—)unsaturation. Examples of such alkynyl groups include acetylenyl(—C≡CH), and propargyl (—CH₂C≡CH). C_(x) alkynyl refers to an alkynylgroup having x number of carbon atoms.

“Substituted alkyl” refers to an alkyl group having from 1 to 5,preferably 1 to 3, or more preferably 1 to 2 substituents selected fromthe group consisting of alkoxy, substituted alkoxy, acyl, acylamino,acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl,aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy,aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl,substituted aryl, aryloxy, substituted aryloxy, arylthio, substitutedarylthio, arylamino, substituted arylamino, heteroarylamino, substitutedheteroarylamino, cycloalkylamino, substituted cycloalkylamino,heterocycloalkylamino, substituted heterocyclylamino, carboxyl, carboxylester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl,substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy,cycloalkylthio, substituted cycloalkylthio, guanidino, substitutedguanidino, halo, hydroxy, heteroaryl, substituted heteroaryl,heteroaryloxy, substituted heteroaryloxy, heteroarylthio, substitutedheteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy,substituted heterocyclyloxy, heterocyclylthio, substitutedheterocyclylthio, nitro, SO₃H, substituted sulfonyl, sulfonyloxy,sulfonylamino, thioacyl, thiol, alkylthio, and substituted alkylthio,wherein said substituents are defined herein.

“Substituted alkenyl” refers to alkenyl groups having from 1 to 3substituents, and preferably 1 to 2 substituents, selected from thegroup consisting of alkoxy, substituted alkoxy, acyl, acylamino,acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl,aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy,aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl,substituted aryl, aryloxy, substituted aryloxy, arylthio, substitutedarylthio, arylamino, substituted arylamino, heteroarylamino, substitutedheteroarylamino, cycloalkylamino, substituted cycloalkylamino,heterocycloalkylamino, substituted heterocyclylamino, carboxyl, carboxylester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl,substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy,cycloalkylthio, substituted cycloalkylthio, guanidino, substitutedguanidino, halo, hydroxy, heteroaryl, substituted heteroaryl,heteroaryloxy, substituted heteroaryloxy, heteroarylthio, substitutedheteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy,substituted heterocyclyloxy, heterocyclylthio, substitutedheterocyclylthio, nitro, SO₃H, substituted sulfonyl, sulfonyloxy,sulfonylamino, thioacyl, thiol, alkylthio, and substituted alkylthio,wherein said substituents are defined herein and with the proviso thatany hydroxy or thiol substitution is not attached to a vinyl(unsaturated) carbon atom.

“Substituted alkynyl” refers to alkynyl groups having from 1 to 3substituents, and preferably 1 to 2 substituents, selected from thegroup consisting of alkoxy, substituted alkoxy, acyl, acylamino,acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl,aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy,aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl,substituted aryl, aryloxy, substituted aryloxy, arylthio, substitutedarylthio, arylamino, substituted arylamino, heteroarylamino, substitutedheteroarylamino, cycloalkylamino, substituted cycloalkylamino,heterocycloalkylamino, substituted heterocyclylamino, carboxyl, carboxylester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl,substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy,cycloalkylthio, substituted cycloalkylthio, guanidino, substitutedguanidino, halo, hydroxy, heteroaryl, substituted heteroaryl,heteroaryloxy, substituted heteroaryloxy, heteroarylthio, substitutedheteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy,substituted heterocyclyloxy, heterocyclylthio, substitutedheterocyclylthio, nitro, SO₃H, substituted sulfonyl, sulfonyloxy,sulfonylamino, thioacyl, thiol, alkylthio, and substituted alkylthio,wherein said substituents are defined herein and with the proviso thatany hydroxyl or thiol substitution is not attached to an acetyleniccarbon atom.

“Alkoxy” refers to the group —O-alkyl wherein alkyl is defined herein.Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy,isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.

“Substituted alkoxy” refers to the group —O-(substituted alkyl) whereinsubstituted alkyl is defined herein. Preferred substituted alkyl groupsin —O-(substituted alkyl) include halogenated alkyl groups andparticularly halogenated methyl groups such as trifluoromethyl,difluromethyl, fluoromethyl and the like.

“Acyl” refers to the groups H—C(O)—, alkyl-C(O)—, substitutedalkyl-C(O)—, alkenyl-C(O)—, substituted alkenyl-C(O)—, alkynyl-C(O)—,substituted alkynyl-C(O)—, cycloalkyl-C(O)—, substitutedcycloalkyl-C(O)—, aryl-C(O)—, substituted aryl-C(O)—, heteroaryl-C(O)—,substituted heteroaryl-C(O)—, heterocyclic-C(O)—, and substitutedheterocyclic-C(O)—, wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkoxy, substituted alkoxy, alkynyl, substitutedalkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl,heteroaryl, substituted heteroaryl, heterocyclic and substitutedheterocyclic are as defined herein. Acyl includes the “acetyl” groupCH₃C(O)—.

“Acylamino” refers to the groups —NR³⁰C(O)alkyl, —NR³⁰C(O)substitutedalkyl, —NR³⁰C(O)cycloalkyl, —NR³⁰C(O)substituted cycloalkyl,—NR³⁰C(O)alkenyl, —NR³⁰C(O)substituted alkenyl, alkoxy, substitutedalkoxy-NR³⁰C(O)alkynyl, —NR³⁰C(O)substituted alkynyl, —NR³⁰C(O)aryl,—NR³⁰C(O)substituted aryl, —NR³⁰C(O)heteroaryl, —NR³⁰C(O)substitutedheteroaryl, —NR³⁰C(O)heterocyclic, and —NR³⁰C(O)substituted heterocyclicwherein R³⁰ is hydrogen, alkyl, substituted alkyl, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, cycloalkyl, or substitutedcycloalkyl; and wherein alkyl, substituted alkyl, alkenyl, substitutedalkenyl, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Acyloxy” refers to the groups alkyl-C(O)O—, substituted alkyl-C(O)O—,alkenyl-C(O)O—, substituted alkenyl-C(O)O—, alkynyl-C(O)O—, substitutedalkynyl-C(O)O—, aryl-C(O)O—, substituted aryl-C(O)O—, cycloalkyl-C(O)O—,substituted cycloalkyl-C(O)O—, heteroaryl-C(O)O—, substitutedheteroaryl-C(O)O—, heterocyclic-C(O)O—, and substitutedheterocyclic-C(O)O— wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic are as definedherein.

“Amino” refers to the group —NH₂.

“Substituted amino” refers to the group —NR³¹R³² where R³¹ and R³² areindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, aryl, substituted aryl,cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl,heterocyclic, substituted heterocyclic, arylamino, substitutedarylamino, heteroarylamino, substituted heteroarylamino,cycloalkylamino, substituted cycloalkylamino, heterocycloalkylamino,substituted heterocyclylamino, sulfonylamino, and substituted sulfonyland wherein R³¹ and R³² are optionally joined, together with thenitrogen bound thereto to form a heterocyclic or substitutedheterocyclic group, provided that R³¹ and R³² are both not hydrogen, andwherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy,substituted alkoxy, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic are as definedherein. When R³¹ is hydrogen and R³² is alkyl, the substituted aminogroup is sometimes referred to herein as alkylamino. When R³¹ and R³²are alkyl, the substituted amino group is sometimes referred to hereinas dialkylamino. When referring to a monosubstituted amino, it is meantthat either R³¹ or R³² is hydrogen but not both. When referring to adisubstituted amino, it is meant that neither R³¹ nor R₃₂ are hydrogen.

“Aminocarbonyl” refers to the group —C(O)NR³³R³⁴ where R³³ and R³⁴ areindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, aryl, substituted aryl,cycloalkyl, substituted cycloalkyl heteroaryl, substituted heteroaryl,heterocyclic, and substituted heterocyclic and where R³³ and R³⁴ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Aminothiocarbonyl” refers to the group —C(S)NR³³R³⁴ where R³³ and R³⁴are independently selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, aryl, substituted aryl,cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl,heterocyclic, and substituted heterocyclic and where R³³ and R³⁴ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Aminocarbonylamino” refers to the group —NR³⁰C(O)NR³³R³⁴ where R³⁰ ishydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,substituted heteroaryl, cycloalkyl, or substituted cycloalkyl, and R³³and R³⁴ are independently selected from the group consisting ofhydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl,alkoxy, substituted alkoxy, alkynyl, substituted alkynyl, aryl,substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl,substituted heteroaryl, heterocyclic, and substituted heterocyclic andwhere R³³ and R³⁴ are optionally joined together with the nitrogen boundthereto to form a heterocyclic or substituted heterocyclic group, andwherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy,substituted alkoxy, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Aminothiocarbonylamino” refers to the group —NR³⁰C(S)NR³³R³⁴ where R³⁰is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,heteroaryl, substituted heteroaryl, cycloalkyl, or substitutedcycloalkyl, and R³³ and R³⁴ are independently selected from the groupconsisting of hydrogen, alkyl, substituted alkyl, alkenyl, substitutedalkenyl, alkoxy, substituted alkoxy, alkynyl, substituted alkynyl, aryl,substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl,substituted heteroaryl, heterocyclic, and substituted heterocyclic andwhere R³³ and R₃₄ are optionally joined together with the nitrogen boundthereto to form a heterocyclic or substituted heterocyclic group, andwherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy,substituted alkoxy, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Aminocarbonyloxy” refers to the group —O—C(O)NR³³R³⁴ where R³³ and R³⁴are independently selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, aryl, substituted aryl,cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl,heterocyclic, and substituted heterocyclic and where R³³ and R³⁴ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Aminosulfonyl” refers to the group —SO₂NR³³R³⁴ where R³³ and R³⁴ areindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, aryl, substituted aryl,cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl,heterocyclic, and substituted heterocyclic and where R³³ and R³⁴ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Aminosulfonyloxy” refers to the group —O—SO₂NR³³R³⁴ where R³³ and R³⁴are independently selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, aryl, substituted aryl,cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl,heterocyclic, and substituted heterocyclic and where R³³ and R³⁴ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Aminosulfonylamino” refers to the group —NR³⁰—SO₂NR³³R³⁴ where R³⁰ ishydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,substituted heteroaryl, cycloalkyl, or substituted cycloalkyl, and R³³and R³⁴ are independently selected from the group consisting ofhydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl,alkoxy, substituted alkoxy, alkynyl, substituted alkynyl, aryl,substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl,substituted heteroaryl, heterocyclic, and substituted heterocyclic andwhere R³³ and R³⁴ are optionally joined together with the nitrogen boundthereto to form a heterocyclic or substituted heterocyclic group, andwherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy,substituted alkoxy, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Amidino” refers to the group —C(═NR³⁵)NR³³R³⁴ where R³³, R³⁴, and R³⁵are independently selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, aryl, substituted aryl,cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl,heterocyclic, and substituted heterocyclic and where R³³ and R³⁴ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substitutedalkoxy, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Aryl” or “Ar” refers to a monovalent aromatic carbocyclic group of from6 to 14 carbon atoms having a single ring (e.g., phenyl (Ph)) ormultiple condensed rings (e.g., naphthyl or anthryl) which condensedrings may or may not be aromatic (e.g., 2-benzoxazolinone,2H-1,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the pointof attachment is at an aromatic carbon atom. Preferred aryl groupsinclude phenyl and naphthyl.

“Substituted aryl” refers to aryl groups which are substituted with 1 to5, preferably 1 to 3, or more preferably 1 to 2 substituents selectedfrom the group consisting of alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substitutedalkoxy, acyl, acylamino, acyloxy, amino, substituted amino,aminocarbonyl, aminothiocarbonyl, aminocarbonylamino,aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl,aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl,aryloxy, substituted aryloxy, arylthio, substituted arylthio, arylamino,substituted arylamino, heteroarylamino, substituted heteroarylamino,cycloalkylamino, substituted cycloalkylamino, heterocycloalkylamino,substituted heterocyclylamino carboxyl, carboxyl ester, (carboxylester)amino, (carboxyl ester)oxy, cyano, cycloalkyl, substitutedcycloalkyl, cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio,substituted cycloalkylthio, guanidino, substituted guanidino, halo,hydroxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substitutedheteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic,substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy,heterocyclylthio, substituted heterocyclylthio, nitro, SO₃H, substitutedsulfonyl, sulfonyloxy, sulfonylamino, thioacyl, thiol, alkylthio, andsubstituted alkylthio, wherein said substituents are defined herein.

“Aryloxy” refers to the group —O-aryl, where aryl is as defined herein,that includes, by way of example, phenoxy and naphthoxy.

“Substituted aryloxy” refers to the group —O-(substituted aryl) wheresubstituted aryl is as defined herein.

“Arylthio” refers to the group —S-aryl, where aryl is as defined herein.

“Substituted arylthio” refers to the group —S-(substituted aryl), wheresubstituted aryl is as defined herein.

“Arylamino” refers to the group —NR³⁷(aryl), where aryl is as definedherein and R³⁷ is hydrogen, alkyl, or substituted alkyl.

“Substituted arylamino” refers to the group —NR³⁷(substituted aryl),where R³⁷ is hydrogen, alkyl, or substituted alkyl where substitutedaryl is as defined herein.

“Carbonyl” refers to the divalent group —C(O)— which is equivalent to—C(═O)—.

“Carboxy” or “carboxyl” refers to —COOH or salts thereof.

“Carboxyl ester” or “carboxy ester” refers to the groups —C(O)O-alkyl,—C(O)O-substituted alkyl, —C(O)O-alkenyl, —C(O)O-substituted alkenyl,—C(O)O-alkynyl, —C(O)O-substituted alkynyl, —C(O)O-aryl,—C(O)O-substituted aryl, —C(O)O-cycloalkyl, —C(O)O-substitutedcycloalkyl, —C(O)O-heteroaryl, —C(O)O-substituted heteroaryl,—C(O)O-heterocyclic, and —C(O)O-substituted heterocyclic wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl,heteroaryl, substituted heteroaryl, heterocyclic, and substitutedheterocyclic are as defined herein.

“(Carboxyl ester)amino” refers to the group —NR³⁰—C(O)O-alkyl,—NR³⁰—C(O)O-substituted alkyl, —NR³⁰—C(O)O-alkenyl,—NR³⁰—C(O)O-substituted alkenyl, —NR³⁰—C(O)O-alkynyl,—NR³⁰—C(O)O-substituted alkynyl, —NR³⁰—C(O)O-aryl,—NR³⁰—C(O)O-substituted aryl, —NR³⁰—C(O)O-cycloalkyl,—NR³⁰—C(O)O-substituted cycloalkyl, —NR³⁰—C(O)O-heteroaryl,—NR³⁰—C(O)O-substituted heteroaryl, —NR³⁰—C(O)O-heterocyclic, and—NR³⁰—C(O)O-substituted heterocyclic wherein R³⁰ is alkyl or hydrogen,and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl,alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

“(Carboxyl ester)oxy” refers to the group —O—C(O)O-alkyl,—O—C(O)O-substituted alkyl, —O—C(O)O-alkenyl, —O—C(O)O-substitutedalkenyl, —O—C(O)O-alkynyl, —O—C(O)O-substituted alkynyl, —O—C(O)O-aryl,—O—C(O)O-substituted aryl, —O—C(O)O-cycloalkyl, —O—C(O)O-substitutedcycloalkyl, —O—C(O)O-heteroaryl, —O—C(O)O-substituted heteroaryl,—O—C(O)O-heterocyclic, and —O—C(O)O-substituted heterocyclic whereinalkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

“Cyano” refers to the group —C≡N.

“Cycloalkyl” refers to saturated or unsaturated but nonaromatic cyclicalkyl groups of from 3 to 10 carbon atoms, preferably from 3 to 8 carbonatoms, and more preferably from 3 to 6 carbon atoms, having single ormultiple cyclic rings including fused, bridged, and spiro ring systems.C_(x) cycloalkyl refers to a cycloalkyl group having x number of ringcarbon atoms. Examples of suitable cycloalkyl groups include, forinstance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, andcyclooctyl. One or more the rings can be aryl, heteroaryl, orheterocyclic provided that the point of attachment is through thenon-aromatic, non-heterocyclic ring saturated carbocyclic ring.“Substituted cycloalkyl” refers to a cycloalkyl group having from 1 to 5or preferably 1 to 3 substituents selected from the group consisting ofoxo, thione, alkyl, substituted alkyl, alkenyl, substituted alkenyl,alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, acyl,acylamino, acyloxy, amino, substituted amino, aminocarbonyl,aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino,aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino,amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio,substituted arylthio, carboxyl, carboxyl ester, (carboxyl ester)amino,(carboxyl ester)oxy, cyano, cycloalkyl, substituted cycloalkyl,cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio, substitutedcycloalkylthio, guanidino, substituted guanidino, halo, hydroxy,heteroaryl, substituted heteroaryl, heteroaryloxy, substitutedheteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic,substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy,heterocyclylthio, substituted heterocyclylthio, nitro, SO₃H, substitutedsulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, and substitutedalkylthio, wherein said substituents are defined herein.

“Cycloalkyloxy” refers to —O-cycloalkyl.

“Substituted cycloalkyloxy” refers to —O-(substituted cycloalkyl).

“Cycloalkylamino” refers to the group —NR³⁷(cycloalkyl) where R³⁷ ishydrogen, alkyl, or substituted alkyl.

“Substituted cycloalkylamino” refers to the group —NR³⁷(substitutedcycloalkyl) where R³⁷ is hydrogen, alkyl, or substituted alkyl andsubstituted cycloalkyl is as defined herein.

“Cycloalkylthio” refers to —S-cycloalkyl.

“Substituted cycloalkylthio” refers to —S-(substituted cycloalkyl).

“Guanidino” refers to the group —NHC(═NH)NH₂.

“Substituted guanidino” refers to —NR³⁶C(═NR³⁶)N(R³⁶)₂ where each R³⁶ isindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic and two R³⁶groups attached to a common guanidino nitrogen atom are optionallyjoined together with the nitrogen bound thereto to form a heterocyclicor substituted heterocyclic group, provided that at least one R³⁶ is nothydrogen, and wherein said substituents are as defined herein.

“Halo” or “halogen” refers to fluoro, chloro, bromo and iodo andpreferably is fluoro or chloro.

“Hydroxy” or “hydroxyl” refers to the group —OH.

“Heteroalkylene” refers to an alkylene group wherein one or more carbonsis replaced with —O—, —S—, —SO₂—, —NR^(Q)—,

moieties where R^(Q) is H or C₁-C₆ alkyl. “Substituted heteroalkylene”refers to heteroalkynylene groups having from 1 to 3 substituents, andpreferably 1 to 2 substituents, selected from the substituents disclosedfor substituted alkylene.

“Heteroaryl” refers to an aromatic group of from 1 to 10 carbon atomsand 1 to 4 heteroatoms selected from the group consisting of oxygen,nitrogen and sulfur within the ring. Such heteroaryl groups can have asingle ring (e.g., pyridinyl or furyl) or multiple condensed rings(e.g., indolizinyl or benzothienyl) wherein the condensed rings may ormay not be aromatic and/or contain a heteroatom provided that the pointof attachment is through an atom of the aromatic heteroaryl group. Inone embodiment, the nitrogen and/or the sulfur ring atom(s) of theheteroaryl group are optionally oxidized to provide for the N-oxide(N→O), sulfinyl, or sulfonyl moieties. Preferred heteroaryls include 5or 6 membered heteroaryls such as pyridinyl, pyrrolyl, thiophenyl, andfuranyl. Other preferred heteroaryls include 9 or 10 memberedheteroaryls, such as indolyl, quinolinyl, quinolonyl, isoquinolinyl, andisoquinolonyl.

“Substituted heteroaryl” refers to heteroaryl groups that aresubstituted with from 1 to 5, preferably 1 to 3, or more preferably 1 to2 substituents selected from the group consisting of the same group ofsubstituents defined for substituted aryl.

“Heteroaryloxy” refers to —O-heteroaryl.

“Substituted heteroaryloxy” refers to the group —O-(substitutedheteroaryl).

“Heteroarylthio” refers to the group —S-heteroaryl.

“Substituted heteroarylthio” refers to the group —S-(substitutedheteroaryl).

“Heteroarylamino” refers to the group —NR³⁷(heteroaryl) where R³⁷ ishydrogen, alkyl, or substituted alkyl.

“Substituted heteroarylamino” refers to the group —NR³⁷(substitutedheteroaryl), where R³⁷ is hydrogen, alkyl, or substituted alkyl andsubstituted heteroaryl is defined as herein.

“Heterocycle” or “heterocyclic” or “heterocycloalkyl” or “heterocyclyl”refers to a saturated or partially saturated, but not aromatic, grouphaving from 1 to 10 ring carbon atoms, preferably from 1 to 8 carbonatoms, and more preferably from 1 to 6 carbon atoms, and from 1 to 4ring heteroatoms, preferably from 1 to 3 heteroatoms, and morepreferably from 1 to 2 heteroatoms selected from the group consisting ofnitrogen, sulfur, or oxygen. C_(x) heterocycloalkyl refers to aheterocycloalkyl group having x number of ring atoms including the ringheteroatoms. Heterocycle encompasses single ring or multiple condensedrings, including fused bridged and spiro ring systems. In fused ringsystems, one or more the rings can be cycloalkyl, aryl or heteroarylprovided that the point of attachment is through the non-aromatic ring.In one embodiment, the nitrogen and/or sulfur atom(s) of theheterocyclic group are optionally oxidized to provide for the N-oxide,sulfinyl, sulfonyl moieties.

“Heterocyclylene” refers to a divalent saturated or partially saturated,but not aromatic, group having from 1 to 10 ring carbon atoms and from 1to 4 ring heteroatoms selected from the group consisting of nitrogen,sulfur, or oxygen. “Substituted heterocyclylene” refers toheterocyclylene groups that are substituted with from 1 to 5 orpreferably 1 to 3 of the same substituents as defined for substitutedcycloalkyl.

“Substituted heterocyclic” or “substituted heterocycloalkyl” or“substituted heterocyclyl” refers to heterocyclyl groups that aresubstituted with from 1 to 5 or preferably 1 to 3 of the samesubstituents as defined for substituted cycloalkyl.

“Heterocyclyloxy” refers to the group —O-heterocycyl.

“Substituted heterocyclyloxy” refers to the group —O-(substitutedheterocycyl).

“Heterocyclylthio” refers to the group —S-heterocycyl.

“Substituted heterocyclylthio” refers to the group —S-(substitutedheterocycyl).

“Heterocyclylamino” refers to the group —NR³⁷(heterocyclyl) where R³⁷ ishydrogen, alkyl, or substituted alkyl.

“Substituted heterocyclylamino” refers to the group —NR³⁷(substitutedheterocyclyl), where R³⁷ is hydrogen, alkyl, or substituted alkyl andsubstituted heterocyclyl is defined as herein.

Examples of heterocyclyl and heteroaryl include, but are not limited to,azetidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazyl,pyrimidyl, pyridazyl, indolizyl, isoindolyl, indolyl, dihydroindolyl,indazolyl, purinyl, quinolizinyl, isoquinolinyl, quinolinyl,phthalazinyl, naphthylpyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl,pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, acridinyl,phenanthrolinyl, isothiazolyl, phenazinyl, isoxazolyl, phenoxazinyl,phenothiazinyl, imidazolidinyl, imidazolinyl, piperidinyl, piperazinyl,indolinyl, phthalimidyl, 1,2,3,4-tetrahydroisoquinolinyl,4,5,6,7-tetrahydrobenzo[b]thiophenyl, thiazolyl, thiazolidinyl,thiophenyl, benzo[b]thiophenyl, morpholinyl, thiomorpholinyl (alsoreferred to as thiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl,pyrrolidinyl, and tetrahydrofuranyl.

“Nitro” refers to the group —NO₂.

“Oxo” refers to the atom (═O) or (0).

“Spiro ring systems” refers to bicyclic ring systems that have a singlering carbon atom common to both rings.

“Sulfinyl” refers to the divalent group —S(O)— or —S(═O)—.

“Sulfonyl” refers to the divalent group —S(O)₂— or —S(═O)₂-.

“Substituted sulfonyl” refers to the group —SO₂-alkyl, —SO₂-substitutedalkyl, —SO₂—OH, —SO₂-alkenyl, —SO₂-substituted alkenyl, —SO₂-cycloalkyl,—SO₂-substituted cycloalkyl, —SO₂-aryl, —SO₂-substituted aryl,—SO₂-heteroaryl, —SO₂-substituted heteroaryl, —SO₂-heterocyclic,—SO₂-substituted heterocyclic, wherein alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein. Substituted sulfonyl includes groups such as methyl-SO₂—,phenyl-SO₂—, and 4-methylphenyl-SO₂—. Preferred substituted alkyl groupson the substituted alkyl-SO₂— include halogenated alkyl groups andparticularly halogenated methyl groups such as trifluoromethyl,difluromethyl, fluoromethyl and the like.

“Substituted sulfinyl” refers to the group —SO-alkyl, —SO-substitutedalkyl, —SO-alkenyl, —SO-substituted alkenyl, —SO-cycloalkyl,—SO-substituted cycloalkyl, —SO-aryl, —SO-substituted aryl,—SO-heteroaryl, —SO-substituted heteroaryl, —SO-heterocyclic,—SO-substituted heterocyclic, wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein. Substituted sulfinyl includes groups such as methyl-SO—,phenyl-SO—, and 4-methylphenyl-SO—. Preferred substituted alkyl groupson the substituted alkyl-SO— include halogenated alkyl groups andparticularly halogenated methyl groups such as trifluoromethyl,difluromethyl, fluoromethyl and the like.

“Sulfonyloxy” or “substituted sulfonyloxy” refers to the group—OSO₂-alkyl, —OSO₂-substituted alkyl, —OSO₂—OH, —OSO₂-alkenyl,—OSO₂-substituted alkenyl, —OSO₂-cycloalkyl, —OSO₂-substitutedcycloalkyl, —OSO₂-aryl, —OSO₂-substituted aryl, —OSO₂-heteroaryl,—OSO₂-substituted heteroaryl, —OSO₂-heterocyclic, —OSO₂-substitutedheterocyclic, wherein alkyl, substituted alkyl, alkenyl, substitutedalkenyl, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic are as defined herein.

“Sulfonylamino” refers to the group —NR³⁷(substituted sulfonyl) whereR³⁷ is hydrogen, alkyl, or substituted alkyl and substituted sulfonyl isas defined here.

“Thioacyl” refers to the groups H—C(S)—, alkyl-C(S)—, substitutedalkyl-C(S)—, alkenyl-C(S)—, substituted alkenyl-C(S)—, alkynyl-C(S)—,substituted alkynyl-C(S)—, cycloalkyl-C(S)—, substitutedcycloalkyl-C(S)—, aryl-C(S)—, substituted aryl-C(S)—, heteroaryl-C(S)—,substituted heteroaryl-C(S)—, heterocyclic-C(S)—, and substitutedheterocyclic-C(S)—, wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Mercapto” or “thiol” refers to the group —SH.

“Formyl” refers to the group —C(O)H.

“Thiocarbonyl” refers to the divalent group —C(S)— which is equivalentto —C(═S)—.

“Thione” refers to the atom (═S).

“Alkylthio” refers to the group —S-alkyl wherein alkyl is as definedherein.

“Substituted alkylthio” refers to the group —S-(substituted alkyl)wherein substituted alkyl is as defined herein. Preferred substitutedalkyl groups on —S-(substituted alkyl) include halogenated alkyl groupsand particularly halogenated methyl groups such as trifluoromethyl,difluromethyl, fluoromethyl and the like.

“Vinyl” refers to unsaturated hydrocarbon radical —CH═CH₂, derived fromethylene.

The terms “optional” or “optionally” as used throughout thespecification means that the subsequently described event orcircumstance may but need not occur, and that the description includesinstances where the event or circumstance occurs and instances in whichit does not. For example, “the nitrogen atom is optionally oxidized toprovide for the N-oxide (N→O) moiety” means that the nitrogen atom maybut need not be oxidized, and the description includes situations wherethe nitrogen atom is not oxidized and situations where the nitrogen atomis oxidized.

The term “optionally substituted” refers to a substituted orunsubstituted group. The substituted group (e.g., the alkyl group in“substituted alkyl”) may be substituted with one or more substituents,such as e.g., 1, 2, 3, 4 or 5 substituents, which may be the same ordifferent. Preferably, the substituents are selected from the functionalgroups provided herein. In certain more preferred embodiments, thesubstituents are selected from oxo, halo, —CN, NO₂, —CO₂R₁ ⁰⁰, —OR¹⁰⁰,—SR¹⁰⁰, —SOR¹⁰⁰, —SO₂R₁ ⁰⁰, —NR¹⁰¹R¹⁰², —CONR¹⁰¹R₁ ⁰², —SO₂NR¹⁰¹R¹⁰²,C₁-C₆ alkyl, C₁-C₆ alkoxy, —CR¹⁰⁰═C(R¹⁰⁰)₂, —CCR¹⁰⁰, C₃-C₁₀ cycloalkyl,C₄-C₁₀ heterocyclyl, C₆-C₁₄ aryl and C₅-C₁₂heteroaryl, wherein each R¹⁰⁰independently is hydrogen or C₁-C₈ alkyl; C₃-C₁₂ cycloalkyl; C₄-C₁₀heterocyclyl; C₆-C₁₄ aryl; or C₂-C₁₂heteroaryl; wherein each alkyl,cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substitutedwith 1-3 halo, 1-3 C₁-C₆ alkyl, 1-3 C₁-C₆ haloalkyl or 1-3 C₁-C₆ alkoxygroups. More preferably, the substituents are selected from the groupconsisting of chloro, fluoro, —OCH₃, methyl, ethyl, iso-propyl,cyclopropyl, —OCF₃, —CF₃ and —OCHF₂.

R¹⁰¹ and R¹⁰² independently are hydrogen; C₁-C₈ alkyl, optionallysubstituted with —CO₂H or an ester thereof, C₁-C₆ alkoxy, oxo,—CR¹⁰³═C(R¹⁰³)₂, —CCR, C₃-C₁₀ cycloalkyl, C₃-C₁₀ heterocyclyl, C₆-C₁₄aryl, or C₂-C₁₂heteroaryl, wherein each R¹⁰³ independently is hydrogenor C₁-C₈ alkyl; C₃-C₁₂ cycloalkyl; C₄-C₁₀ heterocyclyl; C₆-C₁₄ aryl; orC₂-C₁₂heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, orheteroaryl is optionally substituted with 1-3 alkyl groups or 1-3 halogroups, or R¹⁰¹ and R¹⁰² together with the nitrogen atom they areattached to form a 5-7 membered heterocycle.

Unless indicated otherwise, the nomenclature of substituents that arenot explicitly defined herein are arrived at by naming the terminalportion of the functionality followed by the adjacent functionalitytoward the point of attachment. For example, the substituent“alkoxycarbonylalkyl” refers to the group (alkoxy)-C(O)-(alkyl)-.

It is understood that in all substituted groups defined above, polymersarrived at by defining substituents with further substituents tothemselves (e.g., substituted aryl having a substituted aryl group as asubstituent which is itself substituted with a substituted aryl group,etc.) are not intended for inclusion herein. In such cases, the maximumnumber of such substituents is three. That is to say that each of theabove definitions is constrained by a limitation that, for example,substituted aryl groups are limited to—substituted aryl-(substitutedaryl)-substituted aryl.

In some embodiments of a substituted moiety, the moiety is substitutedwith a group that may also be substituted with a further group, but thefurther group cannot be additionally substituted. For example, in someembodiments of “substituted alkyl”, the alkyl moiety is substituted witha group that may be further substituted (e.g., substituted alkoxy,substituted amino, substituted aryl, substituted aryloxy, substitutedarylthio, substituted arylamino, substituted heteroarylamino,substituted cycloalkylamino, substituted heterocyclylamino, substitutedcycloalkyl, substituted cycloalkyloxy, substituted cycloalkylthio,substituted guanidino, substituted heteroaryl, substitutedheteroaryloxy, substituted heteroarylthio, substituted heterocyclic,substituted heterocyclyloxy, substituted heterocyclylthio, substitutedsulfonyl, substituted alkylthio), but the substituted alkoxy,substituted amino, substituted aryl, substituted aryloxy, substitutedarylthio, substituted arylamino, substituted heteroarylamino,substituted cycloalkylamino, substituted heterocyclylamino, substitutedcycloalkyl, substituted cycloalkyloxy, substituted cycloalkylthio,substituted guanidino, substituted heteroaryl, substitutedheteroaryloxy, substituted heteroarylthio, substituted heterocyclic,substituted heterocyclyloxy, substituted heterocyclylthio, substitutedsulfonyl or substituted alkylthio on the alkyl moiety is not substitutedwith a moiety that is itself further substituted. Although “substitutedalkyl” is provided as an example, such an embodiment is intended foreach substituted moiety described herein.

In some embodiments of a substituted moiety, the moiety is substitutedwith a group that is not further substituted. Thus, in some embodiments,“substituted alkyl” is an alkyl moiety substituted with one or more, andin some aspects, 1 or 2 or 3 or 4 or 5 moieties independently selectedfrom the group consisting of alkoxy, acyl, acylamino, acyloxy, amino,aminocarbonyl, aminothiocarbonyl, aminocarbonylamino,aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl,aminosulfonyloxy, aminosulfonylamino, amidino, aryl, aryloxy, arylthio,arylamino, heteroarylamino, cycloalkylamino, heterocycloalkylamino,carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy,cyano, cycloalkyl, cycloalkyloxy, cycloalkylthio, guanidino, halo,hydroxy, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclic,heterocyclyloxy, heterocyclylthio, nitro, SO₃H, sulfonyloxy,sulfonylamino, thioacyl, thiol, and alkylthio. Although “substitutedalkyl” is provided as an example, such an embodiment is intended foreach substituted moiety described herein.

It is understood that the above definitions are not intended to includeimpermissible substitution patterns (e.g., methyl substituted with 4fluoro groups). Such impermissible substitution patterns are well knownto the skilled artisan.

It is appreciated that certain features of the invention, which are, forclarity, described in the context of separate embodiments, may also beprovided in combination in a single embodiment. Conversely, variousfeatures of the invention, which are, for brevity, described in thecontext of a single embodiment, may also be provided separately or inany suitable subcombination. All combinations of the embodimentspertaining to the chemical groups represented by the variables arespecifically embraced by the present invention and are disclosed hereinjust as if each and every combination was individually and explicitlydisclosed, to the extent that such combinations embrace compounds thatare stable compounds (i.e., compounds that can be isolated,characterized, and tested for biological activity). In addition, allsubcombinations of the chemical groups listed in the embodimentsdescribing such variables are also specifically embraced by the presentinvention and are disclosed herein just as if each and every suchsub-combination of chemical groups was individually and explicitlydisclosed herein.

Compounds

In one aspect, provided herein is a compound of formula (I):

wherein:

-   R₁ is substituted or unsubstituted C₁-C₆ alkyl, substituted or    unsubstituted C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈), —N(R₉)C(O)(R₁₀), or    halo;-   R₂ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;-   R₃ is H or halo;-   R₄ is H, or substituted or unsubstituted linear C₁-C₃ alkyl;-   L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—;    R₅ and R₆ are independently H, halo, —CN, or substituted or    unsubstituted C₁-C₆ alkyl, or R₅ and R₆ are taken together with the    carbon atom to which they are attached to form a substituted or    unsubstituted C₃-C₆ cycloalkyl;    R₇ and R₈ are independently H, or substituted or unsubstituted C₁-C₆    alkyl, or R₇ and R₈ are taken together with the nitrogen atom to    which they are attached to form a substituted or unsubstituted 3- to    7-membered heterocycloalkyl;-   R₉ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;-   R₁₀ is substituted or unsubstituted C₁-C₆ alkyl, substituted or    unsubstituted C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁);-   R₁₁ is substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;    M₁ and M₂ are independently halo, or substituted or unsubstituted    C₁-C₆ alkyl; and-   M₃ is H, halo, or substituted or unsubstituted C₁-C₆ alkyl, or M₃ is    taken together with M₂ and the carbon atoms to which they are    attached to form a 5- to 7-membered ring containing 0, 1, or 2    heteroatoms selected from the group consisting of N, O, and S,    or a pharmaceutically acceptable salt thereof.

In some embodiments, provided herein in the compound of formula (I), ora pharmaceutically acceptable salt thereof, wherein:

-   R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈),    —N(R₉)C(O)(R₁₀), or halo, wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl    are optionally substituted by 1-5 substituents selected from the    group consisting of —OH, oxo, —CN, and halo;-   R₂ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and    C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents    selected from the group consisting of —OH, —CN, and halo;-   R₃ is H or halo;-   R₄ is H or linear C₁-C₃ alkyl optionally substituted by 1-5    substituents selected from the group consisting of —OH, oxo, —CN,    halo, and —O(C₁-C₂ alkyl);-   L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—;    R₅ and R₆ are independently H, halo, —CN, or C₁-C₆ alkyl, or R₅ and    R₆ are taken together with the carbon atom to which they are    attached to form a C₃-C₆ cycloalkyl, wherein each C₁-C₆ alkyl or    C₃-C₆ cycloalkyl is optionally independently substituted by 1-5    substituents selected from the group consisting of —OH, —CN, and    halo;    R₇ and R₈ are independently H or C₁-C₆ alkyl, or R₇ and R₈ are taken    together with the nitrogen atom to which they are attached to form a    3- to 7-membered heterocycloalkyl, wherein each C₁-C₆ alkyl or 3- to    7-membered heterocycloalkyl is optionally independently substituted    by 1-5 substituents selected from the group consisting of —OH, —CN,    and halo;-   R₉ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and    C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents    selected from the group consisting of —OH, —CN, and halo;-   R₁₀ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁),    wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted    by 1-5 substituents selected from the group consisting of —OH, —CN,    and halo;-   R₁₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each of which is optionally    substituted by 1-5 substituents selected from the group consisting    of —OH, —CN, and halo;    M₁ and M₂ are independently halo or C₁-C₆ alkyl optionally    substituted by 1-5 substituents selected from the group consisting    of —OH, —CN, and halo; and-   M₃ is H, halo, or C₁-C₆ alkyl optionally substituted by 1-5    substituents selected from the group consisting of —OH, —CN, and    halo, or M₃ is taken together with M₂ and the carbon atoms to which    they are attached to form a 5- to 7-membered ring containing 0, 1,    or 2 heteroatoms selected from the group consisting of N, O, and S.

In some embodiments, R₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each ofwhich is optionally substituted by 1-5 substituents selected from thegroup consisting of —OH, oxo, —CN, and halo. In some embodiments, R₁ iscyclopropyl, isopropyl, ethyl, —CH(CH₂CH₃)₂, —CH(CH₃)(CH₂OH),—CH(OH)(CH₂CH₃), —CH(OH)(CH₃), —CH(CH₃)(CH₂CH₃), or —C(O)(CH₃).

In some embodiments, R₁ is substituted or unsubstituted C₁-C₆ alkyl. Insome embodiments, R₁ is C₁-C₆ alkyl optionally substituted by 1 to 4halogen atoms. In some embodiments, R₁ is C₁-C₆ alkyl optionallysubstituted by 1 to 4 chloro or fluoro atoms. In some embodiments, R₁ ismethyl, ethyl, propyl, isopropyl, butyl, pentyl, or hexyl. In someembodiments, R₁ is substituted or unsubstituted C₃-C₆ alkyl, such as anunsubstituted C₃-C₆ alkyl which in one aspect is a branched C₃-C₆ alkyl.In some embodiments, R₁ is isopropyl. In some embodiments, R₁ issubstituted or unsubstituted C₁-C₃ alkyl, such as an unsubstituted C₁-C₃alkyl which in one aspect is a linear C₁-C₃ alkyl. In some embodiments,R₁ is C₁-C₆ alkyl optionally substituted by 1-5 substituents selectedfrom the group consisting of —OH, oxo, —CN, and halo. In someembodiments, R₁ is C₁-C₆ alkyl optionally substituted by 1-3substituents selected from the group consisting of —OH, oxo, —CN, andhalo. In some embodiments, R₁ is C₁-C₆ alkyl optionally substituted by1-2 —OH groups. In some embodiments, R₁ is C₁-C₆ alkyl substituted byone —OH group, such as —CH(CH₃)(CH₂OH), —CH(OH)(CH₂CH₃), or—CH(OH)(CH₃). In some embodiments, R₁ is C₁-C₆ alkyl optionallysubstituted by one oxo group. In some embodiments, R₁ is C₁-C₆ alkylsubstituted by one oxo group, such as —C(O)(CH₃). In some embodiments,R₁ is unsubstituted C₁-C₆ alkyl, such as methyl, ethyl, isopropyl,—CH(CH₂CH₃)₂, or CH(CH₃)(CH₂CH₃). In some embodiments, R₁ is isopropyl,ethyl, —CH(CH₂CH₃)₂, —CH(CH₃)(CH₂OH), —CH(OH)(CH₂CH₃), —CH(OH)(CH₃),—CH(CH₃)(CH₂CH₃), or —C(O)(CH₃).

In some embodiments, R₁ is substituted or unsubstituted C₃-C₆cycloalkyl. In some embodiments, R₁ is C₃-C₆ cycloalkyl optionallysubstituted by 1 to 4 halogen atoms and/or 1 to 4 C₁-C₆ alkyl groups. Insome embodiments, R₁ is C₃-C₆ cycloalkyl optionally substituted by 1 to4 chloro or fluoro atoms. In some embodiments, R₁ is C₃-C₆ cycloalkyloptionally substituted by 1 to 4 C₁-C₆ alkyl groups. In someembodiments, R₁ is C₃-C₆ cycloalkyl optionally substituted by 1 or 2methyl, ethyl, or propyl groups. In some embodiments, R₁ is cyclopropyl,cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R₁ iscyclopropyl. In some embodiments, R₁ is C₃-C₆ cycloalkyl optionallysubstituted by 1-5 substituents selected from the group consisting of—OH, oxo, —CN, and halo. In some embodiments, R₁ is C₃-C₆ cycloalkyloptionally substituted by 1-3 substituents selected from the groupconsisting of —OH, oxo, —CN, and halo. In some embodiments, R₁ isunsubstituted C₃-C₆ cycloalkyl.

In some embodiments, R₁ is halo. In some embodiments, R₁ is fluoro,chloro, bromo, or iodo. In some embodiments, R₁ is fluoro or chloro. Insome embodiments, R₁ is chloro.

In some embodiments, R₁ is —C(O)N(R₇)(R₈). In some embodiments, R₇ andR₈ are independently H or substituted or unsubstituted C₁-C₆ alkyl. Insome embodiments, R₇ and R₈ are each H. In some embodiments, R₇ is H,and R₈ is substituted or unsubstituted C₁-C₆ alkyl. In some embodiments,R₇ is H, and R₈ is methyl, ethyl, propyl, isopropyl, or butyl. In someembodiments, R₇ and R₈ are independently substituted or unsubstitutedC₁-C₆ alkyl. In some embodiments, R₇ and R₈ are independently methyl,ethyl, propyl, isopropyl, or butyl. In any of these variations whereinR₇ and/or R₈ is C₁-C₆ alkyl, the C₁-C₆ alkyl group is optionallysubstituted by 1 to 4 halogen atoms. In some embodiments, R⁷ and R⁸ aretaken together with the nitrogen atom to which they are attached to forma 3- to 7-membered heterocycloalkyl optionally substituted by 1 to 4halogen atoms and/or 1 to 4 C₁-C₆ alkyl groups. In some embodiments, R⁷and R⁸ are taken together with the nitrogen atom to which they areattached to form a 3- to 5-membered heterocycloalkyl optionallysubstituted by 1 to 4 halogen atoms and/or 1 to 4 C₁-C₆ alkyl groups.

In some embodiments, R₁ is —N(R₉)C(O)(R₁₀). In some embodiments, R₉ isH. In some embodiments, R₉ is substituted or unsubstituted C₁-C₆ alkyl.In some embodiments, R₉ is methyl, ethyl, propyl, isopropyl, or butyl.In some embodiments, R₉ is substituted or unsubstituted C₃-C₆cycloalkyl. In some embodiments, R₉ is cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl. In some embodiments, R₁₀ is substituted orunsubstituted C₁-C₆ alkyl. In some embodiments, R₁₀ is methyl, ethyl,propyl, isopropyl, or butyl. In some embodiments, R₁₀ is substituted orunsubstituted C₃-C₆ cycloalkyl. In some embodiments, R₁₀ is cyclopropyl,cyclobutyl, cyclopentyl, or cyclohexyl. In any of these variationswherein R₉ and/or R₁₀ is C₁-C₆ alkyl, the C₁-C₆ alkyl group isoptionally substituted by 1 to 4 halogen atoms. In any of thesevariations wherein R₉ and/or R₁₀ is C₃-C₆ cycloalkyl, the C₃-C₆cycloalkyl group is optionally substituted by 1 to 4 halogen atomsand/or 1 to 4 C₁-C₆ alkyl groups. In some embodiments, R₉ is H and R₁₀is substituted or unsubstituted C₁-C₆ alkyl. In some embodiments, R₉ isH and R₁₀ is methyl. In some embodiments, R₉ is substituted orunsubstituted C₁-C₆ alkyl and R₁₀ is substituted or unsubstituted C₁-C₆alkyl. In some embodiments, R₉ and R₁₀ are each methyl.

In some embodiments where R₁ is —N(R₉)C(O)(R₁₀), R₁₀ is —N(R₇)(R₈). Insome embodiments, R₇ and R₈ are independently H or substituted orunsubstituted C₁-C₆ alkyl. In some embodiments, R₇ and R₈ are each H. Insome embodiments, R₇ is H, and R₈ is substituted or unsubstituted C₁-C₆alkyl. In some embodiments, R₇ is H, and R₈ is methyl, ethyl, propyl,isopropyl, or butyl. In some embodiments, R₇ and R₈ are independentlysubstituted or unsubstituted C₁-C₆ alkyl. In some embodiments, R₇ and R₈are independently methyl, ethyl, propyl, isopropyl, or butyl. In any ofthese variations wherein R₇ and/or R₈ is C₁-C₆ alkyl, the C₁-C₆ alkylgroup is optionally substituted by 1 to 4 halogen atoms. In someembodiments, R⁷ and R⁸ are taken together with the nitrogen atom towhich they are attached to form a 3- to 7-membered heterocycloalkyloptionally substituted by 1 to 4 halogen atoms and/or 1 to 4 C₁-C₆ alkylgroups. In some embodiments, R⁷ and R⁸ are taken together with thenitrogen atom to which they are attached to form a 3- to 5-memberedheterocycloalkyl optionally substituted by 1 to 4 halogen atoms and/or 1to 4 C₁-C₆ alkyl groups.

In some embodiments where R₁ is —N(R₉)C(O)(R₁₀), R₁₀ is —O(R₁₁). In someembodiments, R₁₁ is substituted or unsubstituted C₁-C₆ alkyl. In someembodiments, R₁₁ is C₁-C₆ alkyl optionally substituted by 1 to 4 halogenatoms. In some embodiments, R₁₁ is methyl, ethyl, propyl, isopropyl, orbutyl. In some embodiments, R₁₁ is substituted or unsubstituted C₃-C₆cycloalkyl. In some embodiments, R₁₁ is cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl. In some embodiments, R₁₁ is C₃-C₆ cycloalkyloptionally substituted by 1 to 4 halogen atoms and/or 1 to 4 C₁-C₆ alkylgroups.

In some embodiments, R₂ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, whereinC₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted by 1-5substituents selected from the group consisting of —OH, —CN, and halo.In some embodiments, R₂ is H or C₁-C₆ alkyl optionally substituted by1-5 substituents selected from the group consisting of —OH, —CN, andhalo. In some embodiments, R₂ is H or methyl.

In some embodiments, R₂ is H. In some embodiments, R₂ is substituted orunsubstituted C₁-C₆ alkyl. In some embodiments, R₂ is C₁-C₆ alkyloptionally substituted by 1 to 4 halogen atoms. In some embodiments, R₂is C₁-C₆ alkyl optionally substituted by 1 or 2 chloro or fluoro atoms.In some embodiments, R₂ is methyl, ethyl, propyl, isopropyl, butyl, orpentyl. In some embodiments, R₂ is methyl. In some embodiments, R₂ isC₁-C₆ alkyl optionally substituted by 1-5 substituents selected from thegroup consisting of —OH, —CN, and halo. In some embodiments, R₂ is C₁-C₆alkyl optionally substituted by 1-3 substituents selected from the groupconsisting of —OH, —CN, and halo. In some embodiments, R₂ isunsubstituted C₁-C₆ alkyl.

In some embodiments, R₃ is H. In some embodiments, R₃ is halo. In someembodiments, R₃ is fluoro, chloro, bromo, or iodo. In some embodiments,R₃ is fluoro or chloro.

In some embodiments, R₄ is H or linear C₁-C₃ alkyl optionallysubstituted by 1-5 substituents selected from the group consisting of—OH, oxo, —CN, halo, and —O(C₁-C₂ alkyl). In some embodiments, R₄ is Hor linear C₁-C₃ alkyl optionally substituted by 1-3 substituentsselected from the group consisting of —OH, oxo, —CN, halo, and —O(C₁-C₂alkyl). In some embodiments, R₄ is H, methyl, ethyl, —CH₂C(O)OCH₂CH₃,—CH₂CF₃, —CH₂CN, or —CH₂CHF₂.

In some embodiments, R₄ is H.

In some embodiments, R₄ is substituted or unsubstituted linear C₁-C₃alkyl. In some embodiments, R₄ is linear C₁-C₃ alkyl optionallysubstituted by 1 to 4 halogen atoms and/or 1 to 4 hydroxyl groups. Insome embodiments, R₄ is linear C₁-C₃ alkyl optionally substituted by 1to 2 halogen atoms and/or 1 to 2 hydroxyl groups. In some embodiments,R₄ is linear C₁-C₃ alkyl optionally substituted by 1 or 2 chloro orfluoro atoms. In some embodiments, R₄ is linear C₁-C₃ alkyl optionallysubstituted by 1 or 2 hydroxyl groups. In some embodiments, R₄ issubstituted or unsubstituted linear C₁-C₂ alkyl. In some embodiments, R₄is linear C₁-C₂ alkyl optionally substituted by 1 to 2 halogen atomsand/or 1 to 2 hydroxyl groups. In some embodiments, R₄ is unsubstitutedlinear C₁-C₃ alkyl. In some embodiments, R₄ is unsubstituted linearC₁-C₂ alkyl. In some embodiments, R₄ is methyl, ethyl, or propyl. Insome embodiments, R₄ is methyl. In some embodiments, R₄ is linear C₁-C₃alkyl optionally substituted by 1-5 substituents selected from the groupconsisting of —OH, oxo, —CN, halo, and —O(C₁-C₂ alkyl). In someembodiments, R₄ is linear C₁-C₃ alkyl optionally substituted by 1-3substituents selected from the group consisting of —OH, oxo, —CN, halo,and —O(C₁-C₂ alkyl). In some embodiments, R₄ is linear C₁-C₃ alkyloptionally substituted by 1-3 halo groups, such as chloro or fluoro. Insome embodiments, R₄ is linear C₁-C₃ alkyl optionally substituted by 1-3fluoro groups. In some embodiments, R₄ is —CF₃, —CH₂CF₃, or —CH₂CHF₂. Insome embodiments, R₄ is linear C₁-C₃ alkyl optionally substituted by oneoxo group. In some embodiments, R₄ is —CH₂C(O)CH₃, —C(O)CH₂CH₃, or—C(O)CH₃. In some embodiments, R₄ is linear C₁-C₃ alkyl optionallysubstituted with one —O(C₁-C₂ alkyl). In some embodiments, R₄ is—CH₂OCH₃, —CH₂OCH₂CH₃, or —CH₂CH₂OCH₃. In some embodiments, R₄ is linearC₁-C₃ alkyl optionally substituted by one oxo group and one —O(C₁-C₂alkyl) group. In some embodiments, R₄ is —CH₂C(O)OCH₃, —C(O)OCH₃, or—C(O)OCH₂CH₃. In some embodiments, R₄ is linear C₁-C₃ alkyl optionallysubstituted by 1-2 cyano groups. In some embodiments, R₄ is linear C₁-C₃alkyl optionally substituted by one cyano group. In some embodiments, R₄is —CH₂CN or —CH₂CH₂CN. It will be understood that when R₄ is linearC₁-C₃ alkyl optionally substituted by a carbon-containing moiety, suchas —CN and —O(C₁-C₂ alkyl), the total number of carbon atoms of R₄ mayexceed three. In some embodiments, R₄ is —CH₂CH₂CH₂CN. In someembodiments, R₄ is —CH₂C(O)OCH₂CH₃, —CH₂CH₂C(O)OCH₂CH₃, or—CH₂CH₂C(O)OCH₃. In some embodiments, R₄ is methyl, ethyl,—CH₂C(O)OCH₂CH₃, —CH₂CF₃, —CH₂CN, or —CH₂CHF₂.

In some embodiments, L is —O— or —C(O)—. In some embodiments, L is —O—.In some embodiments, L is —C(O)—. In some embodiments, L is —S—, —S(O)—,or —S(O)₂—. In some embodiments, L is —C(R₅)(R₆)—. In some embodiments,R₅ and R₆ are independently H, halo, —CN, or substituted orunsubstituted C₁-C₆ alkyl. In some embodiments, R₅ and R₆ are each H. Insome embodiments, R₅ and R₆ are independently C₁-C₆ alkyl optionallysubstituted by 1 to 4 halogen atoms. In some embodiments, R₅ is H and R₆is substituted or unsubstituted C₁-C₆ alkyl. In some embodiments, R₅ andR₆ are taken together with the carbon atom to which they are attached toform a substituted or unsubstituted C₃-C₆ cycloalkyl. In someembodiments, R₅ and R₆ are taken together with the carbon atom to whichthey are attached to form a C₃-C₆ cycloalkyl optionally substituted by 1to 4 halogen atoms and/or 1 to 4 C₁-C₆ alkyl groups. In someembodiments, L is —O—, —C(O)—, or —CH₂—.

In some embodiments, M₁ and M₂ are independently halo or C₁-C₆ alkyloptionally substituted by 1-5 substituents selected from the groupconsisting of —OH, —CN, and halo. In some embodiments, M₁ and M₂ areindependently halo or methyl. In some embodiments, M₁ and M₂ are eachchloro. In some embodiments, M₁ and M₂ are each methyl.

In some embodiments, M₁ and M₂ are independently halo, or substituted orunsubstituted C₁-C₆ alkyl. In some embodiments, M₁ and M₂ areindependently halo. In some embodiments, M₁ and M₂ are independentlyfluoro, chloro, bromo, or iodo. In some embodiments, M₁ and M₂ areindependently fluoro or chloro. In some embodiments, M₁ and M₂ are eachchloro. In some variations, at least one of M₁ and M₂ is substituted orunsubstituted C₁-C₆ alkyl. In some embodiments, at least one of M₁ andM₂ is C₁-C₆ alkyl optionally substituted by 1 to 4 halogen atoms. Insome embodiments, at least one of M₁ and M₂ is C₁-C₆ alkyl optionallysubstituted by 1 or 2 halogen atoms. In some embodiments, at least oneof M₁ and M₂ is C₁-C₄ alkyl optionally substituted by 1 or 2 fluoro orchloro atoms. In some embodiments, M₁ and M₂ are independently C₁-C₆alkyl optionally substituted by 1-5 substituents selected from the groupconsisting of —OH, —CN, and halo. In some embodiments, M₁ and M₂ areindependently C₁-C₆ alkyl optionally substituted by 1-3 substituentsselected from the group consisting of —OH, —CN, and halo. In someembodiments, M₁ and M₂ are independently unsubstituted C₁-C₆ alkyl. Insome embodiments, M₁ and M₂ are independently unsubstituted C₁-C₃ alkyl.In some embodiments, M₁ and M₂ are each methyl. In some embodiments, M₁and M₂ are the same. In other embodiments, M₁ and M₂ are different. Insome embodiments, M₁ is methyl and M₂ is ethyl. In some embodiments, M₁is ethyl and M₂ is methyl. In some embodiments, M₁ is methyl and M₂ ischloro. In some embodiments, M₁ is chloro and M₂ is methyl.

In some embodiments, M₃ is H, halo, or C₁-C₆ alkyl optionallysubstituted by 1-5 substituents selected from the group consisting of—OH, —CN, and halo, or M₃ is taken together with M₂ and the carbon atomsto which they are attached to form a 5- to 7-membered ring containing 0,1, or 2 heteroatoms selected from the group consisting of N, O, and S.In some embodiments, M₃ is H, halo, or C₁-C₃ alkyl optionallysubstituted by 1-3 substituents selected from the group consisting of—OH, —CN, and halo. In some embodiments, M₃ is H, F, or methyl.

In some embodiments, M₃ is H, halo, or substituted or unsubstitutedC₁-C₆ alkyl. In some embodiments, M₃ is H. In some embodiments, M₃ ishalo. In some embodiments, M₃ is fluoro, chloro, bromo, or iodo. In someembodiments, M₃ is fluoro. In some embodiments, M₃ is substituted orunsubstituted C₁-C₆ alkyl. In some embodiments, M₃ is C₁-C₆ optionallysubstituted by 1 to 4 halogen atoms. In some embodiments, M₃ is C₁-C₆optionally substituted by 1 or 2 fluoro or chloro atoms. In someembodiments, M₃ is methyl, ethyl, propyl, isopropyl, butyl, or pentyl.In some embodiments, M₃ is methyl. In some embodiments, M₃ is C₁-C₆alkyl optionally substituted by 1-5 substituents selected from the groupconsisting of —OH, —CN, and halo. In some embodiments, M₃ is C₁-C₆ alkyloptionally substituted by 1-3 substituents selected from the groupconsisting of —OH, —CN, and halo. In some embodiments, M₃ is —CH₂CN,—CH₂CH₂CN, —CH₂CH₂CH₂CN, —CH₂OH, —CH₂CH₂OH, —CH₂CH₂CH₂OH, —CF₃, —CHF₂,—CH₂F, —CCl₃, or —CHCl₂. In some embodiments, M₃ is unsubstituted C₁-C₆alkyl.

In some embodiments, M₃ is taken together with M₂ and the carbon atomsto which they are attached to form a 5- to 7-membered ring containing 0,1, or 2 heteroatoms selected from the group consisting of N, O, and S.In some embodiments, M₃ is taken together with M₂ and the carbon atomsto which they are attached to form a 5- to 7-membered ring containing 0heteroatoms. In some embodiments, M₃ is taken together with M₂ and thecarbon atoms to which they are attached to form a 5- to 7-membered ringcontaining 1 or 2 heteroatoms selected from the group consisting of N,O, and S. In some embodiments, M₃ is taken together with M₂ and thecarbon atoms to which they are attached to form a 5- to 7-membered ringcontaining 1 or 2 heteroatoms selected from the group consisting of Nand O. In some embodiments, M₃ is taken together with M₂ and the carbonatoms to which they are attached to form a 5- to 7-membered ringcontaining 1 heteroatom selected from the group consisting of N and O.In some embodiments, M₃ is taken together with M₂ and the carbon atomsto which they are attached to form a saturated 5- to 7-membered ringcontaining 0, 1, or 2 heteroatoms selected from the group consisting ofN, O, and S. In some embodiments, M₃ is taken together with M₂ and thecarbon atoms to which they are attached to form a partially unsaturated5- to 7-membered ring containing 0, 1, or 2 heteroatoms selected fromthe group consisting of N, O, and S. In some embodiments, M₃ is takentogether with M₂ and the carbon atoms to which they are attached to forman aromatic 5- to 7-membered ring containing 0, 1, or 2 heteroatomsselected from the group consisting of N, O, and S.

It is intended and understood that where present each and everyvariation of L described for formula (I) may be combined with each andevery variation of R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁, M₁, M₂and M₃ described for formula (I) the same as if each and everycombination is specifically and individually described. Similarly, it isintended and understand that each variable described for formula (I) maybe combined with each and every variable described for formula (I-a),(I-b), (I-c), and (I-d) below the same as if each and every combinationis specifically and individually described. In addition, allsubcombinations of the chemical groups listed in the embodimentsdescribing such variables are also specifically embraced by the presentinvention and are disclosed herein just as if each and every suchsub-combination of chemical groups was individually and explicitlydisclosed herein.

In some embodiments, the compound of formula (I) is of formula (I-a):

or a pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₄, andM₃ are as defined for the compound of formula (I). In some embodiments,R₁ is C₁-C₃ alkyl or C₃-C₅ cycloalkyl. In some embodiments, R₁ isisopropyl. In some embodiments, R₁ is cyclopropyl. In some embodiments,R₁ is C₁-C₆ alkyl optionally substituted by 1-5 substituents selectedfrom the group consisting of —OH, oxo, —CN, and halo. In someembodiments, R₁ is ethyl, —CH(CH₂CH₃)₂, —CH(CH₃)(CH₂OH),—CH(OH)(CH₂CH₃), —CH(OH)(CH₃), —CH(CH₃)(CH₂CH₃), or —C(O)(CH₃). In someembodiments, R₂ is H or C₁-C₃ alkyl. In some embodiments, R₂ is H. Insome embodiments, R₂ is methyl. In some embodiments, R₄ is H or linearC₁-C₃ alkyl. In some embodiments, R₄ is H. In some embodiments, R₄ ismethyl. In some embodiments, R₄ is linear C₁-C₃ alkyl optionallysubstituted by 1-5 substituents selected from the group consisting of—OH, oxo, —CN, halo, and —O(C₁-C₂ alkyl). In some embodiments, ethyl,—CH₂C(O)O(CH₂CH₃), —CH₂CF₃, —CH₂CN, or —CH₂CHF₂. In some embodiments, M₃is H or C₁-C₃ alkyl. In some embodiments, M₃ is H. In some embodiments,M₃ is methyl. In some embodiments, M₃ is halo. In some embodiments, M₃is F.

In some embodiments, the compound of formula (I) is of formula (I-b):

or a pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₄, andM₃ are as defined for the compound of formula (I). In some embodiments,R₁ is C₁-C₃ alkyl. In some embodiments, R₁ is isopropyl. In someembodiments, R₂ is H or C₁-C₃ alkyl. In some embodiments, R₂ is H. Insome embodiments, R₂ is methyl. In some embodiments, R₄ is H or linearC₁-C₃ alkyl. In some embodiments, R₄ is H. In some embodiments, R₄ ismethyl. In some embodiments, M₃ is H or C₁-C₃ alkyl. In someembodiments, M₃ is H. In some embodiments, M₃ is methyl.

In some embodiments, the compound of formula (I) is of formula (I-c):

or a pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₄, andM₃ are as defined for the compound of formula (I). In some embodiments,R₁ is C₁-C₃ alkyl. In some embodiments, R₁ is isopropyl. In someembodiments, R₂ is H or C₁-C₃ alkyl. In some embodiments, R₂ is H. Insome embodiments, R₂ is methyl. In some embodiments, R₄ is H or linearC₁-C₃ alkyl. In some embodiments, R₄ is H. In some embodiments, R₄ ismethyl. In some embodiments, M₃ is H or C₁-C₃ alkyl. In someembodiments, M₃ is H. In some embodiments, M₃ is methyl.

In some embodiments, the compound of formula (I) is of formula (I-d):

or a pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₄, andM₃ are as defined for the compound of formula (I). In some embodiments,R₁ is C₁-C₃ alkyl. In some embodiments, R₁ is isopropyl. In someembodiments, R₂ is H or C₁-C₃ alkyl. In some embodiments, R₂ is H. Insome embodiments, R₂ is methyl. In some embodiments, R₄ is H or linearC₁-C₃ alkyl. In some embodiments, R₄ is H. In some embodiments, R₄ ismethyl. In some embodiments, M₃ is H or C₁-C₃ alkyl. In someembodiments, M₃ is H. In some embodiments, M₃ is methyl.

In some embodiments, the compound of formula (I) is an agonist of THRbeta. In some embodiments, the compound of formula (I) is an agonist ofTHR beta and is selective over THR alpha. In some embodiments, thecompound of formula (I) has at least 2-fold selectivity for THR betaover THR alpha. In some embodiments, the compound of formula (I) has atleast 5-fold selectivity for THR beta over THR alpha. In someembodiments, the compound of formula (I) has at least 10-foldselectivity for THR beta over THR alpha. In some embodiments, thecompound of formula (I) has at least 20-fold selectivity for THR betaover THR alpha. In some embodiments, the compound of formula (I) has atleast 50-fold selectivity for THR beta over THR alpha. In someembodiments, the compound of formula (I) has at least 75-foldselectivity for THR beta over THR alpha. In some embodiments, thecompound of formula (I) has at least 100-fold selectivity for THR betaover THR alpha. In some embodiments, the compound of formula (I) has atleast 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-,45-, 50-, 55-, 60-, 65-, 70-, 75-, 80-, 85-, 90-, 95-, or 100-foldselectivity for THR beta over THR alpha. In any such embodiment, in oneaspect selectivity is assessed via a biochemical assay, such as theTR-FRET assay described in Example B1.

In one embodiment, provided herein is a compound of formula (I) selectedfrom those listed in Table 1 below, or a pharmaceutically acceptablesalt thereof:

TABLE 1 Compound Structure and Number

1

2

3

4 *

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

31 P1 **

31 P2 **

32

33 P1 **

33 P2 **

34

35 * Compound 4 does not fall within the scope of formula (I) and isprovided for comparative purposes only. ** Biological data reported inTable 2 for the compounds whose stereochemistry is arbitrarily assignedin Table 1 can be associated with the appropriate compound of Table 1 byreference to the corresponding synthetic example details. It is thuspossible that the compound associated with a given chiral chromatographyelution pattern and biological data set will have the same absolutestereochemistry or a different absolute stereochemistry from thecompound whose stereochemistry is arbitrarily assigned in Table 1.

In some embodiments, the compound of formula (I) is selected fromCompounds 1-3 and 5-35, or a pharmaceutically acceptable salt thereof.

In some embodiments, provided herein is a compound selected from thegroup consisting of:

or a pharmaceutically acceptable salt thereof.

The invention also includes all salts, such as pharmaceuticallyacceptable salts, of compounds referred to herein. The invention alsoincludes any or all of the stereochemical forms, including anyenantiomeric or diastereomeric forms, and any tautomers or other forms,such as N-oxides, solvates, prodrugs, or isotopomers, of the compoundsdescribed. Unless stereochemistry is explicitly indicated in a chemicalstructure or name, the structure or name is intended to embrace allpossible stereoisomers of a compound depicted. In addition, where aspecific stereochemical form is depicted, it is understood that otherstereochemical forms are also embraced by the invention. All forms ofthe compounds are also embraced by the invention, such as crystalline ornon-crystalline forms of the compounds. Compositions comprising acompound of the invention are also intended, such as a composition ofsubstantially pure compound, including a specific stereochemical formthereof. Compositions comprising a mixture of compounds of the inventionin any ratio are also embraced by the invention, including mixtures oftwo or more stereochemical forms of a compound of the invention in anyratio, such that racemic, non-racemic, enantioenriched and scalemicmixtures of a compound are embraced.

Methods of Synthesis—General Schemes

Schemes S1-S8 below show synthetic routes for preparing the compounds ofthe present disclosure. In each of Schemes S1-S8, variables R₁, R₂, R₃,R₄, M₁, M₂, and M₃ are as defined for the compound of formula (I),unless specified otherwise; additional variables V, T, and W (where EWGis an appropriate electron-withdrawing group) are as defined in thespecific schemes; and variable R is H or a suitable boronic esterprotecting group, such as an alkyl.

Scheme S1 shows a general synthesis for compounds of formula (I) whereinL is O or S.

Scheme S2 outlines a general synthesis for compounds of formula (I)wherein L is —C(O)—.

Scheme S3 shows a general synthesis for compounds of formula (I) whereinL is —CH₂—.

Scheme S4 shows a general synthesis for compounds of formula (I) whereinL is —S(O)— or —S(O)₂—.

Scheme S5 shows a general synthesis for compounds of formula (I) whereinL is —CHF—.

Scheme S6 shows a general synthesis for compounds of formula (I) whereinL is —CF₂—.

Scheme S7 outlines a general synthesis for compounds of formula (I)wherein L is —CH(CH₃)—.

Scheme S8 shows a general synthesis for compounds of formula (I) whereinL is

Synthesis of certain compounds provided herein are schematicallyillustrated above and provided in the Examples section below. Synthesisof other compounds provided herein will be apparent to the skilledartisan based on the guidance provided herein and based on syntheticmethods well known to the skilled artisan.

Where it is desired to obtain a particular enantiomer of a compound,this may be accomplished from a corresponding mixture of enantiomersusing any suitable conventional procedure for separating or resolvingenantiomers. Thus, for example, diastereomeric derivatives may beproduced by reaction of a mixture of enantiomers, e.g., a racemate, andan appropriate chiral compound. The diastereomers may then be separatedby any convenient means, for example by crystallization, and the desiredenantiomer recovered. In another resolution process, a racemate may beseparated using chiral High Performance Liquid Chromatography.Alternatively, if desired a particular enantiomer may be obtained byusing an appropriate chiral intermediate in one of the processesdescribed.

Chromatography, recrystallization and other conventional separationprocedures may also be used with intermediates or final products whereit is desired to obtain a particular isomer of a compound or tootherwise purify a product of a reaction.

Solvates and/or polymorphs of a compound provided herein or apharmaceutically acceptable salt thereof are also contemplated. Solvatescontain either stoichiometric or non-stoichiometric amounts of asolvent, and are often formed during the process of crystallization.Hydrates are formed when the solvent is water, or alcoholates are formedwhen the solvent is alcohol. Polymorphs include the different crystalpacking arrangements of the same elemental composition of a compound.Polymorphs usually have different X-ray diffraction patterns, infraredspectra, melting points, density, hardness, crystal shape, optical andelectrical properties, stability, and/or solubility. Various factorssuch as the recrystallization solvent, rate of crystallization, andstorage temperature may cause a single crystal form to dominate.

It is understood that the synthetic process disclosed here may bemodified to arrive at various compounds of the invention by selection ofappropriate reagents and starting materials. It is also understood thatwhere protection of certain active or incompatible groups (e.g., anamine or a carboxylic acid) is required, the formulae in e.g., thescheme(s) provided here intend and include compounds where such activeor incompatible groups are in appropriate protected forms. For a generaldescription of protecting groups and their use, see P. G. M. Wuts and T.W. Greene, Greene's Protective Groups in Organic Synthesis 4^(th)edition, Wiley-Interscience, New York, 2006.

Pharmaceutical Compositions and Formulations

Pharmaceutical compositions of any of the compounds detailed herein areembraced by this invention. Thus, the invention includes pharmaceuticalcompositions comprising a compound of the invention or apharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable carrier or excipient. In one aspect, the pharmaceuticallyacceptable salt is an acid addition salt, such as a salt formed with aninorganic or organic acid. Pharmaceutical compositions according to theinvention may take a form suitable for oral, buccal, parenteral, nasal,topical or rectal administration or a form suitable for administrationby inhalation.

A compound as detailed herein may in one aspect be in a purified formand compositions comprising a compound in purified forms are detailedherein. Compositions comprising a compound as detailed herein or a saltthereof are provided, such as compositions of substantially purecompounds. In some embodiments, a composition containing a compound asdetailed herein or a salt thereof is in substantially pure form. In onevariation, “substantially pure” intends a composition that contains nomore than 10% impurity, wherein the impurity denotes a compound otherthan the compound comprising the majority of the composition or a saltthereof. For example, a composition of a substantially pure compoundselected from a compound of Table 1 intends a composition that containsno more than 10% impurity, wherein the impurity denotes a compound otherthan the compound or a salt thereof. In one variation, a composition ofsubstantially pure compound or a salt thereof is provided wherein thecomposition contains no more than 5% impurity. In another variation, acomposition of substantially pure compound or a salt thereof is providedwherein the composition contains or no more than 2% impurity. In stillanother variation, a composition of substantially pure compound or asalt thereof is provided wherein the composition contains or no morethan 1% impurity. In a further variation, a composition of substantiallypure compound or a salt thereof is provided wherein the compositioncontains or no more than 0.5% impurity. In yet other variations, acomposition of substantially pure compound means that the compositioncontains no more than 10% or preferably no more than 5% or morepreferably no more than 1% or even more preferably no more than 0.5% andmost preferably no more than 0.1% impurity, which impurity may be thecompound in a different stereochemical form. For instance, and withoutlimitation, a composition of substantially pure (S) compound means thatthe composition contains no more than 10% or no more than 5% or no morethan 3% or no more than 1% or no more than 0.5% of the (R) form of thecompound.

In one variation, the compounds herein are synthetic compounds preparedfor administration to a patient such as a human. In another variation,pharmaceutical compositions are provided containing a compound insubstantially pure form. In another variation, the invention embracespharmaceutical compositions comprising a compound detailed herein and apharmaceutically acceptable carrier or excipient. In another variation,methods of administering a compound are provided. The purified forms,pharmaceutical compositions and methods of administering the compoundsare suitable for any compound or form thereof detailed herein.

The compound may be formulated for any available delivery route,including an oral, mucosal (e.g., nasal, sublingual, vaginal, buccal orrectal), parenteral (e.g., intramuscular, subcutaneous or intravenous),topical or transdermal delivery form. A compound may be formulated withsuitable carriers to provide delivery forms that include, but are notlimited to, tablets, caplets, capsules (such as hard gelatin capsules orsoft elastic gelatin capsules), cachets, troches, lozenges, gums,dispersions, suppositories, ointments, cataplasms (poultices), pastes,powders, dressings, creams, solutions, patches, aerosols (e.g., nasalspray or inhalers), gels, suspensions (e.g., aqueous or non-aqueousliquid suspensions, oil-in-water emulsions or water-in-oil liquidemulsions), solutions and elixirs.

One or several compounds described herein can be used in the preparationof a formulation, such as a pharmaceutical formulation, by combining thecompound or compounds as an active ingredient with a pharmaceuticallyacceptable carrier, such as those mentioned above. Depending on thetherapeutic form of the system (e.g., transdermal patch vs. oraltablet), the carrier may be in various forms. In addition,pharmaceutical formulations may contain preservatives, solubilizers,stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters,and salts for the adjustment of osmotic pressure, buffers, coatingagents or antioxidants. Formulations comprising the compound may alsocontain other substances which have valuable therapeutic properties.Pharmaceutical formulations may be prepared by known pharmaceuticalmethods. Suitable formulations can be found, e.g., in Remington: TheScience and Practice of Pharmacy, Lippincott Williams & Wilkins, 21^(st)ed. (2005), which is incorporated herein by reference.

Compounds as described herein may be administered to patients (e.g., ahuman) in a form of generally accepted oral compositions, such astablets, coated tablets, and gel capsules in a hard or in soft shell,emulsions or suspensions. Examples of carriers, which may be used forthe preparation of such compositions, are lactose, corn starch or itsderivatives, talc, stearate or its salts, etc. Acceptable carriers forgel capsules with soft shell are, for instance, plant oils, wax, fats,semisolid and liquid polyols, and so on. In addition, pharmaceuticalformulations may contain preservatives, solubilizers, stabilizers,re-wetting agents, emulgators, sweeteners, dyes, adjusters, and saltsfor the adjustment of osmotic pressure, buffers, coating agents orantioxidants.

Any of the compounds described herein can be formulated in a tablet inany dosage form described.

Pharmaceutical compositions, such as pharmaceutical compositions,comprising a compound provided herein, or a pharmaceutically acceptablesalt thereof, are also described. In one variation, the compositioncomprises a compound, or a pharmaceutically acceptable salt thereof, anda pharmaceutically acceptable carrier or excipient. In anothervariation, a composition of substantially pure compound, or apharmaceutically acceptable salt thereof, is provided.

Methods of Use/Treatment

Compounds and compositions detailed herein, such as a pharmaceuticalcomposition containing a compound of any formula provided herein, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier or excipient, may be used in methods ofadministration and treatment as provided herein. The compounds andcompositions may also be used in in vitro methods, such as in vitromethods of administering a compound, or a salt thereof, or compositionto cells for screening purposes and/or for conducting quality controlassays.

In one aspect, provided herein is a method of agonizing thyroid hormonereceptor beta (THR beta) comprising contacting either an effectiveamount of a compound provided herein, or a salt thereof, such as apharmaceutically acceptable salt thereof, or an effective amount of apharmaceutical composition provided herein, with the THR beta. In oneaspect, provided herein is a method of selectively agonizing THR betaover THR alpha comprising contacting either an effective amount of acompound provided herein, or a pharmaceutically acceptable salt thereof,or an effective amount of a pharmaceutical composition provided herein,with the THR beta. In one such aspect, the method selectively agonizesTHR beta over THR alpha by at least 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-,15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 55-, 60-, 65-, 70-, 75-, 80-,85-, 90-, 95-, or 100-fold. In any such embodiment, in one aspectselectivity is assessed via a biochemical assay, such as the TR-FRETassay described in Example B1.

In one aspect, provided herein is a method of treating a disease ordisorder that is mediated by THR beta in a patient in need thereof,comprising administering to the patient a therapeutically effectiveamount of a compound provided herein, or a therapeutically effectiveamount of a composition provided herein. In one aspect, the disease ordisorder is a liver disease or disorder. In one aspect, provided hereinis a method of treating a disease or disorder of the liver associatedwith sub-optimal THR beta agonism in a patient in need thereof,comprising administering to the patient a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein the compoundselectively agonizes THR beta over THR alpha.

In one aspect, provided herein is a method of treating non-alcoholicfatty liver disease in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound provided herein, or a therapeutically effective amount of acomposition provided herein. In one aspect, provided herein is a methodof treating non-alcoholic steatohepatitis (NASH) in a patient in needthereof, comprising administering to the patient a therapeuticallyeffective amount of a compound provided herein, or a therapeuticallyeffective amount of a composition provided herein. In one aspect,provided herein is a method of treating metabolic syndrome in a patientin need thereof, comprising administering to the patient atherapeutically effective amount of a compound provided herein, or atherapeutically effective amount of a composition provided herein. Inone aspect, provided herein is a method of treating dyslipidemia in apatient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound provided herein, or atherapeutically effective amount of a composition provided herein. Inone aspect, provided herein is a method of treating hypertriglyceridemiain a patient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound provided herein, or atherapeutically effective amount of a composition provided herein. Inone aspect, provided herein is a method of treating hypercholesterolemiain a patient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound provided herein, or atherapeutically effective amount of a composition provided herein.

In any of the embodiments described herein, a patient having a diseaseor disorder associated with THR beta agonism may include, but is notlimited to, a patient with an underlying hypothyroid disorder.

In another aspect is provided a method of delaying the onset and/ordevelopment of a disease or disorder that is mediated by THR beta in apatient (such as a human) who is at risk for developing the disease ordisorder. It is appreciated that delayed development may encompassprevention in the event the individual does not develop the disease ordisorder. An individual at risk of developing a disease or disorder thatis mediated by THR beta in one aspect has one or more risk factors fordeveloping the disease or disorder, such as age, increased waistcircumference, high body to mass index or the presence of an associatedcomorbidity.

In one aspect, provided herein is a method of delaying the onset and/ordevelopment of non-alcoholic fatty liver disease in a patient in needthereof, comprising administering to the patient a therapeuticallyeffective amount of a compound provided herein, or a therapeuticallyeffective amount of a composition provided herein. In one aspect,provided herein is a method of delaying the onset and/or development ofnon-alcoholic steatohepatitis (NASH) in a patient in need thereof,comprising administering to the patient a therapeutically effectiveamount of a compound provided herein, or a therapeutically effectiveamount of a composition provided herein. In one aspect, provided hereinis a method of delaying the onset and/or development of metabolicsyndrome in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of a compound providedherein, or a therapeutically effective amount of a composition providedherein. In one aspect, provided herein is a method of delaying the onsetand/or development of dyslipidemia in a patient in need thereof,comprising administering to the patient a therapeutically effectiveamount of a compound provided herein, or a therapeutically effectiveamount of a composition provided herein. In one aspect, provided hereinis a method of delaying the onset and/or development ofhypertriglyceridemia in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound provided herein, or a therapeutically effective amount of acomposition provided herein. In one aspect, provided herein is a methodof delaying the onset and/or development of hypercholesterolemia in apatient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound provided herein, or atherapeutically effective amount of a composition provided herein.

In one aspect, provided herein is a compound of formula (I) or anyvariation thereof, or a pharmaceutically acceptable salt thereof, foruse in therapy. In some embodiments, provided herein is a compound offormula (I) or any variation thereof, or a pharmaceutically acceptablesalt thereof, or a pharmaceutical composition comprising such compoundor a pharmaceutically acceptable salt thereof, for use in the treatmentof non-alcoholic fatty liver disease. In some embodiments, providedherein is a compound of formula (I) or any variation thereof, or apharmaceutically acceptable salt thereof or pharmaceutical compositioncomprising such compound, or a pharmaceutically acceptable salt thereof,for use in the treatment of non-alcoholic steatohepatitis (NASH). Insome embodiments, provided is a compound of formula (I) or any variationthereof, or a pharmaceutically acceptable salt thereof, or apharmaceutical composition comprising such compound or apharmaceutically acceptable salt thereof, for use in the treatment ofmetabolic syndrome. In some embodiments, provided is a compound offormula (I) or any variation thereof, or a pharmaceutically acceptablesalt thereof, or a pharmaceutical composition comprising such compoundor a pharmaceutically acceptable salt thereof, for use in the treatmentof dyslipidemia. In some embodiments, provided is a compound of formula(I) or any variation thereof, or a pharmaceutically acceptable saltthereof, or a pharmaceutical composition comprising such compound or apharmaceutically acceptable salt thereof, for use in the treatment ofhypertriglyceridemia. In some embodiments, provided is a compound offormula (I) or any variation thereof, or a pharmaceutically acceptablesalt thereof, or a pharmaceutical composition comprising such compoundor a pharmaceutically acceptable salt thereof, for use in the treatmentof hypercholesterolemia.

In another embodiment, provided herein is a compound of formula (I) orany variation thereof, or a pharmaceutically acceptable salt thereof,for use in the manufacture of a medicament for the treatment ofnon-alcoholic fatty liver disease. In another embodiment, providedherein is a compound of formula (I) or any variation thereof, or apharmaceutically acceptable salt thereof, for use in the manufacture ofa medicament for the treatment of non-alcoholic steatohepatitis (NASH).In another embodiment, provided herein is a compound of formula (I) orany variation thereof, or a pharmaceutically acceptable salt thereof,for use in the manufacture of a medicament for the treatment ofmetabolic syndrome. In some embodiments, the medicament is for thetreatment of dyslipidemia. In some embodiments, the medicament is forthe treatment of hypertriglyceridemia. In some embodiments, themedicament is for the treatment of dyslipidemia. In some embodiments,the medicament is for the treatment of hypercholesterolemia.

In some embodiments, the individual is a mammal. In some embodiments,the individual is a primate, dog, cat, rabbit, or rodent. In someembodiments, the individual is a primate. In some embodiments, theindividual is a human. In some embodiments, the human is at least aboutor is about any of 18, 21, 30, 50, 60, 65, 70, 75, 80, or 85 years old.In some embodiments, the human is a child. In some embodiments, thehuman is less than about or about any of 21, 18, 15, 10, 5, 4, 3, 2, or1 years old.

Dosing and Method of Administration

The dose of a compound described herein, or a stereoisomer, tautomer,solvate, or salt thereof, administered to an individual (such as ahuman) may vary with the particular compound or salt thereof, the methodof administration, and the particular disease or disorder, such asnon-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH),metabolic syndrome, hypertriglyceridemia, dyslipidemia, orhypercholesterolemia, being treated. In some embodiments, the amount ofthe compound, or a stereoisomer, tautomer, solvate, or salt thereof, isa therapeutically effective amount.

The compounds provided herein, or a salt thereof, may be administered toan individual via various routes, including, e.g., intravenous,intramuscular, subcutaneous, oral, and transdermal.

The effective amount of the compound may in one aspect be a dose ofbetween about 0.01 and about 100 mg/kg. Effective amounts or doses ofthe compounds of the present disclosure may be ascertained by routinemethods, such as modeling, dose escalation, or clinical trials, takinginto account routine factors, e.g., the mode or route of administrationor drug delivery, the pharmacokinetics of the agent, the severity andcourse of the disease to be treated, the subject's health status,condition, and weight. An exemplary dose is in the range of about fromabout 0.7 mg to 7 g daily, or about 7 mg to 350 mg daily, or about 350mg to 1.75 g daily, or about 1.75 to 7 g daily.

Any of the methods provided herein may in one aspect compriseadministering to an individual a pharmaceutical composition thatcontains an effective amount of a compound provided herein, or astereoisomer, tautomer, solvate, or salt thereof, and a pharmaceuticallyacceptable excipient.

A compound or composition provided herein may be administered to anindividual in accordance with an effective dosing regimen for a desiredperiod of time or duration, such as at least about one month, at leastabout 2 months, at least about 3 months, at least about 6 months, or atleast about 12 months or longer, which in some variations may be for theduration of the individual's life. In one variation, the compound isadministered on a daily or intermittent schedule. The compound can beadministered to an individual continuously (for example, at least oncedaily) over a period of time. The dosing frequency can also be less thanonce daily, e.g., about a once weekly dosing. The dosing frequency canbe more than once daily, e.g., twice or three times daily. The dosingfrequency can also be intermittent, including a ‘drug holiday’ (e.g.,once daily dosing for 7 days followed by no doses for 7 days, repeatedfor any 14 day time period, such as about 2 months, about 4 months,about 6 months or more). Any of the dosing frequencies can employ any ofthe compounds described herein together with any of the dosagesdescribed herein.

Articles of Manufacture and Kits

The present disclosure further provides articles of manufacturecomprising a compound described herein, or a salt thereof, a compositiondescribed herein, or one or more unit dosages described herein insuitable packaging. In certain embodiments, the article of manufactureis for use in any of the methods described herein. Suitable packaging isknown in the art and includes, for example, vials, vessels, ampules,bottles, jars, flexible packaging and the like. An article ofmanufacture may further be sterilized and/or sealed.

The present disclosure further provides kits for carrying out themethods of the present disclosure, which comprises one or more compoundsdescribed herein, or a pharmaceutically acceptable salt thereof, or acomposition comprising a compound described herein, or apharmaceutically acceptable salt thereof. The kits may employ any of thecompounds disclosed herein or a pharmaceutically acceptable saltthereof. In one variation, the kit employs a compound described hereinor a pharmaceutically acceptable salt thereof. The kits may be used forany one or more of the uses described herein, and, accordingly, maycontain instructions for the treatment of any disease or describedherein, for example for the treatment of non-alcoholic steatohepatitis(NASH).

Kits generally comprise suitable packaging. The kits may comprise one ormore containers comprising any compound described herein or apharmaceutically acceptable salt thereof. Each component (if there ismore than one component) can be packaged in separate containers or somecomponents can be combined in one container where cross-reactivity andshelf life permit.

The kits may be in unit dosage forms, bulk packages (e.g., multi-dosepackages) or sub-unit doses. For example, kits may be provided thatcontain sufficient dosages of a compound as disclosed herein, or apharmaceutically acceptable salt thereof, and/or an additionalpharmaceutically active compound useful for a disease detailed herein toprovide effective treatment of an individual for an extended period,such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kitsmay also include multiple unit doses of the compounds and instructionsfor use and be packaged in quantities sufficient for storage and use inpharmacies (e.g., hospital pharmacies and compounding pharmacies).

The kits may optionally include a set of instructions, generally writteninstructions, although electronic storage media (e.g., magnetic disketteor optical disk) containing instructions are also acceptable, relatingto the use of component(s) of the methods of the present disclosure. Theinstructions included with the kit generally include information as tothe components and their administration to an individual.

Exemplary Embodiments

The present disclosure is further described by the followingembodiments. The features of each of the embodiments are combinable withany of the other embodiments where appropriate and practical.

Embodiment 1. A Compound of Formula (I)

wherein:R₁ is substituted or unsubstituted C₁-C₆ alkyl, substituted orunsubstituted C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈), —N(R₉)C(O)(R₁₀), orhalo;R₂ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted orunsubstituted C₃-C₆ cycloalkyl;R₃ is H or halo;R₄ is H, or substituted or unsubstituted linear C₁-C₃ alkyl;L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—;R₅ and R₆ are independently H, halo, —CN, or substituted orunsubstituted C₁-C₆ alkyl, or R₅ and R₆ are taken together with thecarbon atom to which they are attached to form a substituted orunsubstituted C₃-C₆ cycloalkyl;R₇ and R₈ are independently H, or substituted or unsubstituted C₁-C₆alkyl, or R₇ and R₈ are taken together with the nitrogen atom to whichthey are attached to form a substituted or unsubstituted 3- to7-membered heterocycloalkyl;R₉ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted orunsubstituted C₃-C₆ cycloalkyl;R₁₀ is substituted or unsubstituted C₁-C₆ alkyl, substituted orunsubstituted C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁);R₁₁ is substituted or unsubstituted C₁-C₆ alkyl, or substituted orunsubstituted C₃-C₆ cycloalkyl;M₁ and M₂ are independently halo, or substituted or unsubstituted C₁-C₆alkyl; andM₃ is H, halo, or substituted or unsubstituted C₁-C₆ alkyl, or M₃ istaken together with M₂ and the carbon atoms to which they are attachedto form a 5- to 7-membered ring containing 0, 1, or 2 heteroatomsselected from the group consisting of N, O, and S,or a pharmaceutically acceptable salt thereof.

Embodiment 2. The compound of embodiment 1, or a pharmaceuticallyacceptable salt thereof, wherein R₁ is substituted or unsubstitutedC₁-C₆ alkyl or substituted or unsubstituted C₃-C₆ cycloalkyl.

Embodiment 3. The compound of embodiment 2, or a pharmaceuticallyacceptable salt thereof, wherein R₁ is isopropyl.

Embodiment 4. The compound of embodiment 2, or a pharmaceuticallyacceptable salt thereof, wherein R₁ is cyclopropyl.

Embodiment 5. The compound of any one of embodiments 1-4, or apharmaceutically acceptable salt thereof, wherein R₂ is substituted orunsubstituted C₁-C₆ alkyl.

Embodiment 6. The compound of embodiment 5, or a pharmaceuticallyacceptable salt thereof, wherein R₂ is methyl.

Embodiment 7. The compound of any one of embodiments 1-4, or apharmaceutically acceptable salt thereof, wherein R₂ is H.

Embodiment 8. The compound of any one of embodiments 1-7, or apharmaceutically acceptable salt thereof, wherein R₃ is H.

Embodiment 9. The compound of any one of embodiments 1-8, or apharmaceutically acceptable salt thereof, wherein R₄ is H.

Embodiment 10. The compound of any one of embodiments 1-8, or apharmaceutically acceptable salt thereof, wherein R₄ is substituted orunsubstituted linear C₁-C₃ alkyl.

Embodiment 11. The compound of embodiment 10, or a pharmaceuticallyacceptable salt thereof, wherein R₄ is methyl.

Embodiment 12. The compound of any one of embodiments 1-11, or apharmaceutically acceptable salt thereof, wherein L is —O—.

Embodiment 13. The compound of any one of embodiments 1-11, or apharmaceutically acceptable salt thereof, wherein L is —C(O)—.

Embodiment 14. The compound of any one of embodiments 1-11, or apharmaceutically acceptable salt thereof, wherein L is —CH₂—.

Embodiment 15. The compound of any one of embodiments 1-14, or apharmaceutically acceptable salt thereof, wherein M₁ and M₂ areindependently halo.

Embodiment 16. The compound of embodiment 15, or a pharmaceuticallyacceptable salt thereof, wherein M₁ and M₂ are each chloro.

Embodiment 17. The compound of any one of embodiments 1-16, or apharmaceutically acceptable salt thereof, wherein M₃ is H.

Embodiment 18. The compound of any one of embodiments 1-16, or apharmaceutically acceptable salt thereof, wherein M₃ is substituted orunsubstituted C₁-C₆ alkyl.

Embodiment 19. The compound of embodiment 18, or a pharmaceuticallyacceptable salt thereof, wherein M₃ is methyl.

Embodiment 20. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

Embodiment 21. A pharmaceutical composition comprising the compound ofany one of embodiments 1-20, or a pharmaceutically acceptable saltthereof, and a pharmaceutically acceptable excipient.

Embodiment 22. A method of agonizing thyroid hormone receptor beta (THRbeta) comprising contacting an effective amount of the compound of anyone of embodiments 1-20, or a pharmaceutically acceptable salt thereof,or an effective amount of the pharmaceutical composition of embodiment21, with the THR beta.

Embodiment 23. A method of treating a disorder which is mediated by THRbeta in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of the compound of any one ofembodiments 1-20, or a pharmaceutically acceptable salt thereof, or atherapeutically effective amount of the pharmaceutical composition ofembodiment 21.

Embodiment 24. A compound of formula (I):

wherein:

-   R₁ is substituted or unsubstituted C₁-C₆ alkyl, substituted or    unsubstituted C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈), —N(R₉)C(O)(R₁₀), or    halo;-   R₂ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;-   R₃ is H or halo;-   R₄ is H, or substituted or unsubstituted linear C₁-C₃ alkyl;-   L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—;    R₅ and R₆ are independently H, halo, —CN, or substituted or    unsubstituted C₁-C₆ alkyl, or R₅ and R₆ are taken together with the    carbon atom to which they are attached to form a substituted or    unsubstituted C₃-C₆ cycloalkyl;    R₇ and R₈ are independently H, or substituted or unsubstituted C₁-C₆    alkyl, or R₇ and R₈ are taken together with the nitrogen atom to    which they are attached to form a substituted or unsubstituted 3- to    7-membered heterocycloalkyl;-   R₉ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;-   R₁₀ is substituted or unsubstituted C₁-C₆ alkyl, substituted or    unsubstituted C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁);-   R₁₁ is substituted or unsubstituted C₁-C₆ alkyl, or substituted or    unsubstituted C₃-C₆ cycloalkyl;    M₁ and M₂ are independently halo, or substituted or unsubstituted    C₁-C₆ alkyl; and-   M₃ is H, halo, or substituted or unsubstituted C₁-C₆ alkyl, or M₃ is    taken together with M₂ and the carbon atoms to which they are    attached to form a 5- to 7-membered ring containing 0, 1, or 2    heteroatoms selected from the group consisting of N, O, and S, or a    pharmaceutically acceptable salt thereof.

Embodiment 25. The compound of embodiment 24, or a pharmaceuticallyacceptable salt thereof, wherein:

-   R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈),    —N(R₉)C(O)(R₁₀), or halo, wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl    are optionally substituted by 1-5 substituents selected from the    group consisting of —OH, oxo, —CN, and halo;-   R₂ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and    C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents    selected from the group consisting of —OH, —CN, and halo;-   R₃ is H or halo;-   R₄ is H or linear C₁-C₃ alkyl optionally substituted by 1-5    substituents selected from the group consisting of —OH, oxo, —CN,    halo, and —O(C₁-C₂ alkyl);-   L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—;    R₅ and R₆ are independently H, halo, —CN, or C₁-C₆ alkyl, or R₅ and    R₆ are taken together with the carbon atom to which they are    attached to form a C₃-C₆ cycloalkyl, wherein each C₁-C₆ alkyl or    C₃-C₆ cycloalkyl is optionally independently substituted by 1-5    substituents selected from the group consisting of —OH, —CN, and    halo;    R₇ and R₈ are independently H or C₁-C₆ alkyl, or R₇ and R₈ are taken    together with the nitrogen atom to which they are attached to form a    3- to 7-membered heterocycloalkyl, wherein each C₁-C₆ alkyl or 3- to    7-membered heterocycloalkyl is optionally independently substituted    by 1-5 substituents selected from the group consisting of —OH, —CN,    and halo;-   R₉ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and    C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents    selected from the group consisting of —OH, —CN, and halo;-   R₁₀ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁),    wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted    by 1-5 substituents selected from the group consisting of —OH, —CN,    and halo;-   R₁₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each of which is optionally    substituted by 1-5 substituents selected from the group consisting    of —OH, —CN, and halo;    M₁ and M₂ are independently halo or C₁-C₆ alkyl optionally    substituted by 1-5 substituents selected from the group consisting    of —OH, —CN, and halo; and-   M₃ is H, halo, or C₁-C₆ alkyl optionally substituted by 1-5    substituents selected from the group consisting of —OH, —CN, and    halo, or M₃ is taken together with M₂ and the carbon atoms to which    they are attached to form a 5- to 7-membered ring containing 0, 1,    or 2 heteroatoms selected from the group consisting of N, O, and S.

Embodiment 26. The compound of embodiment 24 or 25, or apharmaceutically acceptable salt thereof, wherein:

-   R₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each of which is optionally    substituted by 1-5 substituents selected from the group consisting    of —OH, oxo, —CN, and halo;

Embodiment 27. The compound of embodiment 26, or a pharmaceuticallyacceptable salt thereof, wherein:

-   R₁ is cyclopropyl, isopropyl, ethyl, —CH(CH₂CH₃)₂, —CH(CH₃)(CH₂OH),    —CH(OH)(CH₂CH₃), —CH(OH)(CH₃), —CH(CH₃)(CH₂CH₃), or —C(O)(CH₃).

Embodiment 28. The compound of any one of embodiments 24-27, or apharmaceutically acceptable salt thereof, wherein:

-   R₂ is H or C₁-C₆ alkyl optionally substituted by 1-5 substituents    selected from the group consisting of —OH, —CN, and halo.

Embodiment 29. The compound of embodiment 28, or a pharmaceuticallyacceptable salt thereof, wherein:

-   R₂ is H or methyl.

Embodiment 30. The compound of any one of embodiments 24-29, or apharmaceutically acceptable salt thereof, wherein:

-   R₃ is H.

Embodiment 31. The compound of any one of embodiments 24-30, or apharmaceutically acceptable salt thereof, wherein:

-   R₄ is H or linear C₁-C₃ alkyl optionally substituted by 1-3    substituents selected from the group consisting of —OH, oxo, —CN,    halo, and —O(C₁-C₂ alkyl).

Embodiment 32. The compound of embodiment 31, or a pharmaceuticallyacceptable salt thereof, wherein:

-   R₄ is H, methyl, ethyl, —CH₂C(O)OCH₂CH₃, —CH₂CF₃, —CH₂CN, or    —CH₂CHF₂.

Embodiment 33. The compound of any one of embodiments 24-32, or apharmaceutically acceptable salt thereof, wherein:

-   L is —O—, —C(O)—, or —CH₂—.

Embodiment 34. The compound of any one of embodiments 24-33, or apharmaceutically acceptable salt thereof, wherein:

M₁ and M₂ are independently halo or C₁-C₃ alkyl optionally substitutedby 1-3 substituents selected from the group consisting of —OH, —CN, andhalo.

Embodiment 35. The compound of embodiment 34, or a pharmaceuticallyacceptable salt thereof, wherein:

M₁ and M₂ are independently halo or methyl.

Embodiment 36. The compound of embodiment 35, or a pharmaceuticallyacceptable salt thereof, wherein:

M₁ and M₂ are each chloro.

Embodiment 37. The compound of embodiment 35, or a pharmaceuticallyacceptable salt thereof, wherein:

M₁ and M₂ are each methyl.

Embodiment 38. The compound of any one of embodiments 24-37, or apharmaceutically acceptable salt thereof,

-   M₃ is H, halo, or C₁-C₃ alkyl optionally substituted by 1-3    substituents selected from the group consisting of —OH, —CN, and    halo.

Embodiment 39. The compound of embodiment 38, or a pharmaceuticallyacceptable salt thereof, wherein:

-   M₃ is H, F, or methyl.

Embodiment 40. A compound selected from Compounds 1-3 and 5-35, or apharmaceutically acceptable salt thereof.

Embodiment 41. A pharmaceutical composition comprising the compound ofany one of embodiments 24-40, or a pharmaceutically acceptable saltthereof, and a pharmaceutically acceptable excipient.

Embodiment 42. A method of agonizing thyroid hormone receptor beta (THRbeta) comprising contacting an effective amount of the compound of anyone of embodiments 24-40, or a pharmaceutically acceptable salt thereof,or an effective amount of the pharmaceutical composition of embodiment41, with the THR beta.

Embodiment 43. A method of treating a disorder which is mediated by THRbeta in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of the compound of any one ofembodiments 24-40, or a pharmaceutically acceptable salt thereof, or atherapeutically effective amount of the pharmaceutical composition ofembodiment 41.

Embodiment 44. The method of embodiment 43, wherein the disorder isnon-alcoholic steatohepatitis (NASH).

Examples

The following abbreviations may be relevant for the application.

Abbreviations

Ac: acetylACN: acetonitrileBoc: tertiarybutyloxycarbonylBSA: bis(trimethylsilyl)acetamideBu: butylCAN: ceric ammonium nitrateDBA: dibenzylideneacetoneDCM: dichloromethaneDMAP: dimethylaminopyridineDMF: dimethylformamideDMF-DMA: dimethylformamide dimethylacetalDMSO: dimethylsulfoxideDSC: disuccinimidylcarbonateEt: ethylHPLC: high-performance liquid chromatographyMeOH: methanolOAc: acetatePr: propylPy or Pyr: pyridinert: room temperatureSEMCl: 2-(Trimethylsilyl)ethoxymethyl chlorideSFC: supercritical fluid chromatographyTEA: triethylamineTHF: tetrahydrofuranTFA: trifluoroacetic acidSi-TMT: silica bound 2,4,6-trimercaptotriazineTol.: tolueneTs: tosylt-Bu Xphos: 2-Di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl

SYNTHETIC EXAMPLES Example S1:6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 1)

3,6-dichloro-4-isopropylpyridazine (1a). Sulfuric acid (19.75 g, 201.37mmol, 10.73 mL) was added to a mixture of 3,6-dichloropyridazine (10 g,67.12 mmol), 2-methylpropanoic acid (6.21 g, 70.48 mmol, 6.54 mL) andAgNO₃ (5.70 g, 33.56 mmol, 5.64 mL) in H₂O (200 mL) at 60° C. Then asolution of ammonium persulfate (45.95 g, 201.37 mmol) in H₂O (100 mL)was added by drop-wise to the mixture at 75° C., the resulting mixturewas stirred at 75° C. for 30 min. TLC showed the reaction was completed.After cooling the mixture, it was adjusted to pH=9-10 with NH₃/H₂O. Themixture was extracted with ethyl acetate (200 mL*2), the organic phaseswere washed with brine (100 mL), dried over Na₂SO₄, filtered andconcentrated to give 1a (11 g, 57.57 mmol, 85.77% yield) as light yellowoil. The product was used directly in the next step. MS mass calculatedfor [M+1]⁺ (C₇H₈Cl₂N₂) requires m/z 191.1, LCMS found m/z 191.1;

¹H NMR (400 MHz, CDCl₃) δ 7.38 (s, 1H), 3.24-3.31 (m, 1H), 1.31 (d,J=6.8 Hz, 6H).

3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)aniline (1b). Toa solution of 4-amino-2,6-dichlorophenol (3 g, 16.85 mmol) and3,6-dichloro-4-isopropylpyridazine (1a) (3.22 g, 16.85 mmol) in DMSO (30mL) was added K₂CO₃ (9.32 g, 67.41 mmol) and CuI (1.93 g, 10.11 mmol).Then the mixture was degassed and purged with N₂ 3 times, and stirred at90° C. for 16 hours under N₂ atmosphere. TLC and LCMS showed thestarting material was consumed completely and desired MS was detected.The mixture was concentrated in vacuo. The residue was partitionedbetween ethyl acetate (1000 mL*2) and H₂O (500 mL). The combined organiclayers were washed with brine (50 mL*3), dried with anhydrous Na₂SO₄,filtered and concentrated in vacuo. The residue was purified by columnchromatography (SiO₂, petroleum ether/ethyl acetate=10:1 to 3:1,according TLC) to give 1b (3.5 g, 10.52 mmol, 62.44% yield) as a lightbrown oil. MS mass calculated for [M+1]⁺ (C₁₃H₁₂Cl₃N₃O) requires m/z332.0, LCMS found m/z 332.0;

¹H NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 6.67-6.76 (m, 2H), 5.67 (s,2H), 3.11-3.21 (m, 1H), 1.28 (d, J=6.85 Hz, 6H).

2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)isoindoline-1,3-dione(1c). To a mixture of3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)aniline (1b)(2.6 g, 7.82 mmol) and isobenzofuran-1,3-dione (1.16 g, 7.82 mmol) inHOAc (5 mL) was added NaOAc (3.21 g, 39.08 mmol). The mixture wasstirred at 120° C. for 6 hours. LCMS showed the starting material wasconsumed completely and desired MS was detected. The reaction mixturewas concentrated under reduced pressure to remove AcOH. The solid wasdissolved in water and the pH was adjusted to ˜9 with saturatedNaHCO₃solution (10 mL). Then the mixture was partitioned with ethylacetate (30 mL*2) and H₂O (30 mL). The combined organic layers werewashed with brine (10 mL*3), dried with anhydrous Na₂SO₄, filtered andconcentrated in vacuo. The solid was diluted with ethyl acetate (10 mL),and then petroleum ether (50 mL) was added to the mixture. The mixturewas filtered to collect the solid. The solid was dried to give 1c (2.48g, 3.65 mmol, 46.71% yield) as a brown solid. MS mass calculated for[M+1]⁺ (C₂₁H₁₅Cl₂N₃O₄) requires m/z 444.0, LCMS found m/z 444.1;

¹H NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 7.98-8.06 (m, 2H), 7.90-7.97(m, 2H), 7.78-7.83 (m, 2H), 7.46 (s, 1H), 3.03-3.10 (m, 1H), 1.20 (d,J=6.85 Hz, 6H).

2-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)isoindoline-1,3-dione(1d). A solution of2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)iso-indoline-1,3-dione(1c) (500 mg, 1.13 mmol) in DMF-DMA (4 mL) was stirred at 110° C. for2.5 hours. TLC showed the starting material was consumed completely andtwo new spots formed. The mixture was concentrated in vacuo. The residuewas partitioned between ethyl acetate (10 mL*2) and H₂O (3 mL). Thecombined organic layers were washed with brine (5 mL*3), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuo to give 1d as ayellow solid. The product was used directly in the next step withoutfurther purification.

6-(4-amino-2,6-dichlorophenoxy)-4-isopropyl-2-methylpyridazin-3(2H),-one(1e). A mixture of2-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)isoindoline-1,3-dione(1d) (700 mg, 1.53 mmol) and butyl-1-amine (335.13 mg, 4.58 mmol) inMeOH (10 mL) was stirred at 70° C. for 1 hour. TLC (petroleum ether:ethyl acetate=1:1, P1: R_(f)=0.6) and LCMS showed the starting materialwas consumed completely and desired MS was detected. The mixture wasconcentrated in vacuo to give a residue. The residue was purified bypreparative TLC (petroleum ether: ethyl acetate=1:1, P1: R_(f)=0.6) togive 1e (285 mg, 868.39 umol, 56.85% yield) as a white solid. MS masscalculated for [M+1]⁺ (C₁₄H₁₅Cl₂N₃O₂) requires m/z 328.1, LCMS found m/z328.2;

¹H NMR (400 MHz, MeOH-d4) δ 7.22 (s, 1H) 6.70 (s, 1H) 3.52 (s, 3H) 3.17(dt, J=13.81, 7.13 Hz, 1H) 1.43 (s, 2H) 1.25 (d, J=6.58 Hz, 6H).

6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropyl-2-methylpyrida-zin-3(2H)-one(1f). To a solution of6-(4-amino-2,6-dichloro-phenoxy)-4-isopropyl-2-methyl-pyridazin-3-one(1e) (50 mg, 152.35 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(116.06 mg, 457.05 umol) in CH₃CN (3 mL) was added tert-butyl nitrite(23.57 mg, 228.52 umol, 27.18 uL) drop-wise at 20° C. And the mixturewas stirred at 20° C. for 2 hours. LCMS and TLC (petroleum ether: ethylacetate=5:1, R_(f)=0.6) showed the reaction was completed, and desiredMS was detected. The mixture was extracted with EtOAc (10 mL) and theorganic layer was washed with H₂O (5 mL). The organic layer was driedover Na₂SO₄, filtered and concentrated in vacuo. The residue waspurified by Prep-TLC (petroleum ether: ethyl acetate=5:1, R_(f)=0.6) togive if (40 mg, crude) as a light yellow solid. MS mass calculated for[M+1]⁺ (C₂₀H₂₅BCl₂N₂O₄) requires m/z 439.1, LCMS found m/z 439.0 and356.9 (MS of boric acid);

¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.01-7.09 (m, 1H), 3.46-3.55 (m,2H), 3.18-3.32 (m, 1H) 1.36 (s, 5H), 1.21-1.29 (m, 12H).

6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(1). To a mixture of6-[2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]-4-isopropyl-2-methyl-pyridazin-3-one(1f) (40 mg, 91.09 umol) and 6-bromo-2H-1,2,4-triazine-3,5-dione (26.23mg, 136.63 umol) in dioxane (3 mL) and H₂O (1.5 mL) was added K₂CO₃(25.18 mg, 182.17 umol). Then Pd(dppf)Cl₂ (6.66 mg, 9.11 umol) was addedto the mixture under N₂. Then the mixture was stirred at 80° C. under N₂for 2 hours. LCMS and TLC (petroleum ether: ethyl acetate=0:1,R_(f)=0.6) showed the reaction was completed, and desired MS wasdetected. The mixture was concentrated in vacuo, and the residue wasextracted with EtOAc (10 mL) and H₂O (5 mL). The organic layer was driedover Na₂SO₄, filtered and concentrated in vacuo. The residue waspurified by Prep-HPLC (column: Luna C18 100*30 5u; mobile phase: [water(0.1% TFA)-ACN];B %: 36-66%,10 min) to give 1 (4.5 mg, 10.52 umol,11.55% yield). MS mass calculated for [M+1]⁺ (C₂₀H₂₅BCl₂N₂O₄) requiresm/z 424.1, LCMS found m/z 424.0;

¹H NMR (400 MHz, MeOH-d₄) δ 8.18 (s, 2H), 7.34 (d, J=0.74 Hz, 1H), 3.50(s, 3H), 3.10-3.25 (m, 1H), 1.28 (d, J=6.8 Hz, 6H).

Example S2:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 2)

3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-isopropylpyridazine (2a). To asolution of3,5-dichloro-4-(6-chloro-5-isopropyl-pyridazin-3-yl)oxy-aniline (1b)(500 mg, 1.50 mmol) in HCl (15.03 mmol, 5 M, 1.79 mL) was added NaNO₂(124.47 mg, 1.80 mmol) at 0° C. Then the mixture was stirred at 0° C.for 0.5 hours. Then a solution of KI (499.08 mg, 3.01 mmol) in H₂O (5mL) was added, and the mixture was stirred at 20° C. for another 16hours. TLC (petroleum ether: ethyl acetate=3:1, R_(f)=0.6) indicated 1bwas consumed completely. The reaction mixture was extracted with EtOAc(10 mL*3). The combined organic layers were washed with brine (5 mL*2),dried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by column chromatography (SiO₂, petroleum ether:ethyl acetate=10:1 to 1:1) to give 2a (340 mg, 613.31 umol, 40.80%yield) as a light yellow solid.

3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropylpyridazine(2b). To a solution of3-chloro-6-(2,6-dichloro-4-iodo-phenoxy)-4-isopropyl-pyridazine (2a)(340 mg, 766.64 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(584.04 mg, 2.30 mmol) in dioxane (10 mL) was added Pd(dppf)C₁₂ (28.05mg, 38.33 umol) and KOAc (376.19 mg, 3.83 mmol). The mixture wasdegassed and purged with N₂ for 3 times and stirred at 90° C. for 16hours. TLC (petroleum ether: ethyl acetate=5:1, R_(f)=0.5) indicated 2awas consumed completely. The suspension was filtered through a pad ofCelite and the pad cake was washed with EtOAc (10 mL*3). The combinedfiltrates were concentrated in vacuo. The residue was purified byprep-TLC (SiO₂, Petroleum ether: Ethyl acetate=5:1) to give 2b (380 mg,685.37 umol, 89.40% yield) as a white gum. MS mass calculated for [M+1]⁺(C₁₉H₂₂BCl₃N₂O₃) requires m/z 443.1, LCMS found m/z 443.1.

¹H NMR (400 MHz, CDCl₃) δ 7.82-7.80 (m, 2H), 7.22-7.20 (m, 1H),3.31-3.23 (m, 1H), 1.36-1.36 (m, 3H), 1.36-1.35 (m, 12H), 1.35-1.34 (m,3H).

6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(2c). To a solution of3-chloro-6-[2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]-4-isopropyl-pyridazine(2b) (70 mg, 157.81 umol) and 6-bromo-2H-1,2,4-triazine-3,5-dione (45.44mg, 236.72 umol) in dioxane (4 mL) and H₂O (1 mL) was added Pd(dppf)C₁₂(11.55 mg, 15.78 umol) and K₂CO₃ (65.43 mg, 473.44 umol). The mixturewas degassed and purged with N₂ 3 times, and then was stirred at 80° C.for 16 hours under N₂ atmosphere. TLC (petroleum ether: ethylacetate=1:1, R_(f)=0.30) showed the reaction was completed. Thesuspension was filtered through a pad of Celite and the filter cake waswashed with EtOAc (5 mL*4). The combined filtrates were concentrated invacuo, and the residue was purified by prep-TLC (SiO₂, petroleum ether:ethyl acetate=1:1) to give 2c (10.5 mg, 22.05 umol, 13.97% yield) as alight yellow solid. MS mass calculated for [M+1]⁺ (C₁₆H₁₂Cl₃N₅O₃)requires m/z 428.0, LCMS found m/z 428.1/430.1.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(2). To a solution of6-[3,5-dichloro-4-(6-chloro-5-isopropyl-pyridazin-3-yl)oxy-phenyl]-2H-1,2,4-triazine-3,5-dione(2c) (10 mg, 21.00 umol) in AcOH (2 mL) was added NaOAc (6.89 mg, 83.98umol). The mixture was stirred at 120° C. for 2 hours. LCMS showed ˜10%of 2c was remained and desired MS was detected. The reaction mixture wasconcentrated under reduced pressure. The residue was purified byPrep-HPLC (column: Luna C18 100*30 5u; mobile phase: [water (0.2%FA)-ACN];B %: 25-50%,12 min) to give 2 (2.56 mg, 6.24 umol, 29.72%yield). MS mass calculated for [M+1]⁺ (C₁₆H₁₃Cl₂N₅O₄) requires m/z410.0, LCMS found m/z 410.1/412.1.

¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 2H), 7.34 (s, 1H), 3.12-3.18 (m, 1H),1.27-1.29 (d, J=8.0 Hz, 6H).

Example S3:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 3)

6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a). To a solution of6-bromo-2H-1,2,4-triazine-3,5-dione (200 mg, 1.04 mmol) in MeCN (5 mL)was added BSA (529.85 mg, 2.60 mmol). The mixture was heated at 82° C.for 3 hours. Then Mel (221.81 mg, 1.56 mmol) was added to the mixture,and the resulting mixture was stirred at 90° C. for another 16 hours.TLC (petroleum ether: ethyl acetate=1:1, product R_(f)=0.5) indicatedstarting material was consumed completely. The reaction mixture wasextracted with EtOAc (10 mL*3). The combined organic layers werefiltered and concentrated under reduced pressure. The residue waspurified by prep-TLC (SiO₂, petroleum ether: ethyl acetate=1:1,according TLC) to give 3a (170 mg, 660.20 umol, 63.37% yield) as a whitesolid.

¹H NMR (400 MHz, DMSO-d₆) δ 12.53-12.45 (m, 1H), 3.43 (s, 3H).

6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(3b). To a solution of 6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(3a) (50 mg, 112.72 umol) and3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropylpyridazine(2b) (69.66 mg, 338.17 umol) in dioxane (4 mL) was added Pd(dppf)C₁₂(8.25 mg, 11.27 umol) and K₂CO₃ (46.74 mg, 338.17 umol) in H₂O (1 mL).The mixture was stirred at 80° C. for 2 hours. TLC (petroleum ether:ethyl acetate=5:1, R_(f)=0.4) indicated 2b was consumed completely. Thesuspension was filtered through a pad of Celite and the filter cake waswashed with EtOAc (10 mL*3). The combined filtrates were concentrated todryness to give a residue. The residue was purified by prep-TLC (SiO₂,petroleum ether: ethyl acetate=5:1, according TLC) to give 3b (21 mg,37.95 umol, 33.67% yield) as a white solid. MS mass calculated for[M+1]⁺ (C₁₇H₁₄Cl₃N₅O₃) requires m/z 442.0, LCMS found m/z 444.0.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(3). To a solution of6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(3b) (17 mg, 38.40 umol) in HOAc (5 mL) was added NaOAc (15.75 mg,192.01 umol). The mixture was stirred at 120° C. for 16 hours. LCMSshowed 3b was consumed completely and one main peak with desired MS wasdetected. The reaction mixture was concentrated under reduced pressureto give the crude residue. The residue was purified by prep-HPLC(column: Luna C18 100*30 5u; mobile phase: [water (0.225% FA)-ACN]; B %:30-70%, 15 min) to give 3 (2.57 mg, 5.82 umol, 15.14% yield). MS masscalculated for [M+1]⁺ (C₁₇H₁₅Cl₂N₅O₄) requires m/z 424.1, LCMS found m/z424.0.

¹H NMR (400 MHz, CDCl₃) δ 8.21-8.16 (m, 2H), 7.37-7.34 (m, 1H),3.69-3.66 (m, 3H), 3.21-3.13 (m, 1H), 1.31-1.27 (m, 6H).

Example S4:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 4)

6-bromo-2-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione (4a). To a solutionof 6-bromo-2H-1,2,4-triazine-3,5-dione (150 mg, 781.37 umol) in ACN (6mL) was added BSA (397.38 mg, 1.95 mmol). The mixture was heated at 82°C. for 3 hours, and then 2-iodopropane (199.24 mg, 1.17 mmol) was addedin the mixture. The resulting mixture was stirred at 82° C. for another16 hours. TLC (ethyl acetate: petroleum ether=2:1, R_(f)=0.6) showedstarting material was consumed completely. The reaction mixture wasconcentrated under reduced pressure to give a residue. The residue waspurified by prep-TLC (SiO₂, ethyl acetate: petroleum ether=1:1,according TLC) to give 4a (155 mg, 629.14 umol, 80.52% yield) as a whitesolid.

¹H NMR (400 MHz, DMSO-d₆) δ 12.50-12.28 (m, 1H), 4.76-4.67 (m, 1H),1.23-1.20 (m, 6H).

6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione(4b). To a solution of3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropylpyridazine(2b) (100 mg, 225.45 umol) and6-bromo-2-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione (4a) (105.53 mg,450.90 umol) in dioxane (4 mL) was added Pd(dppf)C₁₂ (16.50 mg, 22.54umol) and K₂CO₃ (93.48 mg, 676.35 umol) in H₂O (1 mL). The mixture wasstirred at 80° C. for 2 hours. TLC (petroleum ether: ethyl acetate=1:1,R_(f)=0.3) and LCMS showed 2b was consumed completely and the desiredmass was detected. The suspension was filtered through a pad of Celiteand the filter cake was washed with EtOAc (10 mL*3). The combinedfiltrates were concentrated to dryness to give a residue. The residuewas purified by prep-TLC (SiO₂, petroleum ether: ethyl acetate=1:1,according TLC) to give 4b (50 mg, 84.97 umol, 37.69% yield) as a whitesolid. MS mass calculated for [M+1]⁺ (C₁₉H₁₈Cl₃N₅O₃) requires m/z 470.0,LCMS found m/z 470.1.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione(4). To a solution of6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione(4b) (50 mg, 106.22 umol) in HOAc (5 mL) was added NaOAc (43.56 mg,531.08 umol). The mixture was stirred at 120° C. for 16 hours. LCMSshowed 4b was consumed completely and one main peak with desired MS wasdetected. The reaction mixture was concentrated under reduced pressureto remove AcOH. The residue was purified by prep-HPLC (column: Luna C18100*30 5u; mobile phase: [water (0.225% FA)-ACN]; B %: 20-60%, 15 min)to give 4 (9.21 mg, 20.16 umol, 18.98% yield). MS mass calculated for[M+1]⁺ (C₁₉H₁₉Cl₂N₅O₄) requires m/z 452.1, LCMS found m/z 452.0.

¹H NMR (400 MHz, MeOH-d₄) δ 8.19-8.16 (m, 2H), 7.37-7.34 (m, 1H),5.01-4.95 (m, 1H), 3.21-3.13 (m, 1H), 1.43-1.40 (m, 6H), 1.30-1.28 (m,6H).

Example S5:6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-2-methylphenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 5)

3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)-2-methylaniline(15a). To a mixture of 4-amino-2,6-dichloro-3-methyl-phenol (1a) (0.1 g,520.72 umol), 3,6-dichloro-4-isopropyl-pyridazine (99.49 mg, 520.72umol) in DMSO (1 mL) at 25° C. was added K₂CO₃ (287.87 mg, 2.08 mmol)and CuI (59.50 mg, 312.43 umol). The mixture was stirred at 90° C. for16 hours. TLC (petroleum ether: ethyl acetate=3:1, R_(f)=0.43) showedthe reaction was completed. H₂O (5 mL) was added to the mixture, and itwas extracted with ethyl acetate (20 mL*2). The combined organic layerswere washed with brine (20 mL*2), dried with anhydrous Na₂SO₄, filteredand concentrated in vacuo to give 5a (0.1 g, 288.48 umol, 55.40% yield)as a yellow solid. MS mass calculated for [M+1]⁺ (C₁₄H₁₄Cl₃N₃O) requiresm/z 346.0, LCMS found m/z 346.0;

¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (s, 1H), 6.78-6.80 (m, 1H), 5.50 (s,2H) 3.13-3.19 (m, 1H), 2.13 (s, 3H), 1.28 (d, J=6.8 Hz, 6H).

2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-2-methylphenyl)isoindoline-1,3-dione(5b). To a mixture of3,5-dichloro-4-(6-chloro-5-isopropyl-pyridazin-3-yl)oxy-2-methyl-aniline(5a) (0.1 g, 288.48 umol) and isobenzofuran-1,3-dione (42.73 mg, 288.48umol) in AcOH (3 mL) was added NaOAc (94.66 mg, 1.15 mmol) at 25° C.,the mixture was stirred at 120° C. for 6 hours. LCMS showed the reactionwas completed. The mixture was concentrated to get residue. To theresidue was added H₂O (10 mL) and extracted with ethyl acetate (20mL*2). The combined organic layers were washed with brine (20 mL*2),dried with anhydrous Na₂SO₄, filtered and concentrated in vacuo. Theresidue was diluted with MTBE (5 mL) and filtered. The filter cake wasdried in vacuo to give 5b (0.05 g, 109.10 umol, 37.82% yield) as yellowsolid. MS mass calculated for [M+1]⁺ (C₂₂H₁₇Cl₂N₃O₄) requires m/z 458.1,LCMS found m/z 458.0;

¹H NMR (400 MHz, CDCl₃) δ 9.91 (br s, 1H), 8.00 (dd, J=5.5, 3.0 Hz, 2H),7.85 (dd, J=5.5, 3.0 Hz, 2H), 7.30 (s, 1H), 7.16 (s, 1H), 3.23-3.29 (m,1H), 3.22 (s, 1H), 2.25 (s, 3H), 1.30 (d, J=6.85 Hz, 6H).

2-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-2-methylphenyl)isoin-doline-1,3-dione(5c). A mixture of2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]-2-methyl-phenyl]isoindoline-1,3-dione(5b) (0.37 g, 807.34 umol) in DMF-DMA (5 mL) was stirred at 105° C. for4 hours. LCMS showed the reaction was completed. H₂O (20 mL) was addedto the mixture and it was extracted with ethyl acetate (20 mL*2). Thecombined organic layers were washed with brine (20 mL*2), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuo to give 5c asyellow solid. The crude was used in the next step directly. MS masscalculated for [M+1]⁺ (C₂₃H₁₉Cl₂N₃O₄) requires m/z 472.1, LCMS found m/z472.1.

6-(4-amino-2,6-dichloro-3-methylphenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(5d). To a solution of2-[3,5-dichloro-4-(5-isopropyl-1-methyl-6-oxo-pyridazin-3-yl)oxy-2-methyl-phenyl]isoin-doline-1,3-dione(5c) (440 mg, 931.57 umol) in MeOH (1 mL) was added butyl-1-amine (2 M,1.40 mL) at 70° C. The mixture was stirred at 70° C. for 1 h. TLC(petroleum ether: ethyl acetate=1:1, R_(f)=0.6) and LCMS showed thestarting material was consumed completely and desired MS was detected.The mixture was concentrated in vacuo. The residue was purified byprep-TLC (SiO₂, petroleum ether/ethyl acetate=1:1) to give 5d as a whitesolid. MS mass calculated for [M+1]⁺ (C₁₅H₁₇Cl₂N₃O₂) requires m/z 341.1,LCMS found m/z 342.1; ¹H NMR (400 MHz, MeOH-d4) δ 7.22 (s, 1H), 6.77 (s,1H), 3.50 (s, 3H), 3.17 (td, J=6.8, 13.8 Hz, 1H), 2.20 (s, 3H), 1.26 (d,J=6.6 Hz, 6H).

6-(2,6-dichloro-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(5e). To a mixture of6-(4-amino-2,6-dichloro-3-methylphenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(5d) (20 mg, 58.44 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(742.03 mg, 2.92 mmol) in CH₃CN (8 mL) was added t-BuONO (12.05 mg,116.88 umol, 13.90 uL) at 20° C. Then the mixture was stirred at 20° C.for 16 hours. TLC (petroleum ether: ethyl acetate=5:1, R_(f)=0.4) andLCMS showed the starting material was consumed completely and thedesired MS was found. The mixture was concentrated in vacuo. The residuewas purified by prep-TLC (SiO₂, petroleum ether: ethyl acetate=5:1, P1:R_(f)=0.4) to give 5e (25 mg, crude) as a white solid. MS masscalculated for [M+1]⁺ (C₂₁H₂₇BCl₂N₂O₄) requires m/z 453.2, LCMS foundm/z 453.0;

¹H NMR (400 MHz, CDCl₃) δ 7.76 (s, 1H), 7.04 (s, 1H), 3.58-3.63 (m, 3H),3.49-3.51 (m, 5H), 3.24 (s, 1H), 2.62 (s, 3H), 1.21-1.30 (m, 6H).

6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-2-methylphenyl)-1,2,4-triazine-3,5(2H,4H)-dione(5). To a mixture of6-(2,6-dichloro-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(5e) (25 mg, 55.17 umol) and 6-bromo-2H-1,2,4-triazine-3,5-dione (10.59mg, 55.17 umol) in dioxane (2 mL) and H₂O (0.5 mL) was added K₂CO₃(22.87 mg, 165.50 umol) and Pd(dppf)C₁₂ (4.04 mg, 5.52 umol). Themixture was degassed and purged with N₂ for 3 times, and then it wasstirred at 90° C. for 16 hours under N₂ atmosphere. HPLC and LCMS showedthe starting material was consumed completely and desired MS wasdetected. The reaction mixture was concentrated in vacuo to give aresidue. The residue was purified by Prep-HPLC (column: Luna C18 100*305u; mobile phase: [water(0.1% TFA)-ACN];B %: 25-60%, 12 min) to give thedesired compound (20 mg, 40.77 umol, 73.89% yield, 89.33% purity). Thenthe product was re-purified by Prep-HPLC (column: HUAPU C₈ Extreme BDS150*30 5u; mobile phase: [water(10 mM NH₄HCO₃)-ACN];B %: 20%-50%,10 min)to give 5 (0.26 mg, 2.60% yield). MS mass calculated for [M+1]⁺(C₁₈H₁₇Cl₂N₅O₄) requires m/z 438.3, LCMS found m/z 438.0; ¹H NMR (400MHz, DMSO-d₆) δ 7.57 (s, 1H), 7.46 (s, 1H), 3.39 (br s, 3H), 3.08 (s,1H), 2.25 (s, 3H), 1.19 (d, J=7.0 Hz, 6H).

Example S6:6-(3,5-dichloro-4-((5-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 6)

3,6-dichloro-4-cyclopropylpyridazine (6a). H₂SO₄ (1.98 g, 20.14 mmol,1.07 mL) was added to a solution of 3,6-dichloropyridazine (1 g, 6.71mmol), cyclopropanecarboxylic acid (577.86 mg, 6.71 mmol, 530.15 uL) andAgNO₃ (1.14 g, 6.71 mmol) in H₂O (20 mL) at 60° C., then ammoniumpersulfate (4.60 g, 20.14 mmol, 4.38 mL) in H₂O (10 mL) was added to themixture at 70° C., the resulting mixture was stirred at 70° C. for 30min. TLC (petroleum ether: ethyl acetate=5:1, R_(f)=0.5) showed thereaction was completed, the mixture was extracted with ethyl acetate (20mL*2), the combined organic layers were washed with brine (20 mL), driedover Na₂SO₄, filtered and concentrated. The residue was purified by MPLC(SiO₂, petroleum ether: ethyl acetate=5: 1) to give 6a (0.64 g, 3.39mmol, 50.44% yield) as colorless oil. MS mass calculated for [M+1]⁺(C₇H₆Cl₂N₂) requires m/z 189.0, LCMS found m/z 189.1;

¹H NMR (400 MHz, CDCl₃) δ 6.94 (s, 1H), 2.22 (tt, J=5.0, 8.4 Hz, 1H),1.37-1.28 (m, 2H), 0.93-0.83 (m, 2H).

3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)aniline (6b).3,6-dichloro-4-cyclopropylpyridazine (6a) (0.3 g, 1.59 mmol),4-amino-2,6-dichlorophenol (282.50 mg, 1.59 mmol), K₂CO₃ (328.99 mg,2.38 mmol) and CuI (60.45 mg, 317.39 umol) in DMA (5 mL) was de-gassedand then heated to 100° C. for 16 hours under N₂. LCMS showed desiredMS, TLC (petroleum ether: ethyl acetate=3:1, R_(f)=0.33) showed one newspot. The mixture was filtered; the filtrate was extracted with water(20 mL) and ethyl acetate (15 mL*2). The combined organic layers werewashed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated,the residue was purified by Prep-TLC (petroleum ether: ethylacetate=5:1) to give 6b (0.3 g, 907.45 umol, 57.18% yield) as a yellowsolid. MS mass calculated for [M+1]⁺ (C₁₃H₁₀Cl₃N₃O) requires m/z 330.0,LCMS found m/z 330.1;

¹H NMR (400 MHz, DMSO-d₆) δ 7.34 (s, 1H), 6.70 (s, 2H), 5.67 (s, 2H),2.17-2.11 (m, 1H), 1.23-1.19 (m, 2H), 1.07-1.01 (m, 2H).

3-chloro-4-cyclopropyl-6-(2,6-dichloro-4-iodophenoxy)pyridazine (6c). Toa solution of3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)aniline (6b)(0.1 g, 302.48 umol) in conc. HCl (2 mL) and H₂O (2 mL) was added NaNO₂(31.30 mg, 453.72 umol) in portions at 0° C. and stirred for 30 min,then KI (100.43 mg, 604.97 umol) in H₂O (1 mL) was added dropwise to themixture, the resulting mixture was stirred at 25° C. for 1.5 hr to givea brown suspension. LCMS showed desired MS was detected, TLC (petroleumether: ethyl acetate=5:1, R_(f)=0.59) showed the reaction was completed,the mixture was filtered, the filter cake washed with water (2 mL*2) anddried, the solid was purified by prep-TLC (petroleum ether: ethylacetate=5:1) to give 6c (0.11 g, 249.16 umol, 82.37% yield) as a yellowsolid. MS mass calculated for [M+1]⁺ (C₁₃H₈Cl₃IN₂O) requires m/z 440.9,LCMS found m/z 440.9;

¹H NMR (400 MHz, CDCl₃) δ 7.77-7.69 (m, 2H), 6.78 (s, 1H), 2.25-2.18 (m,1H), 1.31-1.26 (m, 2H), 0.94-0.89 (m, 2H).

(3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)phenyl)boronicacid (6d).3-chloro-4-cyclopropyl-6-(2,6-dichloro-4-iodophenoxy)pyridazine (6c)(0.11 g, 249.16 umol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (189.82 mg,747.49 umol, 3 eq), KOAc (146.72 mg, 1.49 mmol) and Pd(dppf)C₁₂ (18.23mg, 24.92 umol) in dioxane (5 mL) was de-gassed and then heated to 90°C. for 16 hours under N₂. LCMS showed desired MS was detected, TLC(petroleum ether: ethyl acetate=3:1, R_(f)=0.35) showed new spot. Themixture was filtered, the filter cake was washed with ethyl acetate (10mL*2), and the filtrate was concentrated. The residue was purified byprep-TLC (petroleum ether: ethyl acetate=3:1) to give 6d (85 mg, 236.51umol, 94.92% yield) as white solid. MS mass calculated for [M+1]⁺(C₁₃H₁₀BCl₃N₂O₃) requires m/z 359.0, LCMS found m/z 359.0;

6-(3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(6e).(3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)phenyl)boronicacid (6d) (85 mg, 236.51 umol), 6-bromo-2H-1,2,4-triazine-3,5-dione(59.02 mg, 307.46 umol), Pd(dppf)C₁₂ (17.31 mg, 23.65 umol) and K₂CO₃(65.37 mg, 473.01 umol) in dioxane (5 mL) and H₂O (0.5 mL) was de-gassedand then heated to 90° C. for 16 hours under N₂. LCMS showed desired MSwas found, TLC (DCM: MeOH=10:1, R_(f)=0.42) showed a new spot wasformed. The mixture was filtered and the filtrate was concentrated. Theresidue was purified by prep-TLC (DCM: MeOH=10:1) to give 6e (30 mg,70.32 umol, 29.73% yield) as a yellow solid. MS mass calculated for[M+1]⁺ (C₁₆H₁₀Cl₃N₅O₃) requires m/z 426.0, LCMS found m/z 426.0;

¹H NMR (400 MHz, MeOH-d4) δ 8.23 (s, 2H), 7.26 (s, 1H), 2.33-2.26 (m,1H), 1.33-1.30 (m, 2H), 1.08-1.02 (m, 2H).

6-(3,5-dichloro-4-((5-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(6). A mixture of6-(3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(6e) (30 mg, 70.32 umol) and NaOAc (28.84 mg, 351.58 umol) in HOAc (3mL) was heated to 110° C. for 16 hours, LCMS showed the reaction wascompleted, and desired MS was found. The mixture was concentrated. Theresidue was purified by prep-HPLC (FA) to give 6 (10.19 mg, 24.96 umol,35.50% yield). MS mass calculated for [M+1]⁺ (C₁₆H₁₀Cl₃N₅O₃) requiresm/z 408.0, LCMS found m/z 408.0;

¹H NMR (400 MHz, DMSO-d₆) δ 12.60 (s, 1H), 12.18 (br s, 1H), 8.01 (s,2H), 7.15 (s, 1H), 2.12 (br s, 1H), 1.06 (br d, J=6.8 Hz, 2H), 0.99 (brs, 2H).

Example S7:6-(3,5-dichloro-4-(5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazine-3-carbonyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 7)

ethyl 2-cyano-2-(2,6-dichloro-4-nitro-phenyl)acetate (7a). To asuspension of NaH (3.53 g, 88.32 mmol, 60% purity) in DMSO (100 mL) at0° C. was added ethyl 2-cyanoacetate (9.99 g, 88.32 mmol, 9.42 mL)drop-wise and then the mixture was stirred at 25° C. for 30 min. Then1,2,3-trichloro-5-nitro-benzene (10 g, 44.16 mmol) was added to themixture, and the resulting mixture was stirred at 25° C. for 16 hours.TLC (petroleum ether: ethyl acetate=5:1, R_(f)=0.49) showed the reactionwas completed. The reaction mixture was quenched by addition of water(100 mL) at 25° C. Then adjusted to pH=1 with HCl (4 M) and the yellowprecipitate was collected by suction filtration and dried under vacuumto give 7a (12.5 g, 41.24 mmol, 93.39% yield) as a yellow solid. Theproduct was used directly in the next step without further purification.

2-(2,6-dichloro-4-nitro-phenyl)acetonitrile (7b). A mixture of ethyl2-cyano-2-(2,6-dichloro-4-nitro-phenyl)acetate (7a) (12.5 g, 41.24 mmol)and LiCl (2.62 g, 61.86 mmol) in DMSO (16 mL) and H₂O (6 mL) was heatedto 165° C. for 1 hour. TLC (petroleum ether: ethyl acetate=3:1,R_(f)=0.8) the reaction was completed, and one new spot was formed. Thereaction was clean according to TLC. After cooling, the mixture wasquenched with water (100 mL*4) and extracted with ethyl acetate (50mL*4). The combined organic phases were washed with brine (20 mL*2),dried over Na₂SO₄, filtered and concentrated in vacuo to give 7b (9.2 g,39.82 mmol, 96.56% yield) as a brown solid. The product was useddirectly in the next step without further purification.

¹H NMR (400 MHz, CDCl₃) δ 8.33-8.21 (m, 2H), 4.11-4.07 (m, 3H).

2-(4-amino-2,6-dichloro-phenyl)acetonitrile (7c). To a solution of2-(2,6-dichloro-4-nitro-phenyl)acetonitrile (7b) (5 g, 21.64 mmol) inHOAc (30 mL) was added iron powder (6.04 g, 108.21 mmol). The mixturewas stirred at 25° C. for 1 hour. TLC (petroleum ether: ethylacetate=3:1, R_(f)=0.4) showed the reaction was completed, and one newspot was formed. The mixture was filtered; the filtrate was extractedwith water (100 mL*4) and ethyl acetate (50 mL*4). The combined organiclayers were neutralized with sat. NaHCO₃(30 ml*5), washed with brine (30mL*2), dried over Na₂SO₄, filtered and concentrated to give 7c (4.2 g,20.89 mmol, 96.53% yield) as a brown solid. The product was used in nextstep without further purification.

¹H NMR (400 MHz, CDCl₃) δ 6.67 (s, 2H), 3.88 (s, 2H).

2-(4-amino-2,6-dichloro-phenyl)-2-(6-chloro-5-isopropyl-pyridazin-3-yl)acetonitrile(7d). To a solution of 2-(4-amino-2,6-dichloro-phenyl)acetonitrile (7c)(4.2 g, 20.89 mmol) and 3,6-dichloro-4-isopropyl-pyridazine (3.99 g,20.89 mmol) in THF (20 mL) was added t-BuOK (1 M in THF, 41.78 mL) bydrop-wise at 60° C. The resulting mixture was stirred at thistemperature for 2 hours. TLC (petroleum ether: ethyl acetate=2:1,R_(f)=0.49) indicated one new major spot with lower polarity wasdetected. After cooling the mixture, it was exacted with ethyl acetate(100 mL*3) and the organic layers were washed with brine (50 mL*2). Thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated in vacuo. The residue was purified by column chromatography(SiO₂, petroleum ether: ethyl acetate=10:1 to 1:1) to give 7d (4 g,11.25 mmol, 53.84% yield) as an orange solid.

¹H NMR (400 MHz, CDCl₃) δ 7.62-7.56 (m, 1H), 6.68 (s, 2H), 6.32 (s, 1H),3.35-3.27 (m, 1H), 1.33-1.28 (m, 6H).

(4-amino-2,6-dichloro-phenyl)-(6-chloro-5-isopropyl-pyridazin-3-yl)methanone(7e). To a solution of2-(4-amino-2,6-dichloro-phenyl)-2-(6-chloro-5-isopropyl-pyridazin-3-yl)acetonitrile(7d) (2.2 g, 6.19 mmol) in MeCN (15 mL) was added t-BuOK (1 M in THF,6.19 mL) at 25° C. The mixture was stirred at this temperature for 0.5hours, and then it was cooled to 0° C., H₂O₂(1.40 g, 12.37 mmol, 1.19mL, 30% purity) was added to the mixture by drop-wise at 0° C. Theresulting mixture was stirred at 25° C. for 2 hours. TLC (petroleumether: ethyl acetate=2:1, R_(f)=0.69) showed one new spot was formed.LCMS showed the desired mass was found. The reaction mixture wasquenched by the addition of Na₂SO₃ (5 mL), and then stirred at 20° C.for 1 hour. Then the mixture was concentrated in vacuo. The residue wasextracted with ethyl acetate (20 mL*2). The combined organic layers werewashed with brine, dried over Na₂SO₄, filtered and concentrated invacuo. The residue was purified by prep-TLC (petroleum ether: ethylacetate=2:1) to give 7e (885 mg, 2.57 mmol, 41.51% yield) as a lightyellow solid. MS mass calculated for [M+1]⁺ (C₁₄H₁₂Cl₃N₃O) requires m/z344.0, LCMS found m/z 344.1.

¹H NMR (400 MHz, MeOH-d4) δ 8.23-8.21 (m, 1H), 6.69-6.66 (m, 2H),3.44-3.36 (m, 1H), 1.40-1.36 (m, 6H).

2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1H-pyridazine-3-carbonyl)phenyl]isoindoline-1,3-dione(7f). To a solution of(4-amino-2,6-dichloro-phenyl)-(6-chloro-5-isopropyl-pyridazin-3-yl)methanone(7e) (250 mg, 725.43 umol) in HOAc (10 mL) was added NaOAc (297.55 mg,3.63 mmol) and isobenzofuran-1,3-dione (107.45 mg, 725.43 umol). Themixture was stirred at 120° C. for 16 hours. TLC (petroleum ether: ethylacetate=2:1, R_(f)=0.31) showed one new spot was formed. LCMS showed thedesired mass was detected. The mixture was concentrated in vacuo, andthe residue was diluted with H₂O (50 mL) and aqueous NaHCO₃(50 mL). Thenthe mixture was extracted with ethyl acetate (30 mL*2). The combinedorganic layers were concentrated in vacuo to give 7f (200 mg, 438.33umol, 60.42% yield) as a white solid. The crude product was used intothe next step without further purification. MS mass calculated for[M+1]⁺ (C₂₂H₁₅Cl₂N₃O₄) requires m/z 456.0, LCMS found m/z 456.1.

2-[3,5-dichloro-4-(5-isopropyl-1-methyl-6-oxo-pyridazine-3-carbonyl)phenyl]isoindoline-1,3-dione(7g). A solution of2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1H-pyridazine-3-carbonyl)phenyl]isoindoline-1,3-dione(7f) (350 mg, 767.08 umol) in DMF-DMA (10 mL) was stirred at 110° C. for3 hours. LCMS showed the reaction was completed, and the desired masswas found. The reaction mixture was partitioned between H₂O (50 mL*2)and ethyl acetate (50 mL*2). The organic phase was concentrated in vacuoto give 7g (300 mg, 637.89 umol, 83.16% yield) as a white solid. Theproduct was used in next step without further purification. MS masscalculated for [M+1]⁺ (C₂₃H₁₇Cl₂N₃O₄) requires m/z 470.1, LCMS found m/z470.1.

6-(4-amino-2,6-dichloro-benzoyl)-4-isopropyl-2-methyl-pyridazin-3-one(7h). To a solution of2-[3,5-dichloro-4-(5-isopropyl-1-methyl-6-oxo-pyridazine-3-carbonyl)phenyl]isoindoline-1,3-dione(7g) (300 mg, 637.89 umol) in MeOH (2 mL) was added N-butylamine (285.58mg, 1.91 mmol, 307.08 uL). The mixture was stirred at 70° C. for 0.5hours. TLC (petroleum ether: ethyl acetate=2:1) showed two new spots(R_(f)=0.41,0.31) was formed. The mixture was concentrated in vacuo. Theresidue was purified by prep-TLC (Petroleum ether: Ethyl acetate=2:1) togive 7h (122 mg, 358.61 umol, 56.22% yield) as a light yellow solid.

¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J=1.0 Hz, 1H), 6.65-6.61 (m, 2H),3.77-3.74 (m, 3H), 3.27-3.18 (m, 1H), 1.27 (d, J=6.8 Hz, 6H).

6-[2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-4-isopropyl-2-methyl-pyridazin-3-one(7i). To a solution of6-(4-amino-2,6-dichloro-benzoyl)-4-isopropyl-2-methyl-pyridazin-3-one(7h) (40 mg, 117.58 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(89.57 mg, 352.73 umol) in MeCN (2 mL) was added t-BuONO (24.25 mg,235.15 umol, 27.97 uL). The mixture was stirred at 25° C. for 16 hours.LCMS showed the reaction was completed. The reaction mixture wasconcentrated under reduced pressure to remove MeCN. The residue waspurified by prep-TLC (petroleum ether: ethyl acetate=4:1) to give 7i (31mg, 68.71 umol, 58.44% yield) as a light yellow solid. MS masscalculated for [M+1]⁺ (C₂₁H₂₄BCl₂N₂O₄) requires m/z 451.1, LCMS foundm/z 451.2.

¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J=0.6 Hz, 1H), 7.75 (s, 2H), 3.71 (s,3H), 3.27-3.19 (m, 1H), 1.37 (s, 12H), 1.29-1.27 (m, 6H).

6-[3,5-dichloro-4-(5-isopropyl-1-methyl-6-oxo-pyridazine-3-carbonyl)phenyl]-2H-1,2,4-triazine-3,5-dione(7). A mixture of 7i (30 mg, 66.50 umol,6-bromo-2H-1,2,4-triazine-3,5-dione (12.77 mg, 66.50 umol) in dioxane (4mL) and H₂O (1 mL) was degassed and purged with N₂3 times, and thenPd(dppf)C₁₂ (4.87 mg, 6.65 umol) and K₂CO₃ (27.57 mg, 199.49 umol) wereadded. Then the mixture was stirred at 90° C. for 1 hour under N₂atmosphere. LCMS showed the desired mass was found. The mixture wasfiltered and the filtrate was concentrated. The residue was purified byprep-HPLC (NH₄CO₃) to give 7 (7.65 mg, 17.44 umol, 26.23% yield). MSmass calculated for [M+1]⁺ (C₁₈H₁₅Cl₂N₅O₄) requires m/z 436.2, LCMSfound m/z 436.0.

¹H NMR (400 MHz, MeOH-d₄) δ 8.16 (s, 2H), 7.93-7.91 (m, 1H), 3.72-3.68(m, 3H), 3.24-3.16 (m, 1H), 1.29 (d, J=6.8 Hz, 6H).

Example S8:6-(3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazine-3-carbonyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 8)

(6-chloro-5-isopropylpyridazin-3-yl)(2,6-dichloro-4-iodophenyl)methanone(8a). To a solution of(4-amino-2,6-dichlorophenyl)(6-chloro-5-isopropylpyridazin-3-yl)methanone(7e) (120 mg, 348.21 umol) in HCl (5 M, 2 mL) was added NaNO₂ (28.83 mg,417.85 umol) at 0° C., the mixture was stirred for 0.5 hours. Then tothe mixture was added a solution of KI (115.60 mg, 696.41 umol) in H₂O(5 mL), the resulting mixture was stirred at 20° C. for another 16hours. TLC (petroleum ether: ethyl acetate=5:1, R_(f)=0.6) indicated 7ewas consumed completely. The reaction mixture was extracted with EtOAc(10 mL*3). The combined organic layers were washed with brine (10 mL),dried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by prep-TLC (SiO₂, petroleum ether: ethylacetate=5:1, according TLC) to give 8a (75 mg, 131.72 umol, 37.83%yield) as a white solid. MS mass calculated for [M+1]⁺ (C₁₄H₁₀Cl₃IN₂O)requires m/z 454.9, LCMS found m/z 454.9.

(6-chloro-5-isopropylpyridazin-3-yl)(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone(8b). To a solution of(6-chloro-5-isopropylpyridazin-3-yl)(2,6-dichloro-4-iodophenyl)methanone(8a) (100 mg, 219.54 umol) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (167.25 mg,658.61 umol) in dioxane (3 mL) was added Pd(dppf)C₁₂ (8.03 mg, 10.98umol) and KOAc (107.73 mg, 1.10 mmol). The mixture was degassed andpurged with N₂3 times and stirred at 90° C. for 16 hours. TLC (petroleumether: ethyl acetate=5:1, R_(f)=0.5) and LCMS showed 8a was consumedcompletely and the desired mass was detected. The suspension wasfiltered through a pad of Celite and the pad cake was washed with EtOAc(10 mL*3). The combined filtrates were concentrated in vacuo. Theresidue was purified by prep-TLC (SiO₂, petroleum ether: ethylacetate=5:1, according TLC) to give 8b (150 mg, crude) as a white solid.MS mass calculated for [M+1]⁺ (C₂₀H₂₂BCl₃N₂O₃) requires m/z 455.1, LCMSfound m/z 455.0.

¹H NMR (400 MHz, CDCl₃) δ 8.20-8.18 (m, 1H), 7.79-7.74 (m, 2H),3.40-3.32 (m, 1H), 1.38-1.34 (m, 18H).

6-(3,5-dichloro-4-(6-chloro-5-isopropylpyridazine-3-carbonyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(8c). To a solution of(6-chloro-5-isopropylpyridazin-3-yl)(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone(8b) (50 mg, 109.75 umol) and 6-bromo-1,2,4-triazine-3,5(2H,4H)-dione(63.21 mg, 329.26 umol) in dioxane (4 mL) was added Pd(dppf)C₁₂ (8.03mg, 10.98 umol) and K₂CO₃ (45.51 mg, 329.26 umol) in H₂O (1 mL). Themixture was stirred at 80° C. for 2 hours. TLC (petroleum ether: ethylacetate=5:1) and LCMS showed 18b was consumed completely and the desiredmass was detected. The suspension was filtered through a pad of Celiteand the pad cake was washed with EtOAc (10 ml*3). The combined filtrateswere concentrated to dryness to give a residue. The residue was purifiedby prep-TLC (SiO2, DCM: MeOH=20:1, according TLC) to give 8c (25 mg,28.37 umol, 25.85% yield) as a white solid. MS mass calculated for[M+1]⁺ (C₁₇H₂Cl₃N₅O₃) requires m/z 440.0, LCMS found m/z 442.0.

6-(3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazine-3-carbonyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(8). To a solution of6-(3,5-dichloro-4-(6-chloro-5-isopropylpyridazine-3-carbonyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(8c) (25 mg, 56.73 umol) in HOAc (3 mL) was added NaOAc (23.27 mg,283.66 umol). The mixture was stirred at 120° C. for 16 hours. LCMSshowed 8c was consumed completely and one major peak with desired MS wasdetected. The reaction mixture was concentrated under reduced pressureto remove AcOH. The residue was purified by prep-HPLC (column:Nano-Micro UniSil 5-100 C₁₈ ULTRA 100*250 mm 5 um; mobile phase: [water(0.225% FA)-ACN]; B %: 25-65%, 10 min) to give 8 (1.86 mg, 4.19 umol,7.38% yield). MS mass calculated for [M+1]⁺ (C₁₇H₁₃Cl₂N₅O₄) requires m/z422.0, LCMS found m/z 422.1.

¹H NMR (400 MHz, MeOH-d₄) δ 8.16-8.12 (m, 2H), 7.92-7.90 (m, 1H),3.21-3.12 (m, 1H), 1.29 (d, J=7.0 Hz, 6H).

Example S9:6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 9)

6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(9). To a solution of6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(1f) (30 mg, 68.32 umol) and6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a) (42.22 mg, 204.95umol) in dioxane (2 mL) was added Pd (dppf) C₁₂ (5.00 mg, 6.83 umol) anda solution of K₂CO₃ (28.33 mg, 204.95 umol) in H₂O (0.5 mL). The mixturewas stirred at 80° C. for 3 hours. LCMS showed if was consumedcompletely and the desired mass was detected. To the mixture was addedpalladium scavenger Si-TMT (1g) and stirred at 20° C. for 2 hours. Themixture was filtered and the filtrate was concentrated under reducedpressure. The residue was purified by Prep-HPLC (column: Waters Xbridge150*25 5u; mobile phase: [water (10 mM NH₄HCO₃)-ACN]) to give 9. MS masscalculated for [M+1]⁺ (C₁₈H₁₇Cl₂N₅O₄) requires m/z 438.1, LCMS found m/z438.0.

¹H NMR (400 MHz, MeOH-d₄) δ 8.14-8.24 (m, 2H), 7.32-7.35 (m, 1H),3.64-3.72 (m, 3H), 3.49 (s, 3H), 3.20 (td, J=7.0, 13.6 Hz, 1H), 1.28 (d,J=6.8 Hz, 6H).

Example S10:6-(3,5-dichloro-4-((5-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 10)

6-(3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(10a). The mixture of3-chloro-4-cyclopropyl-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridazine(6d) (75 mg, 169.86 umol),6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a) (45.49 mg, 220.82umol), Pd(dppf)C₁₂ (12.43 mg, 16.99 umol) and K₂CO₃ (46.95 mg, 339.72umol, 2 eq) in dioxane (5 mL), H₂O (0.5 mL) was heated to 90° C. for 16hours under N₂. LCMS showed 6d was consumed completely and the desiredMS was detected. The mixture was filtered and the filtrate wasconcentrated. The residue was purified by Prep-TLC (Ethyl acetate: MeOH)to give 10a. MS mass calculated for [M+1]⁺ (C₁₇H₁₂Cl₃N₅O₃) requires m/z440.0, LCMS found m/z 440.1.

¹H NMR (400 MHz, DMSO-d₆) δ 8.16-8.10 (m, 2H), 7.51 (s, 1H), 3.58 (s,4H), 1.22-1.20 (m, 1H), 1.23-1.20 (m, 1H), 1.19-1.14 (m, 1H), 1.19-1.14(m, 1H), 1.11-1.05 (m, 1H), 1.10-1.05 (m, 1H).

6-(3,5-dichloro-4-((5-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(10). A mixture of6-(3,5-dichloro-4-((6-chloro-5-cyclopropylpyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(10a) (28 mg, 63.54 umol) and NaOAc (26.06 mg, 317.70 umol) in HOAc (1mL) was heated to 110° C. for 16 hours. LCMS showed the 10a was consumedcompletely and desired MS was detected. The mixture was concentrated.The residue was purified by Prep-HPLC (column: Welch Ultimate AQ-C18150*30 mm*5 um; mobile phase: [water (0.1% TFA)-ACN]) to give 10. MSmass calculated for [M+1]⁺ (C₁₇H₁₃Cl₂N₅O₄) requires m/z 422.0, LCMSfound m/z 422.0.

¹H NMR (400 MHz, DMSO-d₆) δ 12.43 (s, 1H), 12.17 (s, 1H), 8.07 (s, 2H),7.16 (s, 1H), 3.57 (s, 3H), 2.19-2.10 (m, 1H), 1.11-1.05 (m, 2H), 1.01(td, J=2.8, 5.2 Hz, 2H).

Example S11:6-(3,5-dichloro-4-((5-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 11)

Compound 11 can be prepared using intermediate 6b according to theprocedure described for Example S5 by replacing 5a with 6b and followingthe remaining synthetic sequence.

Example S12:6-(3,5-dichloro-4-((5-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 12)

Compound 12 can be prepared by reaction of the boronic ester derivatived, the synthesis of which is outlined in Example S11, with 3A accordingto the reaction conditions used for the preparation of Compound 7.

Example S13:6-(3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazine-3-carbonyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 13)

6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)-4-isopropylpyridazin-3(2H)-one(13a). To a solution of(6-chloro-5-isopropylpyridazin-3-yl)(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone(8b) (200 mg, 439.01 umol) in HOAc (10 mL) was added NaOAc (180.07 mg,2.20 mmol). The mixture was stirred at 120° C. for 16 hours. LCMS showedone major peak with the desired mass was formed. The reaction mixturewas concentrated under reduced pressure. The residue was extracted withEthyl acetate (10 mL*3) and H₂O (10 mL). The combined organic layerswere washed with NaHCO₃(10 mL), dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified byPrep-TLC (SiO₂, Petroleum ether: Ethyl acetate) to give 13a. MS masscalculated for [M+1]⁺ (C₂₀H₂₃BCl₂N₂O₄) requires m/z 437.1, LCMS foundm/z 437.1.

¹H NMR (400 MHz, CD₃OD) 6 7.90 (s, 1H), 7.68-7.70 (m, 1H), 7.43-7.46 (m,1H), 3.13-3.20 (m, 1H), 1.29-1.30 (m, 6H), 1.20 (s, 12H).

6-(3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazine-3-carbonyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 13). A mixture of6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)-4-isopropylpyridazin-3(2H)-one(13a) (60 mg, 137.26 umol),6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a) (28.28 mg, 137.26umol), Pd(dppf)C₁₂ (10.04 mg, 13.73 umol), and K₂CO₃ (56.91 mg, 411.78umol) in dioxane (4 mL) and H₂O (1 mL) was degassed and purged with N₂for 3 times, and then the mixture was stirred at 90° C. for 16 hoursunder N₂ atmosphere. LCMS showed one major peak with the desired masswas formed. The reaction mixture was concentrated under reducedpressure. The residue was purified by Prep-HPLC (column: Welch UltimateAQ-C18 150*30 mm*5 um; mobile phase: [water (0.225% FA)-ACN]) to give13. MS mass calculated for [M+1]⁺ (C₁₈H₁₅Cl₂N₅O₄) requires m/z 436.1,LCMS found m/z 436.0.

¹H NMR (400 MHz, CD₃OD) 6 8.14-8.17 (m, 2H), 7.90-7.93 (m, 1H),3.67-3.70 (m, 3H), 3.35 (s, 3H), 3.13-3.21 (m, 1H), 1.30 (d, J=6.8 Hz,6H).

Example 14:6-(3,5-dichloro-4-(5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazine-3-carbonyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 14)

Compound 14 can be prepared by reaction of 7i with 3A according to thereaction conditions used for the preparation of Compound 7.

Example S15:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 15)

6-(4-amino-2,6-dichlorobenzyl)-4-isopropylpyridazin-3(2H)-one (15a). Asolution of2-(4-amino-2,6-dichlorophenyl)-2-(6-chloro-5-isopropylpyridazin-3-yl)acetonitrile(7d) (0.15 g, 421.76 umol) in HOAc (0.6 mL), H₂O (0.6 mL) and conc. HCl(2.4 mL) was heated to 120° C. for 32 hours. LCMS showed the reactionwas completed, and desired MS was detected. After cooling, the mixturewas adjusted to pH-7 with 4M NaOH at 0° C., the solid was filtered anddried to give 15a (0.12 g, crude). MS mass calculated for [M+1]⁺(C₁₄H₁₅Cl₂N₃O) requires m/z 312.1, LCMS found m/z 312.1.

6-(4-amino-2,6-dichlorobenzyl)-4-isopropyl-2-(4-methoxybenzyl)pyridazin-3(2H)-one(15b). To a solution of6-(4-amino-2,6-dichlorobenzyl)-4-isopropylpyridazin-3(2H)-one (15a) (200mg, 640.63 umol) in DMF (5 mL) was added PMB-Cl (120.39 mg, 768.75 umol,104.69 uL) and K₂CO₃ (106.25 mg, 768.75 umol). The mixture was stirredat 20° C. for 16 hours. TLC showed ˜10% of 15a was remained and one newspot was formed. The suspension was filtered through a pad of Celite andthe pad cake was washed with EtOH (5 mL*3). The combined filtrates wereconcentrated in vacuum. The residue was purified by Prep-TLC (SiO₂,Petroleum ether: Ethyl acetate) to give 15b.

¹H NMR (400 MHz, DMSO-d₆) δ 7.17 (d, J=8.6 Hz, 2H), 7.04 (s, 1H),6.85-6.80 (m, 2H), 6.65 (s, 2H), 5.63 (s, 2H), 5.02 (s, 2H), 4.01 (s,2H), 3.71 (s, 3H), 2.97 (td, J=6.8, 13.5 Hz, 1H), 1.07 (d, J=7.0 Hz,6H).

6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-isopropyl-2-(4-methoxybenzyl)pyridazin-3(2H)-one(15c). To a solution of6-(4-amino-2,6-dichlorobenzyl)-4-isopropyl-2-(4-methoxybenzyl)pyridazin-3(2H)-one(15b) (70 mg, 161.91 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(822.29 mg, 3.24 mmol) in CH₃CN (2 mL) was added t-BuONO (33.39 mg,323.82 umol, 38.51 uL) at 0° C., then the mixture was stirred at 0° C.for 4 hours. Then the mixture was stirred at 25° C. for another 12hours. TLC indicated reactant 15b was consumed completely and many newspots were formed. The reaction mixture was diluted with water (5 mL),and extracted with ethyl acetate (5 mL). The organic phase wasseparated, washed with brine (5 mL*3), dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified by columnchromatography (SiO₂, Petroleum teeth: Ethyl acetate) to give 15c (100mg, crude). MS mass calculated for [M+1]⁺ (C₂₈H₃₃BCl₂N₂O₄) requires m/z543.2, LCMS found m/z 543.1.

6-(3,5-dichloro-4-((5-isopropyl-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(15d). To a solution of6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-isopropyl-2-(4-methoxybenzyl)pyridazin-3(2H)-one(15c) (20 mg, 36.81 umol) and 6-bromo-2H-1,2,4-triazine-3,5-dione (10.60mg, 55.22 umol) in dioxane (2 mL) and H₂O (0.5 mL) were addedPd(dppf)C₁₂ (2.69 mg, 3.68 umol) and K₂CO₃ (15.26 mg, 110.44 umol). Themixture was stirred at 90° C. for 12 hours. LCMS showed the 15c wasconsumed and desired MS was detected. The reaction mixture waspartitioned between ethyl acetate 5 mL and H₂O 5 mL. The organic phasewas separated, washed with brine (3 mL*3), dried over Na₂SO₄, filteredand concentrated under reduced pressure. The residue was purified byPrep-TLC (SiO₂) to give 15d. MS mass calculated for [M+1]⁺(C₂₅H₂₃Cl₂N₅O₄) requires m/z 528.1, LCMS found m/z 528.0.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(15). To a solution of6-(3,5-dichloro-4-((5-isopropyl-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(15d) (15 mg, 28.39 umol) in CH₃CN (2 mL) and H₂O (0.5 mL) was added CAN(77.82 mg, 141.94 umol, 70.74 uL). The mixture was stirred at 25° C. for16 hours. LC-MS showed 15d was consumed completely and one main peakwith desired m/z. The mixture was concentrated under reduced pressure.The residue was purified by Prep-HPLC to give 15. MS mass calculated for[M+1]⁺ (C₁₇H₁₅Cl₂N₅O₃) requires m/z 408.1, LCMS found m/z 408.0.

¹H NMR (400 MHz, MeOH-d4) δ 8.10-8.13 (m, 2H), 7.24-7.27 (m, 1H), 4.36(s, 2H), 3.07-3.15 (m, 1H), 1.19-1.23 (m, 6H).

Example S16:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 16)

6-(3,5-dichloro-4-((5-isopropyl-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(16a). A mixture of6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-isopropyl-2-(4-methoxybenzyl)pyridazin-3(2H)-one(15c) (130 mg, 239.28 umol),6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a) (73.94 mg, 358.93umol), Pd(dppf)C₁₂ (17.51 mg, 23.93 umol), and K₂CO₃ (99.21 mg, 717.85umol) in dioxane (4 mL) and H₂O (1 mL) was degassed and purged with N₂for 3 times, and then the mixture was stirred at 90° C. for 16 hoursunder N₂ atmosphere. LCMS showed one peak with the desired mass wasformed. The reaction mixture was extracted with ethyl acetate (10 mL*3)and H₂O (10 mL). The combined organic layers were washed with brine (5mL), dried over anhydrous Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by Prep-TLC (Dichloromethane:Methanol) to give 16a. MS mass calculated for [M+1]⁺ (C₂₆H₂₅Cl₂N₅O₄)requires m/z 542.1, LCMS found m/z 542.1.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(16). To a solution of6-(3,5-dichloro-4-((5-isopropyl-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(16a) (20 mg, 36.87 umol) in CH₃CN (2 mL) and H₂O (0.5 mL) was added CAN(80.86 mg, 147.49 umol, 73.51 uL) at 20° C. And the mixture was stirredat 20° C. for 16 hours. TLC and LCMS showed one main peak with thedesired mass was detected. The reaction mixture was concentrated underreduced pressure. The residue was purified by Prep-HPLC (column: LunaC18 100*30 5u; mobile phase: [water (0.225% FA)-ACN) to give 16. MS masscalculated for [M+1]⁺ (C₁₈H₁₇Cl₂N₅O₃) requires m/z 422.1, LCMS found m/z422.0.

¹H NMR (400 MHz, CD₃OD) 6 8.12-8.14 (m, 2H), 7.24-7.26 (m, 1H),4.35-4.37 (m, 2H), 3.66-3.68 (m, 3H), 3.12-3.15 (m, 1H), 1.21 (d, J=6.8Hz, 6H).

Example S17:6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 17)

2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)isoindoline-1,3-dione(17a). To a solution of6-(4-amino-2,6-dichlorobenzyl)-4-isopropylpyridazin-3(2H)-one (15a) (450mg, 1.44 mmol) in HOAc (5 mL) was added isobenzofuran-1,3-dione (213.50mg, 1.44 mmol). The mixture was stirred at 130° C. for 4 hours. LCMSshowed one peak with the desired mass was detected. The reaction mixturewas concentrated under reduced pressure to remove HOAc. This mixture wasextracted with water (50 mL) and ethyl acetate (50 mL), and then washedwith NaHCO₃ (20 mL*3), dried over Na₂SO₄, filtered and concentratedunder reduced pressure to give 17a. MS mass calculated for [M+1]⁺(C₂₂H₁₇Cl₂N₃O₃) requires m/z 442.1, LCMS found m/z 442.1.

2-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)isoindoline-1,3-dione(17b). A mixture of2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)isoindoline-1,3-dione(17a) (600 mg, 1.36 mmol) and DMF-DMA (5 mL) was heated to 105° C. for 3hours. LCMS showed one peak with the desired mass was formed. Thereaction mixture was and concentrated under reduced pressure to give17b. MS mass calculated for [M+1]⁺ (C₂₃H₁₉Cl₂N₃O₃) requires m/z 456.1,LCMS found m/z 456.1.

6-(4-amino-2,6-dichlorobenzyl)-4-isopropyl-2-methylpyridazin-3(2H)-one(17c). A solution of2-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)isoindoline-1,3-dione(17b) (600 mg, 1.31 mmol) in N-BUTYLANILINE (981.11 mg, 6.57 mmol, 1.05mL) and MeOH (3 mL) was heated to 70° C. for 3 hours. LCMS showed onepeak with the desired mass was formed. The reaction mixture concentratedunder reduced pressure. The residue was purified by columnchromatography (SiO₂, Petroleum ether: Ethyl acetate) to give 17c. MSmass calculated for [M+1]⁺ (C₁₅H₁₇Cl₂N₃O) requires m/z 326.1, LCMS foundm/z 326.1.

¹H NMR (400 MHz, CD₃OD) 6 7.04-7.08 (m, 1H), 6.69-6.72 (m, 2H), 4.13 (s,2H), 3.70 (s, 3H), 3.06-3.14 (m, 1H), 1.15 (d, J=6.8 Hz, 6H).

6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-isopropyl-2-methylpyridazin-3(2H)-one(17d). To a solution of6-(4-amino-2,6-dichlorobenzyl)-4-isopropyl-2-methylpyridazin-3(2H)-one(17c) (33 mg, 101.16 umol) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (77.06 mg,303.48 umol) in MeCN (1 mL) was added t-BuONO (20.86 mg, 202.32 umol,24.06 uL). The mixture was stirred at 20° C. for 16 hours. LCMS showedone peak with the desired mass was formed. The reaction mixture wasextracted with ethyl acetate (20 mL*3) and H₂O (20 mL). The combinedorganic layers were washed with brine (10 mL), dried over anhydrousNa₂SO₄, filtered and concentrated under reduced pressure. The residuewas purified by Prep-TLC (Petroleum ether: Ethyl acetate) to give 17d.MS mass calculated for [M+1]⁺ (C₂₁H₂₇BCl₂N₂O₃) requires m/z 437.1, LCMSfound m/z 437.1.

¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 2H), 6.88 (s, 1H), 4.27 (s, 2H), 3.71(s, 3H), 3.16 (td, J=7.0, 13.8 Hz, 1H), 1.36 (s, 12H), 1.15 (d, J=6.8Hz, 6H).

6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(17). A mixture of6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-isopropyl-2-methylpyridazin-3(2H)-one(17d) (24.7 mg, 56.50 umol), 6-bromo-1,2,4-triazine-3,5(2H,4H)-dione(10.85 mg, 56.50 umol), Pd(dppf)C₁₂ (4.13 mg, 5.65 umol) and K₂CO₃(23.43 mg, 169.50 umol, 3 eq) in dioxane (1 mL) and H₂O (0.5 mL) wasdegassed and purged with N₂ for 3 times, and then the mixture wasstirred at 90° C. for 16 hours under N₂ atmosphere. LCMS showed one peakwith the desired mass was formed. The mixture was added palladiumscavenger Si-TMT (3 g) and stirred at 20° C. for 1 hour, then filteredand concentrated under reduced pressure. The residue was purified byPrep-HPLC (column: Luna C18 100*30 5u; mobile phase: [water (0.225%FA)-ACN]) to give 17. MS mass calculated for [M+1]⁺ (C₁₈H₁₇Cl₂N₅O₃)requires m/z 422.1, LCMS found m/z 422.1.

¹H NMR (400 MHz, MeOH-d₄) δ 8.10-8.14 (m, 2H), 7.21-7.23 (m, 1H),4.35-4.37 (m, 2H), 3.64 (s, 3H), 3.13 (quin, J=6.9 Hz, 1H), 1.19 (d,J=6.8 Hz, 6H).

Example S18:6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 18)

Compound 18 can be prepared by reaction of 17d with 3A according to theprocedure described for Example S17.

Example S19:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-ethyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 19)

6-bromo-2-ethyl-1,2,4-triazine-3,5(2H, 4H)-dione (19a). To a solution of6-bromo-1,2,4-triazine-3,5(2H, 4H)-dione (50 mg, 260.46 umol) in CH₃CN(2 mL) was added BSA (132.46 mg, 651.15 umol, 160.95 uL). Then themixture was stirred at 82° C. for 3 hours. Then iodoethane (60.93 mg,390.69 umol, 31.25 uL) was added in the mixture. The resulting mixturewas stirred at 82° C. for another 16 hours. LCMS and TLC showed thestarting material was consumed, and the desired MS was detected. Themixture was concentrated in vacuum. The residue were purified byPrep-TLC (Dichloromethane: Methanol) to give 19a. MS mass calculated for[M+1]⁺ (C₅H₆BrN₃O₂) requires m/z 220.0, LCMS found m/z 219.9.

¹H NMR (400 MHz, DMSO-d₆) δ 12.45 (br s, 1H), 3.79-3.89 (m, 2H), 1.19(t, J=7.2 Hz, 3H).

6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-ethyl-1,2,4-triazine-3,5(2H,4H)-dione (19b). To a solution of3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropylpyridazine(2b) (40 mg, 90.18 umol) and 6-bromo-2-ethyl-1,2,4-triazine-3,5(2H,4H)-dione (19a). (19.84 mg, 90.18 umol) in dioxane (4 mL) and H₂O (1 mL)was added K₂CO₃ (37.39 mg, 270.54 umol) and Pd(dppf)C₁₂ (659.85 ug).Then the mixture was stirred at 80° C. for 2 hours under N₂. LCMS showedthe 19a was completed. The mixture was concentrated in vacuum. Theresidue was extracted with Ethyl acetate (10 mL*2) and H₂O (5 mL). Thecombined organic layer was concentrated in vacuum. The residue waspurified by Prep-TLC (Dichloromethane: Methanol) to give 19b (20 mg,crude). The product was used directly in next step. MS mass calculatedfor [M+1]⁺ (C₁₈H₁₆Cl₃N₅O₃) requires m/z 456.0, LCMS found m/z 456.1.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-ethyl-1,2,4-triazine-3,5(2H,4H)-dione(19). To a solution of6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-ethyl-1,2,4-triazine-3,5(2H,4H)-dione (19b) (20 mg, 43.79 umol) in AcOH (3 mL) was added NaOAc(17.96 mg, 218.96 umol). Then the mixture was stirred at 120° C. for 16hours. LCMS and HPLC showed the 19b was completed, and desired was foundin the major peak. The mixture was concentrated in vacuum. The residuewas purified by Prep-HPLC (column: Nano-Micro UniSil 5-100 C₁₈ ULTRA100*250 mm Sum; mobile phase: [water (0.1% TFA)-ACN]) to give 19. MSmass calculated for [M+1]⁺ (C18H17Cl2N5O4) requires m/z 438.1, LCMSfound m/z 438.0.

¹H NMR (400 MHz, MeOH-d4) δ 8.18 (s, 2H), 7.36 (s, 1H), 4.10 (q, J=7.2Hz, 2H), 3.15 (d, J=13.2 Hz, 1H), 1.39 (t, J=7.0 Hz, 3H), 1.29 (d, J=7.0Hz, 6H).

Example S20: ethyl2-(6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetate(Compound 20)

Ethyl 2-(6-bromo-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetate(20a). BSA (1.32 g, 6.51 mmol, 1.61 mL) was added to a mixture of6-bromo-1,2,4-triazine-3,5(2H,4H)-dione (500 mg, 2.60 mmol) in CH₃CN (5mL) at 82° C. for 3 hours, Then ethyl 2-bromoacetate (652.45 mg, 3.91mmol, 432.08 uL) was added, the resulting mixture was stirred at 82° C.for 16 hours. LCMS showed the starting material was consumed completelyand desired MS was detected. The mixture was concentrated in vacuum. Theresidue was partitioned between ethyl acetate (10 mL*2) and H₂O (3 mL).The combined organic phase was washed with brine (5 mL*3), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by Prep-TLC (SiO₂, DCM: MeOH) to give 20a. MS mass calculatedfor [M+1]⁺ (C₇H₈BrN₃O₄) requires m/z 278.0, LCMS found m/z 278.0.

¹H NMR (400 MHz, MeOH-d4) δ 4.70 (s, 2H), 4.25 (q, J=7.2 Hz, 2H), 1.29(t, J=7.2 Hz, 3H).

ethyl2-(6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetate(20b). To a solution of ethyl2-(6-bromo-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetate (20a)(80 mg, 287.71 umol) and3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropylpyridazine(2b) (128.20 mg, 287.71 umol) in THF (2 mL) was added Pd(dppf)C₁₂(18.75mg, 28.77 umol) and K₃PO₄ (122.14 mg, 575.42 umol) in H₂O (0.5 mL). Themixture was stirred at 80° C. for 16 hours under N₂. LCMS showed the 20awas consumed completely and desired MS was detected. The mixture wasconcentrated in vacuum. The residue was partitioned between ethylacetate (10 mL*2) and H₂O (3 mL). The combined organic phase was washedwith brine (5 mL*3), dried with anhydrous Na₂SO₄, filtered andconcentrated in vacuum. The residue was purified by Prep-TLC (Petroleumether: Ethyl acetate) to give 20b. MS mass calculated for [M+1]⁺(C₂₀H₁₈Cl₃N₅O₅) requires m/z 514.0, LCMS found m/z 514.0.

ethyl2-(6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetate(20). A mixture of ethyl2-(6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetate(20b) (48 mg, 93.25 umol) and NaOAc (38.25 mg, 466.25 umol) in HOAc (3mL) was heated to 110° C. and stirred for 16 hours. LCMS showed 20b wasconsumed completely and the desired MS was detected. The mixture wasconcentrated. The residue was purified by Prep-HPLC (column: Luna C18100*30 5u; mobile phase: [water (0.225% FA)-ACN]) to give 20. MS masscalculated for [M+1]⁺ (C₂₀H₁₉Cl₂N₅O₆) requires m/z 496.1, LCMS found m/z496.1.

¹H NMR (400 MHz, DMSO-d₆) δ 12.67 (s, 1H), 12.21 (s, 1H), 8.09 (s, 2H),7.43 (s, 1H), 4.83 (s, 2H), 4.19 (q, J=7.2 Hz, 2H), 3.05 (td, J=6.8,13.5 Hz, 1H), 1.25-1.18 (m, 9H).

Example S21:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-(2,2,2-trifluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 21)

4-allyl-6-bromo-1,2,4-triazine-3,5(2H,4H)-dione (21a). To a solution of6-bromo-2H-1,2,4-triazine-3,5-dione (1) (200 mg, 1.04 mmol) and3-bromoprop-1-ene (126.04 mg, 1.04 mmol) in DMSO (2.5 mL) was addedportion-wise NaH (41.67 mg, 1.04 mmol, 60% purity) at 25° C. Thereaction mixture was stirred for 1 hour. LCMS showed the startingmaterial was consumed completely and desired MS was detected. Thereaction mixture was diluted with water (10 mL) and extracted with ethylacetate (10 mL*2). The combined organic layers was washed with brine (10mL), dried over Na₂SO₄, filtered and concentrated under reducedpressure. The residue was purified by Prep-TLC (Petroleum ether: Ethylacetate) to give 21a.

¹H NMR (400 MHz, MeOH-d4) δ 5.85-5.90 (m, 1H), 5.19-5.28 (m, 2H),4.49-4.50 (d, 2H).

4-allyl-6-bromo-2-(2,2,2-trifluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(21b). To a solution of 4-allyl-6-bromo-1,2,4-triazine-3,5(2H,4H)-dione(21a) (55 mg, 237.03 umol) in DMF (2 mL) was added Cs₂CO₃ (154.46 mg,474.07 umol). Then 2,2,2-trifluoroethyl trifluoromethanesulfonate (66.02mg, 284.44 umol, 25.00 uL) was added in the mixture. And the resultingmixture was stirred at 20° C. for 1 hour. TLC showed the reaction wascompleted, and one new spot was formed. The mixture was concentrated invacuum. The residue was purified by Prep-TLC (SiO₂, Petroleum ether:Ethyl acetate) to give 21b.

¹H NMR (400 MHz, CDCl₃) δ 7.28-7.98 (m, 1H), 5.86 (ddt, J=17.0, 10.4,6.2, 6.2 Hz, 1H), 5.24-5.47 (m, 2H), 4.53-4.66 (m, 4H).

6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-(2,2,2-trifluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(21c). To a solution of4-allyl-6-bromo-2-(2,2,2-trifluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(21b) (20 mg, 63.68 umol) and3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropylpyridazine(2b) (33.90 mg, 76.42 umol) in dioxane (3 mL) and H₂O (1 mL) was addedK₂CO₃ (17.60 mg, 127.36 umol) and Pd(dppf)C₁₂ (4.66 mg, 6.37 umol) underN₂. Then the mixture was stirred at 90° C. for 16 hours under N₂. LCMSand TLC showed the reaction was completed and desired MS was detected.The mixture was concentrated in vacuum. The residue was extracted withethyl acetate (10 mL) and brine (5 mL). The organic layer wasconcentrated in vacuum. The residue was purified by Prep-TLC (SiO₂,Dichloromethane: Methanol) to give 21c (20 mg, crude). MS masscalculated for [M+1]⁺ (C₁₈H₁₃Cl₃F₃N₅O₃) requires m/z 510.0, LCMS foundm/z 510.1.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-(2,2,2-trifluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(21). To a solution of6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-(2,2,2-trifluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(21c) (20 mg, 39.16 umol) in HOAc (3 mL) was added NaOAc (16.06 mg,195.82 umol). Then the mixture was stirred at 120° C. for 16 hours. LCMSshowed the reaction was completed. The mixture was concentrated invacuum. The residue was extracted with ethyl acetate (10 mL*2) and H₂O(5 mL). The combined organic layer was dried over Na₂SO₄, filtered andconcentrated in vacuum. The residue was purified by Prep-HPLC (column:Kromasil 150*25 mm*10 um; mobile phase: [water (0.04% NH₃H₂O+10 mMNH₄HCO₃)-ACN]) to give 21. MS mass calculated for [M+1]⁺(C₁₈H₁₄Cl₂F₃N₅O₄) requires m/z 492.0, LCMS found m/z 492.0.

¹H NMR (400 MHz, MeOH-d4) δ 8.17 (s, 2H), 7.38 (d, J=1 Hz, 1H), 4.80 (q,J=8.6 Hz, 2H), 3.10-3.25 (m, 1H), 1.31 (d, J=7.0 Hz, 6H).

Example S22:2-(6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetonitrile(Compound 22)

2-(6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetamide(22a). A mixture of ethyl2-(6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetate(27 mg, 54.40 umol) in NH₃.H₂O (3 mL) was stirred at 20° C. for 1 hourunder N₂. LCMS showed 20 was consumed completely and the desired MS wasdetected. The mixture was concentrated to give 22a. The product was useddirectly for next step. MS mass calculated for [M+1]⁺ (C₁₈H₁₆Cl₂N₆O₅)requires m/z 467.1, LCMS found m/z 467.1.

2-(6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetonitrile(22). A solution of SOCl₂ (31.83 mg, 267.52 umol, 19.41 uL) in dry DMF(2 mL) was added drop-wise to a solution of2-(6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)acetamide(22a) (25 mg, 53.50 umol) in dry DMF (1 mL) at 25° C. under stirring.The mixture was heated to 120° C. for 3 hours. LCMS showed 22a wasconsumed completely and the desired MS was detected. The mixture wasconcentrated in vacuum. The residue was partitioned between ethylacetate (10 mL*2) and H₂O (3 mL). The combined organic phase was washedwith brine (5 mL*3), dried with anhydrous Na₂SO₄, filtered andconcentrated in vacuum. The residue was purified by Prep-HPLC(condition; column: Xtimate C18 150*25 mm*5 um; mobile phase: [water (10mM NH₄HCO₃)-ACN]) to give 22. MS mass calculated for [M+1]⁺(C₁₈H₁₄Cl₂N₆O₄) requires m/z 449.0, LCMS found m/z 449.0.

¹H NMR (400 MHz, CDCl₃) δ 9.93 (br s, 1H), 8.08 (s, 2H), 7.18 (br s,1H), 5.00 (s, 2H), 3.27 (br s, 1H), 1.33 (br d, J=6.4 Hz, 6H).

Example S23:6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 23)

4-allyl-6-bromo-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(23a). To a solution of 4-allyl-6-bromo-1,2,4-triazine-3,5(2H,4H)-dione(21a) (10 mg, 43.10 umol) in DMF (1 mL) was added Cs₂CO₃ (28.08 mg,86.19 umol). Then 2,2-difluoroethyl trifluoromethanesulfonate (11.07 mg,51.72 umol, 25.00 uL) was added in the mixture. And the resultingmixture was stirred at 20° C. for 1 hour. TLC showed the reaction wascompleted, and one new spot was formed. The mixture was concentrated invacuum. The residue was purified by Prep-TLC (Petroleum ether: Ethylacetate) to give 23a.

¹H NMR (400 MHz, DMSO-d₆) δ 12.45 (br s, 1H), 3.79-3.89 (m, 2H), 1.19(t, J=7.2 Hz, 3H).

6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(23b). To a solution of3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropylpyridazine(2b) (50 mg, 112.72 umol) and4-allyl-6-bromo-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(23a) (36.71 mg, 124.00 umol) in dioxane (3 mL) and H₂O (1 mL) was addedPd(dppf)C₁₂ (8.25 mg, 11.27 umol) and K₂CO₃ (31.16 mg, 225.45 umol).Then the mixture was stirred at 90° C. for 16 hours under N₂. LCMS andTLC showed the reaction was completed. The mixture was concentrated invacuum. The residue was extracted with ethyl acetate (10 mL) and brine(5 mL). The organic layer was concentrated in vacuum. The residue waspurified by Prep-TLC (Dichloromethane: Methanol) to give 23b (20 mg,crude). MS mass calculated for [M+1]⁺ (C₁₈H₁₄C₁₃F₂N₅O₃) requires m/z492.0, LCMS found m/z 492.1.

6-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(23). To a solution of6-(3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(23b) (20 mg, 40.59 umol) in HOAc (2 mL) was added NaOAc (16.65 mg,202.97 umol). Then the mixture was stirred at 120° C. for 16 hours. LCMSshowed the reaction was completed. The mixture was extracted with ethylacetate (5 mL*2) and H₂O (5 mL). The organic layer was dried over invacuum. The residue was purified by Prep-HPLC (column: Luna C18 100*305u; mobile phase: [water (0.1% TFA)-ACN]) to give 23. MS mass calculatedfor [M+1]⁺ (C₁₈H₁₅Cl₂F₂N₅O₄) requires m/z 474.0, LCMS found m/z 474.0.

¹H NMR (400 MHz, MeOH-d₄) δ 8.17 (s, 2H), 7.36 (s, 1H), 6.05-6.46 (m,1H), 4.87 (s, 13H), 4.43 (td, J=13.6, 4.0 Hz, 2H), 3.17 (dt, J=13.6, 7.0Hz, 1H), 1.29 (d, J=6.8 Hz, 6H).

Example S24:6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 24)

6-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(24). To a solution of4-allyl-6-bromo-2-(2,2-difluoroethyl)-1,2,4-triazine-3,5(2H,4H)-dione(23a) (40 mg, 135.10 umol) and6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(if) (59.33 mg, 135.10 umol) in dioxane (3 mL) and H₂O (1 mL) was addedK₂CO₃ (37.34 mg, 270.21 umol) and Pd(dppf)C₁₂ (9.89 mg, 13.51 umol)under N₂. Then the mixture was stirred at 90° C. for 16 hours under N₂.LCMS and TLC showed the reaction was completed. The mixture wasconcentrated in vacuum. The residue was extracted with ethyl acetate (10mL) and brine (5 mL). The organic layer was concentrated in vacuum. Theresidue was purified by Prep-TLC (SiO₂, Dichloromethane: Methanol) togive 24. MS mass calculated for [M+1]⁺ (C₁₉H₁₇Cl₂F₂N₅O₄) requires m/z488.0, LCMS found m/z 488.0.

¹H NMR (400 MHz, DMSO-d₆) δ 12.62 (br s, 1H), 8.13 (s, 2H), 7.46 (s,1H), 6.24-6.60 (m, 1H), 4.34-4.49 (m, 2H), 3.39 (s, 3H), 3.08-3.12 (m,1H), 1.21 (d, J=7.0 Hz, 6H).

Example S25:6-(3,5-dichloro-2-fluoro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 25)

6-(4-amino-2,6-dichloro-3-fluorophenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(25a). To a solution of6-(4-amino-2,6-dichlorophenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(1e) (500 mg, 1.52 mmol) in MeCN (10 mL) was added Select F (593.68 mg,1.68 mmol). The mixture was stirred at 15° C. for 3 hours. TLC and LCMSshowed 1e was consumed completely and the desired MS was detected. Thereaction mixture was quenched by addition H₂O 10 mL. The reactionmixture was partitioned between ethyl acetate (20 mL) and H₂O (30 mL).The organic phase was separated, dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified by columnchromatography (SiO₂, Petroleum ether: Ethyl acetate) to give 25a. MSmass calculated for [M+1]⁺ (C₁₄H₁₄C₁₂FN₃O₂) requires m/z 346.0, LCMSfound m/z 346.2.

¹H NMR (400 MHz, CDCl₃) δ 7.02 (d, J=0.6 Hz, 1H), 6.78-6.85 (m, 1H),3.88 (s, 1H), 3.52-3.57 (m, 3H), 3.24 (dt, J=14.2, 7.0 Hz, 1H), 1.26 (d,J=6.8 Hz, 6H).

(3,5-dichloro-2-fluoro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phen-yl)boronicacid (25b). To a mixture of6-(4-amino-2,6-dichloro-3-fluorophenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one(25a) (150 mg, 433.30 umol) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.20 g,8.67 mmol) in CH₃CN (8 mL) was added t-BuONO (89.36 mg, 866.59 umol,103.07 uL) at 15° C. Then the mixture was stirred at 15° C. for 16hours. TLC, LCMS and HPLC showed 25a was consumed completely and thedesired MS was detected. The mixture was concentrated in vacuum. Theresidue was purified by Prep-HPLC (column: Welch Ultimate AQ-C18 150*30mm*5 um; mobile phase: [water (0.1% TFA)-ACN]) to give 25b. MS masscalculated for [M+1]⁺ (C₁₄H₁₄BCl₂FN₂O₄) requires m/z 375.0, LCMS foundm/z 375.1.

¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.07 (s, 1H), 3.51 (s, 3H),3.23-3.29 (m, 1H), 1.38 (s, 3H), 1.27-1.29 (m, 6H).

6-(3,5-dichloro-2-fluoro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)p-henyl)-1,2,4-triazine-3,5(2H,4H)-dione(25). To a mixture of(3,5-dichloro-2-fluoro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phen-yl)boronicacid (25b) (10 mg, 26.67 umol) and6-bromo-1,2,4-triazine-3,5(2H,4H)-dione (7.68 mg, 40.00 umol) in THF (2mL) and H₂O (0.5 mL) was addedditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (1.74 mg, 2.67umol) and K₃PO₄ (11.32 mg, 53.34 umol). Then the mixture was degassedand purged with N₂ for 3 times, and the mixture was stirred at 90° C.for 16 hours under N₂ atmosphere. LCMS and HPLC showed 25b was consumedcompletely and the desired MS was detected. The reaction mixture wasconcentrated under reduced pressure. The residue was purified byPrep-HPLC (column: Luna C18 100*30 5u; mobile phase: [water (0.1%TFA)-ACN]) to give 25. MS mass calculated for [M+1]⁺ (C₁₇H₁₄Cl₂FN₅O₄)requires m/z 442.0, LCMS found m/z 442.0.

¹H NMR (400 MHz, MeOH-d₄) δ 7.72 (d, J=6.8 Hz, 1H), 7.38 (s, 1H), 3.51(s, 3H), 3.20 (dt, J=13.6, 6.8 Hz, 1H), 1.28 (d, J=6.8 Hz, 6H).

Example S26:6-(4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)-3,5-dimethylphenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 26)

5-bromo-2-(bromomethyl)-1,3-dimethylbenzene (26a). To a solution of(4-bromo-2,6-dimethylphenyl)methanol (1 g, 4.65 mmol) in DCM (30 mL) wasadded PPh₃ (1.83 g, 6.97 mmol) under N₂. Then the mixture was cooled to0-5° C. and CBr₄ (2.31 g, 6.97 mmol) was added to the mixture byportions. Then the mixture was stirred at 15° C. for 0.5 hours under N₂.TLC showed the starting material was consumed completely and one newspot was formed. The mixture was concentrated in vacuum. The residue waspurified by column chromatography (SiO₂, Petroleum ether: Ethyl acetate)to give 26a.

¹H NMR (400 MHz, CDCl₃) δ 7.21 (s, 2H), 4.50 (s, 2H), 2.39 (s, 6H).

2-(4-bromo-2,6-dimethylphenyl)acetonitrile (26b). To a solution of5-bromo-2-(bromomethyl)-1,3-dimethylbenzene (26a) (1.26 g, 4.53 mmol) inDMF (30 mL) was added NaCN (244.35 mg, 4.99 mmol) at 15° C. Then themixture was stirred at 15° C. for 16 hours. TLC showed 26a was consumedcompletely and one new spot was formed. The mixture was poured intoNH₄Cl aqueous solution (20 mL), and extracted with Ethyl acetate (30mL*3). The combined organic phase was washed with brine (30 mL*2), driedwith anhydrous Na₂SO₄, filtered and concentrated in vacuum. The residuewas purified by column chromatography (SiO₂, Petroleum ether: Ethylacetate) to give 26b.

¹H NMR (400 MHz, MeOH-d4) δ 7.28 (s, 2H), 3.79 (s, 2H), 2.38 (s, 6H).

2-(4-bromo-2,6-dimethylphenyl)-2-(6-chloro-5-isopropylpyridazin-3-yl)acetonitrile(26c). To a solution of 2-(4-bromo-2,6-dimethylphenyl)acetonitrile (26b)(800 mg, 3.57 mmol) and 3,6-dichloro-4-isopropylpyridazine (682.05 mg,3.57 mmol) in THF (10 mL) was added t-BuOK (1 M, 7.14 mL) by drop-wiseat 60° C., the resulting mixture was heated to 60° C. for 1 hour. TLCand LCMS showed 26b was consumed completely and the desired MS wasdetected. The mixture was poured into water (20 mL) and extracted withethyl acetate (30 mL*2). The combined organic phase was washed withbrine (20 mL*3), dried with anhydrous Na₂SO₄, filtered and concentrated.The residue was purified by column chromatography (SiO₂, Petroleumether: Ethyl acetate) to give 26c. MS mass calculated for [M+1]⁺(C₁₇H₁₇BrClN₃) requires m/z 378.0, LCMS found m/z 378.2.

¹H NMR (400 MHz, MeOH-d4) δ 7.34 (s, 3H), 7.21 (s, 1H), 6.28 (s, 1H),3.01 (dt, J=13.4, 6.8 Hz, 1H), 2.89 (dt, J=13.8, 6.8 Hz, 1H), 2.27 (s,6H), 1.30-1.27 (m, 6H).

6-(4-bromo-2,6-dimethylbenzyl)-4-isopropylpyridazin-3(2H)-one (26d). Asolution of2-(4-bromo-2,6-dimethylphenyl)-2-(6-chloro-5-isopropylpyridazin-3-yl)acetonitrile(26c) (1 g, 2.78 mmo) in AcOH (10 mL), H₂O (10 mL) and HCl (40 mL) washeated to 120° C. for 48 hours. LCMS showed 26c was consumed completelyand the desired MS was detected. The mixture was adjusted to pH-7 with3M NaOH at 15° C., and lots the solid was collected by filtration anddried to give 26d. MS mass calculated for [M+1]⁺ (C₁₆H₁₉BrN2O) requiresm/z 335.1, LCMS found m/z 335.2.

¹H NMR (400 MHz, DMSO-d₆) δ 12.56 (s, 1H), 7.24 (s, 2H), 7.11 (s, 1H),3.90 (s, 2H), 2.97 (quin, J=6.8 Hz, 1H), 2.21 (s, 6H), 1.11 (d, J=6.8Hz, 6H).

6-(2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-isopropylpyridazin-3(2H)-one(26e). To a solution of6-(4-bromo-2,6-dimethylbenzyl)-4-isopropylpyridazin-3(2H)-one (26d) (50mg, 149.15 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(113.62 mg, 447.44 umol) in dioxane (3 mL) was added KOAc (73.19 mg,745.74 umol) and Pd(dppf)C₁₂ (10.91 mg, 14.91 umol). The mixture wasdegassed and purged with N₂ for 3 times and stirred at 90° C. for 16hours. TLC and LCMS showed 26d was consumed completely and the desiredMS was detected. The mixture was poured into water (10 mL) and extractedwith ethyl acetate (20 mL*2). The combined organic phase was washed withbrine (10 mL*2), dried with anhydrous Na₂SO₄, filtered and concentratedin vacuum. The residue was purified by Prep-TLC (Petroleum ether: Ethylacetate) to give 26e. MS mass calculated for [M+1]⁺ (C₂₂H₃₁BN₂O₃)requires m/z 383.2, LCMS found m/z 383.4.

¹H NMR (400 MHz, MeOH-d4) δ 7.42 (s, 2H), 6.98 (s, 1H), 4.05 (s, 2H),3.06 (dt, J=13.6, 6.8 Hz, 1H), 2.29 (s, 6H), 1.34 (s, 12H), 1.14 (d,J=6.8 Hz, 6H).

6-(4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)-3,5-dimethylphenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(26). To a mixture of6-(2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-isopropylpyridazin-3(2H)-one(26e) (32 mg, 83.70 umol) and6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a) (25.86 mg, 125.55umol) in THF (4 mL) and H₂O (1 mL) was added Pd(dppf)C₁₂ (5.46 mg, 8.37umol) and K₃PO₄ (35.53 mg, 167.41 umol). Then the mixture was degassedand purged with N₂ for 3 times. Then the mixture was stirred at 90° C.for 16 hours under N₂ atmosphere. HPLC and LCMS showed 26e was consumedcompletely and the desired MS was detected. The reaction mixture wasconcentrated under reduced pressure. The residue was purified byPrep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (10 mMNH₄HCO₃)-ACN]) to give 26. MS mass calculated for [M+1]⁺ (C₂₀H₂₃N₅O₃)requires m/z 382.2, LCMS found m/z 382.2.

¹H NMR (400 MHz, MeOH-d4) δ 7.68 (s, 2H), 7.04 (s, 1H), 4.07 (s, 2H),3.65 (s, 3H), 3.07 (dt, J=13.8, 6.6 Hz, 1H), 2.33 (s, 6H), 1.15 (d,J=6.8 Hz, 6H).

Example S27:6-(3,5-dichloro-4-((6-oxo-5-(pentan-3-yl)-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 27)

3,6-dichloro-4-(pentan-3-yl)pyridazine (27a). To a mixture of3,6-dichloropyridazine (1 g, 6.71 mmol) and 2-ethylbutanoic acid (779.70mg, 6.71 mmol, 845.66 uL) in H₂O (20 mL) was added AgNO₃ (1.14 g, 6.71mmol) and TFA (2.30 g, 20.14 mmol, 1.49 mL) in one portion at 50° C.,Then a solution of (NH₄)₂S₂O₈(4.60 g, 20.14 mmol, 4.38 mL) in H₂O (10mL) was added in the mixture, and the mixture was stirred at 70° C. for30 minutes. LCMS showed the reaction was completed. The reaction mixturewas poured into water (20 mL) and extracted with Ethyl acetate (30mL*2). The combined organic phase was washed with brine (2 mL*2), driedwith anhydrous Na₂SO₄, filtered and concentrated in vacuum. The residuewas purified by column chromatography (SiO₂, Petroleum ether: Ethylacetate) to give 27a.

¹H NMR (400 MHz, CDCl₃) δ 7.23 (s, 1H), 2.89-2.98 (m, 1H), 1.67-1.80 (m,2H), 1.55-1.64 (m, 2H), 0.82 (t, J=7.4 Hz, 6H).

3,5-dichloro-4-((6-chloro-5-(pentan-3-yl)pyridazin-3-yl)oxy)aniline(27b). To a solution of 3,6-dichloro-4-(pentan-3-yl)pyridazine (27a)(530 mg, 2.42 mmol) and 4-amino-2,6-dichlorophenol (516.72 mg, 2.90mmol) in DMSO (20 mL) was added K₂CO₃ (1.34 g, 9.68 mmol) and CuI(276.40 mg, 1.45 mmol). The reaction mixture was degassed and purgedwith N₂ for 3 times, and then stirred at 90° C. for 16 hours under N₂atmosphere. TLC and LCMS showed 27a was consumed completely and thedesired MS was detected. The mixture was concentrated in vacuum. Theresidue was extracted with ethyl acetate (50 mL*2) and H₂O (20 mL). Thecombined organic phase was washed with brine (20 mL*3), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by column chromatography (SiO₂, Petroleum ether: Ethyl acetate)to give 27b. MS mass calculated for [M+1]⁺ (C₁₅H₁₆Cl₃N₃O) requires m/z360.0, LCMS found m/z 360.1.

¹H NMR (400 MHz, MeOH-d₄) δ 7.40 (s, 1H), 6.74 (s, 2H), 4.86 (s, 4H),2.96-3.05 (m, 1H), 1.65-1.88 (m, 4H), 0.87 (t, J=7.4 Hz, 6H).

3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(pentan-3-yl)pyridazine (27c).To a solution of3,5-dichloro-4-((6-chloro-5-(pentan-3-yl)pyridazin-3-yl)oxy)aniline(27b) (575 mg, 1.59 mmol) in HCl (5 mL) was added NaNO₂ (132.00 mg, 1.91mmol) at 0° C., and the mixture was stirred at 0° C. for 0.5 hours. Thena solution of KI (529.31 mg, 3.19 mmol) in H₂O (5 mL) was added in thereaction mixture, and the mixture was stirred at 15° C. for another 1.5hours. TLC and LCMS showed 27b was consumed completely and the desiredmass was detected. The mixture was extracted with ethyl acetate (100mL*2) and H₂O (50 mL). The combined organic phase was washed with brine(50 mL*3), dried with anhydrous Na₂SO₄, filtered and concentrated invacuum. The residue was purified by column chromatography (SiO₂,Petroleum ether: Ethyl acetate) to give 27c. MS mass calculated for[M+1]⁺ (C₁₅H₁₄Cl₃IN₂O) requires m/z 470.9, LCMS found m/z 470.8.

¹H NMR (400 MHz, CDCl₃) δ 7.73 (s, 2H), 7.13 (s, 1H), 2.96-3.05 (m, 1H),1.61-1.87 (m, 4H), 0.89 (t, J=7.46 Hz, 6H).

3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-(pentan-3-yl)pyridazine(27d). To a solution of3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(pentan-3-yl)pyridazine (27c)(500 mg, 1.06 mmol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(807.78 mg, 3.18 mmol) in dioxane (15 mL) was added KOAc (520.32 mg,5.30 mmol) and Pd(dppf)C₁₂ (77.59 mg, 106.03 umol). The mixture wasdegassed and purged with N₂ for 3 times and stirred at 90° C. for 16hours. TLC and LCMS showed 27d was consumed completely and the desiredmass was detected. The mixture was extracted with ethyl acetate (50mL*2) and H₂O (20 mL). The combined organic phase was washed with brine(20 mL*3), dried with anhydrous Na₂SO₄, filtered and concentrated invacuum. The residue was purified by column chromatography (SiO₂,Petroleum ether: Ethyl acetate) to give 27d. MS mass calculated for[M+1]⁺ (C₂₁H₂₆BCl₃N₂O₃) requires m/z 471.1, LCMS found m/z 471.1.

¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 2H), 7.13 (s, 1H), 2.94-3.04 (m, 1H),1.62-1.86 (m, 4H), 1.35 (s, 11H), 0.89 (t, J=7.4 Hz, 6H).

6-(3,5-dichloro-4-((6-chloro-5-(pentan-3-yl)pyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(27e). To a mixture of3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-(pentan-3-yl)pyridazine(27d) (150 mg, 318.06 umol) and6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (98.28 mg, 477.09 umol)in THF (4 mL) and H₂O (1 mL) was added Pd(dppf)C₁₂ (20.73 mg, 31.81umol) and K₃PO₄ (135.03 mg, 636.12 umol) was degassed and purged with N₂for 3 times, and then the mixture was stirred at 90° C. for 2 hoursunder N₂ atmosphere. TLC and LCMS showed 27d was consumed completely andthe desired MS was detected. The reaction mixture was dissolved in waterand the pH was adjusted to 4 with HCl (1M, 1 mL). Then the mixture waspartitioned with ethyl acetate (20 mL*2). The combined organic phase waswashed with brine (10 mL*3), dried with anhydrous Na₂SO₄, filtered andconcentrated in vacuum. The residue was purified by Prep-TLC (Petroleumether: Ethyl acetate) to give 27e. MS mass calculated for [M+1]⁺(C₁₉H₁₈Cl₃N₅O₃) requires m/z 470.0, LCMS found m/z 470.1.

¹H NMR (400 MHz, MeOH-d₄) δ 8.25 (s, 2H), 7.61 (s, 1H), 4.10 (q, J=7.2Hz, 1H), 3.69 (s, 3H), 1.71-1.90 (m, 5H), 0.90 (t, J=7.4 Hz, 7H).

6-(3,5-dichloro-4-((6-oxo-5-(pentan-3-yl)-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(27). To a solution of6-(3,5-dichloro-4-((6-chloro-5-(pentan-3-yl)pyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(27e) (80 mg, 169.95 umol) in AcOH (5 mL) was added NaOAc (69.71 mg,849.73 umol) at 15° C. Then the mixture was stirred at 120° C. for 16hours. LCMS and HPLC showed 27e was consumed completely and the desiredMS was detected. The reaction mixture was concentrated under reducedpressure. The residue was purified by Prep-HPLC (column: Luna C18 100*305u; mobile phase: [water (0.225% FA)-ACN]) to give 27. MS masscalculated for [M+1]⁺ (C₁₉H₁₉Cl₂N₅O₄) requires m/z 452.1, LCMS found m/z452.1.

¹H NMR (400 MHz, DMSO-d₆) δ 12.44 (br s, 1H), 12.19 (s, 1H), 8.09 (s,2H), 7.43 (s, 1H), 3.57 (s, 3H), 2.78 (quin, J=7.0 Hz, 1H), 1.59-1.68(m, 4H), 0.79 (t, J=7.4 Hz, 6H).

Example S28:6-(3,5-dichloro-4-((5-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 28)

3,6-dichloro-4-ethylpyridazine (28a). To a mixture of3,6-dichloropyridazine (1 g, 6.71 mmol) and propionic acid (497.24 mg,6.71 mmol, 500.75 uL) in H₂O (30 mL) was added TFA (2.30 g, 20.14 mmol,1.49 mL) and AgNO₃ (1.14 g, 6.71 mmol) and (NH₄)₂S₂O₈(4.60 g, 20.14mmol, 4.38 mL) in one portion at 50° C. The mixture was stirred at 70°C. for 30 minutes. LCMS showed 3,6-dichloropyridazine was completed. Theresidue was poured into NaHCO₃(20 mL). The aqueous phase was extractedwith ethyl acetate(30 mL*2). The combined organic phase was washed withbrine (15 mL*2), dried with anhydrous Na₂SO₄, filtered and concentratedin vacuum. The residue was purified by column chromatography (SiO₂,Petroleum ether: Ethyl acetate) to give 28a. MS mass calculated for[M+1]⁺ (C₆H₆Cl₂N₂) requires m/z 177.0, LCMS found m/z 177.0.

¹H NMR (400 MHz, CDCl₃) δ 8.12-8.16 (m, 2H), 7.90-7.92 (m, 1H),3.12-3.21 (m, 1H), 1.29 (d, J=7.0 Hz, 6H).

6-(4-bromo-2,6-dichlorophenoxy)-3-chloro-4-ethylpyridazine (28b). Asolution of 3,6-dichloro-4-ethylpyridazine (28a) (340 mg, 1.92 mmol) and4-bromo-2,6-dichlorophenol (511.04 mg, 2.11 mmol) in Py (5 mL) wasstirred at 130° C. for 16 hours in microwave tube. LCMS and TLC(Petroleum ether: Ethyl acetate=5:1, R_(f)=0.5) showed 28a was consumedcompletely, and desired MS was detected. The residue was poured intowater (5 mL). The aqueous phase was extracted with ethyl acetate (10mL*2). The combined organic phase was washed with brine (5 mL*2), driedwith anhydrous Na₂SO₄, filtered and concentrated in vacuum. The residuewas purified by Prep-TLC (Petroleum ether: Ethyl acetate) to give 28b(200 mg, crude). MS mass calculated for [M+1]⁺ (C₁₂H₈BrCl₃N₂O) requiresm/z 380.9, LCMS found m/z 380.9.

¹H NMR (400 MHz, CDCl₃) δ 7.44 (s, 4H), 7.15 (s, 1H), 7.10 (s, 1H),2.72-2.80 (m, 3H), 2.66-2.71 (m, 2H), 1.22-1.31 (m, 7H), 1.17 (br t,J=7.58 Hz, 3H).

3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-ethylpyridazine(28c). To a solution of6-(4-bromo-2,6-dichlorophenoxy)-3-chloro-4-ethylpyridazine (28b) (150mg, 392.19 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(298.78 mg, 1.18 mmol) in dioxane (6 mL) was added Pd(dppf)C₁₂ (28.70mg, 39.22 umol) and KOAc (192.45 mg, 1.96 mmol). The mixture was stirredat 90° C. for 16 hours under N₂ atmosphere. TLC (Petroleum ether: Ethylacetate) indicated 28b was consumed completely. The suspension wasfiltered through a pad of Celite and the pad cake was washed with ethylacetate (15 mL*3). The combined filtrates were concentrated in vacuum.The residue was purified by Prep-TLC (SiO₂, Petroleum ether: Ethylacetate) to give 28c. MS mass calculated for [M+1]⁺ (C₁₈H₂O BCl₃N₂O₃)requires m/z 429.1, LCMS found m/z 429.1.

6-(3,5-dichloro-4-((6-chloro-5-ethylpyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(28d). To a solution of3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-ethylpyridazine(28c) (160 mg, 372.50 umol) and6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a) (115.10 mg, 558.75umol) in THF (4 mL) was added Pd(dppf)C₁₂ (24.28 mg, 37.25 umol) andK₃PO₄ (158.14 mg, 745.00 umol) in H₂O (1 mL). The mixture was stirred at80° C. for 16 hours. LCMS showed 28c was consumed completely and thedesired MS was detected. The mixture was filtered and concentrated underreduced pressure. The residue was purified by Prep-HPLC (column: LunaC18 100*30 5u; mobile phase: [water (0.2% FA)-ACN]) to give 28d. MS masscalculated for [M+1]⁺ (C₁₆H₁₂Cl₃N₅O₃) requires m/z 428.0, LCMS found m/z428.0.

¹H NMR (400 MHz, MeOH-d₄) δ 8.25 (s, 2H), 7.59 (s, 1H), 3.69 (s, 3H),2.83-2.90 (m, 2H), 1.36 (t, J=7.6 Hz, 3H).

6-(3,5-dichloro-4-((5-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(28). To a solution of6-(3,5-dichloro-4-((6-chloro-5-ethylpyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(28d) (78 mg, 181.96 umol) in HOAc (3 mL) was added NaOAc (74.64 mg,909.82 umol). The mixture was stirred at 120° C. for 16 hours. LCMSshowed 28d was consumed completely and the desired mass was detected.The reaction mixture was concentrated under reduced pressure to removeAcOH. The residue was purified by Prep-HPLC (column: Luna C18 100*30 5u;mobile phase: [water (0.225% FA)-ACN]) to give 28. MS mass calculatedfor [M+1]⁺ (C₁₆H₁₃Cl₂N₅O₄) requires m/z 410.0, LCMS found m/z 410.0;

¹H NMR (400 MHz, DMSO-d6) δ 8.32 (br s, 1H), 8.14 (s, 2H), 7.46 (s, 1H),3.54 (s, 3H), 1.17 (t, J=7.4 Hz, 3H).

Example S29:6-(3,5-dichloro-4-((5-(1-hydroxypropan-2-yl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(29)

2-methyl-6-(trimethylstannyl)-1,2,4-triazine-3,5(2H,4H)-dione (29a). Toa solution of 6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (900 mg,4.37 mmol) in toluene (15 mL) was addedtrimethyl(trimethylstannyl)stannane (1.72 g, 5.24 mmol, 1.09 mL),Pd(PPh₃)₄(504.86 mg, 436.90 umol), the mixture was stirred at 110° C.for 16 hours under N₂ atmosphere. TLC indicated trace of startingmaterial was remained, and one new spot was formed. The reaction mixturewas concentrated in vacuum, and then diluted with ethyl acetate (15 mL)and washed with KF aqueous (10 mL*2), dried over with Na₂SO₄, filteredand concentrated under reduced pressure. The residue was purified bycolumn chromatography (SiO₂, Petroleum ether: Ethyl acetate) to give29a. MS mass calculated for [M+1]⁺ (C₇H₁₃N₃₀₂Sn) requires m/z 292.0,LCMS found m/z 292.2.

2-(3,6-dichloropyridazin-4-yl)propan-1-ol (29b). To a mixture of3,6-dichloropyridazine (2 g, 13.42 mmol) and 2-methylpropane-1,3-diol(2.65 g, 29.40 mmol, 2.62 mL) in H₂O (10 mL) was added TFA (1.88 g,16.48 mmol, 1.22 mL) and AgNO₃ (3.07 g, 18.07 mmol) at 80° C. Then(NH₄)₂S₂O₈(6.72 g, 10.93 mmol) was added in the mixture by one portionat 80° C. The mixture was stirred at 80° C. for 30 minutes. TLC showedthe starting material was consumed completely. The residue was pouredinto water (10 mL). The aqueous phase was extracted with ethyl acetate(10 mL*2). The combined organic phase was washed with brine (5 mL*2),dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum. Theresidue was purified by column chromatography (SiO₂, Petroleum ether:Ethyl acetate) to give 29b.

¹H NMR (400 MHz, CDCl₃) δ 7.51 (s, 1H), 3.84-3.91 (m, 2H), 3.33-3.42 (m,1H), 1.35 (d, J=7.0 Hz, 3H).

4-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-3,6-dichloropyridazine(29c). To a solution of 2-(3,6-dichloropyridazin-4-yl)propan-1-ol (29b)(700 mg, 3.38 mmol) and tert-butyl-chloro-dimethyl-silane (509.55 mg,3.38 mmol, 414.26 uL) in DMF (15 mL) was added imidazole (276.18 mg,4.06 mmol). The mixture was stirred at 25° C. for 1 hour under N₂atmosphere. TLC indicated 29b was consumed completely. The reactionmixture was diluted with water (50 mL) and extracted with ethyl acetate(50 mL*3), The combined organic phase was washed with brine (50 mL*2),dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum to give29c. The product was used directly for the next step without furtherpurification. MS mass calculated for [M+1]⁺ (C₁₃H₂₂Cl₂N₂OSi) requiresm/z 321.1, LCMS found m/z 321.2.

¹H NMR (400 MHz, CDCl₃) δ 7.48 (s, 1H), 3.73-3.81 (m, 2H), 3.29-3.39 (m,1H), 1.32 (d, J=7.2 Hz, 3H), 0.84 (s, 9H), 0.01 (s, 3H), −0.04 (s, 3H).

4-((5-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-6-chloropyridazin-3-yl)oxy)-3,5-dichloroaniline(29d). To a solution of4-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-3,6-dichloropyridazine(29c) (300 mg, 933.66 umol) in DMSO (10 mL) was added4-amino-2,6-dichlorophenol (225.85 mg, 933.66 umol), K₂CO₃ (387.12 mg,2.80 mmol) and CuI (106.69 mg, 560.19 umol). The mixture was stirred at90° C. for 6 hours under N₂ atmosphere. LCMS indicated 29c was consumedcompletely and the desired mass was detected. The suspension wasfiltered through a pad of Celite and the pad cake was washed with Ethylacetate (50 mL). The reaction mixture was quenched by addition H₂O (30mL) at 20° C., and then diluted with ethyl acetate (50 mL) and extractedwith ethyl acetate (50 mL*5). The combined organic layers were washedwith brine (50 mL*2), dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by Prep-HPLC (column: WelchXtimate C18 150*25 mm*5 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN])to give 29d. MS mass calculated for [M+1]⁺ (C₁₉H₂₆Cl₃N₃O₂Si) requiresm/z 462.1, LCMS found m/z 462.1.

¹H NMR (400 MHz, MeOH-d₄) δ 7.44 (s, 1H), 6.73 (s, 2H), 3.83-3.92 (m,2H), 3.37-3.45 (m, 1H), 1.34 (d, J=7.0 Hz, 3H), 0.83 (s, 9H), −0.01 (d,J=7.2 Hz, 6H).

4-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-3-chloro-6-(2,6-dichloro-4-iodophenoxy)pyridazine(29e). To a solution of4-((5-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-6-chloropyridazin-3-yl)oxy)-3,5-dichloroaniline(29d) (50 mg, 108.02 umol) in ACN (1 mL) was added tertbutylnitrite(22.28 mg, 216.04 umol) and KI (35.86 mg, 216.04 umol). Then thereaction mixture was degassed and purged with N₂ for 3 times. Themixture was stirred at 20° C. for 2 hours. TLC indicated 29d wasconsumed completely. The reaction mixture was concentrated under reducedpressure. The residue was diluted in H₂O (5 mL) and ethyl acetate (10mL). The mixture was extracted with ethyl acetate (5 mL*3). The combinedorganic layers were washed with brine (10 mL), dried over Na₂SO₄,filtered and concentrated under reduced pressure. The residue waspurified by Prep-TLC (SiO₂, Petroleum ether: Ethyl acetate) to give 29e.MS mass calculated for [M+1]⁺ (C₁₉H₂₄Cl₃IN₂O₂Si) requires m/z 573.0,LCMS found m/z 573.0.

6-(4-((5-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-6-chloropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(29f). To a solution of4-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-3-chloro-6-(2,6-dichloro-4-iodophenoxy)pyridazine(29e) (27 mg, 47.06 umol) in dioxane (1 mL) were added2-methyl-6-(tributylstannyl)-1,2,4-triazine-3,5(2H,4H)-dione (29a)(13.92 mg, 48.00 umol) and Pd(dppf)C₁₂.CH₂Cl₂ (3.84 mg, 4.71 umol). Thenthe mixture was degassed and purged with N₂ for 3 times, and then themixture was stirred at 110° C. for 16 hours under N₂ atmosphere. LCMSindicated 40% of 29e remained and the desired mass was detected. Thesuspension was filtered through a pad of Celite and the pad cake waswashed with ethyl acetate (5 mL*3). The combined filtrates wereconcentrated in vacuum. The residue was purified by Prep-TLC (SiO₂,Petroleum ether: Ethyl acetate) to give 29f. MS mass calculated for[M+1]⁺ (C₂₃H₂₈Cl₃N₅O₄Si) requires m/z 572.1, LCMS found m/z 572.1.

2-(6-(2,6-dichloro-4-(2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenoxy)-3-oxo-2,3-dihydropyridazin-4-yl)propylacetate (29g). To a solution of6-(4-((5-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-6-chloropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(29f) (19 mg, 33.16 umol) in HOAc (1 mL) was added NaOAc (13.60 mg,165.81 umol). The mixture was stirred at 120° C. for 16 hours. LCMSshowed 29f was consumed completely and one main peak with the desired MSwas detected. The reaction mixture was concentrated under reducedpressure to remove AcOH to give 29g (30 mg, crude). The product was usedinto the next step without further purification. MS mass calculated for[M+1]⁺ (C₁₉H₁₇Cl₂N₅O₆) requires m/z 482.1, LCMS found m/z 482.1.

6-(3,5-dichloro-4-((5-(1-hydroxypropan-2-yl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(29). To a solution of2-(6-(2,6-dichloro-4-(2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenoxy)-3-oxo-2,3-dihydropyridazin-4-yl)propylacetate (29g) (30 mg, 62.21 umol) in THF (1 mL) was added LiOH.H₂O (1 M,3 mL). The mixture was stirred at 20° C. for 16 hours. LCMS showed 29gwas consumed completely and the desired mass was detected. The reactionmixture was concentrated under reduced pressure. The residue waspurified by Prep-HPLC (column: Nano-micro Kromasil C18 100*30 mm 5 um;mobile phase: [water (0.225% FA)-ACN]) to give 29. MS mass calculatedfor [M+1]⁺ (C₁₇H₁₅C₂N₅O₅) requires m/z 440.0, LCMS found m/z 440.0.

¹H NMR (400 MHz, MeOH-d₄) δ 8.18 (s, 2H), 7.39 (s, 1H), 3.78-3.86 (m,1H), 3.64-3.74 (m, 4H), 3.21-3.27 (m, 1H), 1.30 (d, J=7.0 Hz, 3H).

Example S30:6-(3,5-dichloro-4-((5-(1-hydroxypropyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 30)

1-(3,6-dichloropyridazin-4-yl)propan-1-ol (30a). To a solution of3,6-dichloro-1,2,4,5-tetrazine (300 mg, 1.99 mmol) in Tol. (5 mL) wasadded pent-1-yn-3-ol (334.34 mg, 3.97 mmol, 342.91 uL). The mixture wasstirred at 110° C. for 16 hours in a sealed tube. TLC showed thestarting material was consumed completely and many new spots wereformed. LCMS showed the desired MS was detected. The reaction mixturewas concentrated under reduced pressure. The residue was purified byPrep-TLC (SiO₂, Petroleum ether: Ethyl acetate) to give 30a. MS masscalculated for [M+1]⁺ (C₇H₈Cl₂N₂O) requires m/z 207.0, LCMS found m/z207.1.

¹H NMR (400 MHz, CDCl3) δ ppm 7.77 (s, 1H), 4.91-4.96 (m, 1H), 2.31 (d,J=4.0 Hz, 1H), 1.95 (dqd, J=14.4, 7.4, 7.4, 7.4, 3.4 Hz, 1H), 1.67(dquin, J=14.6, 7.4, 7.4, 7.4, 7.4 Hz, 1H), 1.06 (t, J=7.4 Hz, 3H).

3,6-dichloro-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazine(30b). To a solution of 1-(3,6-dichloropyridazin-4-yl)propan-1-ol (30a)(370 mg, 1.79 mmol) and DHP (751.56 mg, 8.93 mmol, 816.91 uL) in DCM (8mL) was added TsOH (15.39 mg, 89.35 umol). The mixture was stirred at20° C. for 1 hour. LCMS and TLC showed 30a was consumed completely anddesired MS was detected. The reaction mixture was concentrated underreduced pressure. The residue was purified by Prep-TLC (SiO₂, Petroleumether: Ethyl acetate) to give 30b. MS mass calculated for [M+1]⁺(C₁₂H₁₆Cl₂N₂O₂) requires m/z 291.1, LCMS found m/z 291.1.

¹H NMR (400 MHz, CDCl₃) δ ppm 7.71 (s, 1H), 7.56 (s, 1H), 4.97 (dt,J=7.8, 4.0 Hz, 3H), 4.78 (dd, J=7.0, 4.0 Hz, 1H), 4.68-4.71 (m, 1H),4.58 (br s, 6H), 4.40 (t, J=3.4 Hz, 1H), 1.02-1.09 (m, 4H), 0.95 (t,J=7.4 Hz, 3H).

3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazin-3-yl)oxy)aniline(30c). To a solution of3,6-dichloro-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazine (30b)(500 mg, 1.72 mmol) and 4-amino-2,6-dichlorophenol (305.69 mg, 1.72mmol) in DMSO (15 mL) was added K₂CO₃ (949.33 mg, 6.87 mmol) and CuI(196.22 mg, 1.03 mmol) was degassed and purged with N₂ for 3 times, andthen the mixture was stirred at 90° C. for 16 hours under N₂ atmosphere.TLC showed 30b was consumed completely and one new spot was formed. LCMSshowed desired MS was detected. The mixture was diluted in Ethyl acetate(5 mL) and the filtrate was extracted with ethyl acetate (10 mL*3) andH₂O (5 mL). The combined organic phase was washed with brine (10 mL*2),dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum. Themixture was purified by Prep-TLC (Petroleum ether: Ethyl acetate) togive 30c. MS mass calculated for [M+1]⁺ (C₁₈H₂O Cl₃N₃O₃) requires m/z432.1, LCMS found m/z 432.0.

¹H NMR (400 MHz, CDCl₃) δ ppm 7.48 (s, 1H), 7.29 (s, 1H), 6.69 (s, 2H),4.97 (dd, J=7.2, 3.8 Hz, 1H), 4.76-4.83 (m, 1H), 4.58 (br s, 1H), 4.46(br s, 1H), 3.98 (br d, J=7.6 Hz, 1H), 3.79 (br d, J=3.6 Hz, 2H),3.33-3.63 (m, 3H), 1.06 (br t, J=7.2 Hz, 2H), 0.96 (br t, J=7.2 Hz, 2H).

3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazine(30d). A solution of3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazin-3-yl)oxy)aniline(30c) (170 mg, 392.86 umol) in ACN (3 mL) was added KI (130.43 mg,785.71 umol) and t-BuONO (202.56 mg, 1.96 mmol, 233.63 uL). The mixturewas stirred at 20° C. for 2 hours. TLC showed 30c was consumedcompletely and one new spot was formed. LCMS showed desired MS. Thereaction mixture was concentrated under reduced pressure. The residuewas purified by Prep-TLC (SiO₂, Petroleum ether: Ethyl acetate) to give30d. MS mass calculated for [M+1]⁺ (C₁₈H₁₈Cl₃IN₂O₃) requires m/z 542.9,LCMS found m/z 542.9.

¹H NMR (400 MHz, CDCl₃) δ 7.73 (s, 2H), 7.57 (s, 1H), 4.94 (dt, J=7.6,3.8 Hz, 1H), 2.19 (d, J=4.0 Hz, 1H), 2.03-1.94 (m, 1H), 1.85 (dt,J=14.6, 7.2 Hz, 1H), 1.70 (dquin, J=14.6, 7.34, 7.4, 7.4, 7.4 Hz, 1H),1.27 (t, J=7.2 Hz, 1H), 1.12-1.05 (m, 3H).

6-(3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(30e). To a solution of3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazine(30d) (70 mg, 128.77 umol) and2-methyl-6-(trimethylstannyl)-1,2,4-triazine-3,5(2H,4H)-dione (29a)(41.06 mg, 141.65 umol) in dioxane (4 mL) was added Pd(dppf)C₁₂.CH₂Cl₂(10.52 mg, 12.88 umol). The mixture was degassed and purged with N₂ for3 times and stirred at 110° C. for 16 hours. TLC and LCMS showed ˜⅔ of30d was remained, and desired MS was detected. The mixture was pouredinto water (10 mL) and extracted with ethyl acetate (20 mL*2). Thecombined organic phase was washed with brine (10 mL*3), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by Prep-TLC (Petroleum ether: Ethyl acetate) to give 30e. MSmass calculated for [M+1]⁺ (C₂₂H₂₂Cl₃N₅O₅) requires m/z 542.1, LCMSfound m/z 452.1.

¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, 1H), 7.58 (s, 1H), 7.40 (s, 1H),7.40-7.41 (m, 1H), 5.00 (dd, J=7.4, 3.6 Hz, 1H), 4.77-4.85 (m, 1H),4.48-4.52 (m, 1H), 3.94-4.02 (m, 1H), 3.76 (s, 2H), 3.56-3.67 (m, 1H),3.36-3.43 (m, 1H), 1.51-2.01 (m, 6H), 1.19-1.32 (m, 1H), 1.19-1.32 (m,1H), 1.08 (t, J=7.4 Hz, 1H), 0.98 (t, J=7.4 Hz, 1H).

1-(6-(2,6-dichloro-4-(2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenoxy)-3-oxo-2,3-dihydropyridazin-4-yl)propylacetate (30f). To a solution of6-(3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(30e) (15 mg, 27.63 umol) in HOAc (2 mL) was added NaOAc (11.33 mg,138.17 umol). The mixture was stirred at 120° C. for 16 hours. LCMSshowed 30e was consumed completely and the desired MS was detected. Thereaction mixture was concentrated under reduced pressure to give 30f (20mg, crude). MS mass calculated for [M+1]⁺ (C₁₉H₁₇Cl₂N₅O₆) requires m/z482.1, LCMS found m/z 482.0.

6-(3,5-dichloro-4-((5-(1-hydroxypropyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(30). To a solution of1-(6-(2,6-dichloro-4-(2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenoxy)-3-oxo-2,3-dihydropyridazin-4-yl)propylacetate (30f) (20 mg, 41.47 umol) in MeOH (3 mL) and H₂O (0.5 mL) wasadded LiOH.H₂O (1 M, 82.94 uL). The mixture was stirred at 25° C. for 1hour. HPLC and LCMS showed 30f was consumed completely and the desiredMS was detected. The reaction mixture was concentrated under reducedpressure to remove AcOH. The residue was diluted with water (5 mL) andextracted with ethyl acetate (15 mL*3). The combined organic layers weredried over anhydrous Na₂SO₄, filtered and concentrated under reducedpressure. The residue was purified by Prep-HPLC (column: Phenomenex LunaC18 100*30 mm*5 um; mobile phase: [water (0.2% FA)-ACN]) to give 30. MSmass calculated for [M+1]⁺ (C₁₇H₁₅C₂N₅O₅) requires m/z 440.0, LCMS foundm/z 440.1.

¹H NMR (400 MHz, MeOH-d4) δ 8.19 (s, 2H), 7.50 (d, J=1.0 Hz, 1H), 4.74(dd, J=7.6, 2.8 Hz, 1H), 3.68 (s, 3H), 1.89-2.00 (m, 1H), 1.59 (dquin,J=14.2, 7.2, 7.2, 7.2, 7.2 Hz, 1H), 1.03 (t, J=7.4 Hz, 3H).

Example S31:6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 31)

3,6-dichloro-4-(2-methyl-1,3-dioxolan-2-yl)pyridazine (31a). To asolution of 3,6-dichloro-1,2,4,5-tetrazine (1000 mg, 6.62 mmol) in Tol.(15 mL) was added 2-ethynyl-2-methyl-1,3-dioxolane (1.49 g, 13.25 mmol,311.62 uL). The mixture was stirred at 110° C. for 16 hours in a sealedtube. TLC indicated the starting material was consumed completely. Thereaction mixture was concentrated under reduced pressure. The residuewas purified by column chromatography (SiO₂, Petroleum ether: Ethylacetate) to give 31a.

¹H NMR (400 MHz, CDCl₃) δ 7.74 (s, 1H), 4.19-4.08 (m, 2H), 3.89-3.77 (m,2H), 1.80 (s, 3H).

3,5-dichloro-4-((6-chloro-5-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3-yl)oxy)aniline(31b). To a solution of 4-amino-2,6-dichlorophenol (591.45 mg, 3.32mmol) and 3,6-dichloro-4-(2-methyl-1,3-dioxolan-2-yl)pyridazine (31a)(710 mg, 3.02 mmol) in DMSO (25 mL) was added K₂CO₃ (1.25 g, 9.06 mmol)and CuI (345.14 mg, 1.81 mmol) was degassed and purged with N₂ for 3times, and then the mixture was stirred at 90° C. for 16 hours under N₂atmosphere. TLC showed reactants were consumed completely. The reactionmixture was diluted with H₂O (50 mL), and then the pH was adjusted to4-6 with HCl (1M). The mixture was extracted with Ethyl acetate 150 mL(50 mL*3). The combined organic layers were washed with brine 50 mL,dried over anhydrous Na₂SO₄, filtered and concentrated under reducedpressure. The residue was purified by column chromatography (SiO2,Petroleum ether: Ethyl acetate) to give 31b.

¹H NMR (400 MHz, CDCl₃) δ 7.50 (s, 1H), 6.69 (s, 2H), 4.20-4.11 (m, 2H),3.93-3.85 (m, 2H), 3.79 (br s, 2H), 1.83 (s, 3H).

3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(2-methyl-1,3-dioxolan-2-yl)pyridazine(31c). To a solution of3,5-dichloro-4-((6-chloro-5-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3-yl)oxy)aniline(31b) (600 mg, 1.59 mmol) in ACN (30 mL) was added t-BuONO (821.41 mg,7.97 mmol, 947.41 uL) and KI (528.91 mg, 3.19 mmol) at 0° C. And thenthe mixture was stirred at 20° C. for 1 hour. TLC showed 31b wasconsumed completely and one major new spot was formed. The reactionmixture was concentrated under reduced pressure. The residue waspurified by column chromatography (SiO₂, Petroleum ether: Ethyl acetate)to give 31c.

¹H NMR (400 MHz, CDCl₃) δ 7.74 (s, 2H), 7.57 (s, 1H), 4.21-4.11 (m, 2H),3.95-3.84 (m, 2H), 1.84 (s, 3H).

6-(3,5-dichloro-4-((6-chloro-5-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31d). A mixture of3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(2-methyl-1,3-dioxolan-2-yl)pyridazine(31c) (200 mg, 410.25 umol),2-methyl-6-(trimethylstannyl)-1,2,4-triazine-3,5(2H,4H)-dione (30a)(237.87 mg, 820.51 umol), Pd(dppf)C₁₂.CH₂Cl₂ (33.50 mg, 41.03 umol) indioxane (10 mL) was degassed and purged with N₂ for 3 times, and thenthe mixture was stirred at 110° C. for 16 hours under N₂ atmosphere. TLCand LCMS indicated 31c was consumed completely. The reaction mixture wasconcentrated under reduced pressure. The residue was diluted with ethylacetate (10 mL), and then filtered to give 31d (162 mg, crude). MS masscalculated for [M+1]⁺ (C₁₈H₁₄Cl₃N₅O₅) requires m/z 486.0, LCMS found m/z486.0.

¹H NMR (400 MHz, DMSO-d₆) δ 12.46 (s, 1H), 8.19-8.13 (m, 2H), 7.83-7.80(m, 1H), 4.08 (br t, J=7.0 Hz, 2H), 3.87-3.82 (m, 2H), 3.61-3.55 (m,3H), 1.77-1.74 (m, 3H).

6-(4-((5-acetyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31e). To a solution of6-(3,5-dichloro-4-((6-chloro-5-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31d) (160 mg, 328.75 umol) in dioxane (4 mL) was added HCl (4 M, 4.11mL). The mixture was stirred at 80° C. for 1 hour. LCMS showed one mainpeak with desired MS was formed. The suspension was filtered through apad of Celite and the pad cake was washed with ethyl acetate (5 mL*3).The combined filtrates were extracted with ethyl acetate (10 mL*3). Thecombined organic layers were washed with brine 10 mL, dried over Na₂SO₄,filtered and concentrated under reduced pressure to give 31e (80 mg,crude). MS mass calculated for [M+1]⁺ (C₁₆H₁₁Cl₂N₅O₅) requires m/z424.0, LCMS found m/z 424.0.

6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31). To a solution of6-(4-((5-acetyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31e) (80 mg, 141.44 umol) in MeOH (5 mL) was added NaBH₄ (26.75 mg,707.22 umol) at 0° C. The mixture was stirred at 0-20° C. for 0.5 hour.LCMS showed 31e was consumed completely and the desired MS was detected.The reaction mixture was concentrated under reduced pressure to removeMeOH. The residue was diluted with water (15 mL) and extracted withethyl acetate 30 mL (10 mL*3). The combined organic layers were washedwith brine 15 mL, dried over anhydrous Na₂SO₄, filtered and concentratedunder reduced pressure. The residue was purified by Prep-HPLC (column:Phenomenex Luna C18 200*40 mm*10 um; mobile phase: [water (0.225%FA)-ACN]) to give 31. MS mass calculated for [M+1]⁺(C₁₆H₁₃Cl₂N₅O₅)requires m/z 426.0, LCMS found m/z 426.0.

¹H NMR (400 MHz, DMSO-d₆) δ 12.44 (br s, 1H), 12.29 (br s, 1H), 8.10 (s,2H), 7.43 (d, J=1.0 Hz, 1H), 4.75-4.68 (m, 1H), 3.58 (s, 3H), 3.57 (brs, 1H), 1.34 (d, J=6.8 Hz, 3H).

Example S31 P1 and P2:(S)-6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dioneand(R)-6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compounds 31 P1 and 31 P2)

6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31). Dichloro (p-cymene) ruthenium(II) dimer (1.08 mg, 1.77 umol) wassuspended in degassed H₂O (2 mL) and the mixture was degassed withnitrogen for 10 min. A solution of6-(4-((5-acetyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31f) (20 mg, 35.36 umol) in degassed THF (1 mL) and sodium formate(4.81 mg, 70.72 umol, 3.82 uL) was added in the mixture. The reactionmixture was degassed with nitrogen 5 minutes and stirred at 20° C. for30 minutes. TLC and LCMS showed 31f was consumed completely. The mixturewas diluted with water (5 mL) and extracted with ethyl acetate 30 mL (10mL*3). The combined organic layers were washed with brine (5 mL), driedover anhydrous Na₂SO₄, filtered and concentrated under reduced pressure.The residue was purified by Prep-HPLC (column: Welch Ultimate AQ-C18150*30 mm*5 um; mobile phase: [water (0.1% TFA)-ACN]) to give 31. MSmass calculated for [M+1]⁺ (C₁₆H₁₃Cl₂N₅O₅) requires m/z 426.0, LCMSfound m/z 426.0.

¹H NMR (400 MHz, MeOH-d4) δ 8.21 (s, 2H), 7.54 (d, J=1.0 Hz, 1H),4.96-4.92 (m, 1H), 3.70 (s, 3H), 1.48 (d, J=6.4 Hz, 3H).

(S)-6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31 P1) and(R)-6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31 P2). The6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(31) (4.8 mg, 9.20 umol) was separated by SFC (column: DAICEL CHIRALPAKAS (250 mm*30 mm, 10 um); mobile phase: [Neu-EtOH]; B %: 30%-30%, 8 min)to give 31 P1 (1.05 mg, 2.43 umol): MS mass calculated for [M+1]⁺(C₁₆H₁₃Cl₂N₅O₅) requires m/z 426.0, LCMS found m/z 426.0; ¹H NMR (400MHz, MeOH-d4) δ 8.20 (s, 2H), 7.53 (d, J=1.1 Hz, 1H), 4.94-4.92 (m, 1H),3.69 (s, 3H), 1.47 (d, J=6.4 Hz, 3H); and 31 P2 (1.57 mg, 3.68 umol): MSmass calculated for [M+1]⁺ (C₁₆H₁₃Cl₂N₅O₅) requires m/z 426.0, LCMSfound m/z 426.0;

¹H NMR (400 MHz, MeOH-d₄) δ 8.19 (s, 2H), 7.52 (s, 1H), 4.94-4.90 (m,1H), 3.68 (s, 3H), 1.46 (d, J=6.4 Hz, 3H). In this Example, the isomers31 P1 and 31 P2 were separated by chiral chromatography but the absolutechirality of each isomer was not determined. Elution order was used totrack the individual isomers.

Example S32:6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 32)

4-(sec-butyl)-3,6-dichloropyridazine (32a). To a mixture of3,6-dichloropyridazine (200 mg, 1.34 mmol) and (2S)-2-methylbutanoicacid (137.11 mg, 1.34 mmol, 146.17 uL) in H₂O (2 mL) was added AgNO₃(228.05 mg, 1.34 mmol) and TFA (459.22 mg, 4.03 mmol, 298.20 uL) in oneportion at 50° C. Then added (NH₄)₂S₂O₈(919.07 mg, 4.03 mmol, 875.30 uL)in H₂O (2 mL) at 70° C. The mixture was stirred at 70° C. for 1 hour.TLC showed the starting material was consumed completely, and one newspot was formed. The mixture was poured into water (15 mL) and extractedwith ethyl acetate (20 mL*2). The combined organic phase was washed withbrine (10 mL*2), dried with anhydrous Na₂SO₄, filtered and concentratedin vacuum. The residue was purified by Prep-TLC (Petroleum ether: Ethylacetate) to give 32a.

¹H NMR (400 MHz, CDCl₃) δ 7.34 (s, 1H), 3.08 (sxt, J=7.0 Hz, 1H),1.59-1.76 (m, 1H), 1.58-1.61 (m, 1H), 1.28 (d, J=6.8 Hz, 2H), 1.26-1.31(m, 1H), 0.95 (t, J=7.4 Hz, 3H).

4-((5-(sec-butyl)-6-chloropyridazin-3-yl)oxy)-3,5-dichloroaniline (32b).To a solution of 4-(sec-butyl)-3,6-dichloropyridazine (32a) (100 mg,487.61 umol) and 4-amino-2,6-dichlorophenol (104.16 mg, 585.13 umol) inDMSO (5 mL) was added K₂CO₃ (269.57 mg, 1.95 mmol) and CuI (55.72 mg,292.56 umol). The reaction mixture degassed and purged with N₂ for 3times, and then the mixture was stirred at 90° C. for 16 hours under N₂atmosphere. TLC and LCMS showed 32a was consumed completely and desiredMS was detected. The mixture was concentrated in vacuum. The mixture wasextracted with Ethyl acetate (30 mL*2) and H₂O (10 mL). The combinedorganic phase was washed with brine (10 mL*3), dried with anhydrousNa₂SO₄, filtered and concentrated in vacuum. The mixture was purified byPrep-TLC (Petroleum ether: Ethyl acetate) to give 32b. MS masscalculated for [M+1]⁺ (C₁₄H₁₄Cl₃N₃O) requires m/z 346.0, LCMS found m/z346.1.

¹H NMR (400 MHz, MeOH-d₄) δ 7.42 (s, 1H), 6.72-6.76 (m, 2H), 3.06-3.15(m, 1H), 1.62-1.84 (m, 2H), 1.32 (d, J=7.0 Hz, 3H), 0.93-0.98 (m, 3H).

4-(sec-butyl)-3-chloro-6-(2,6-dichloro-4-iodophenoxy)pyridazine (32c).To a solution of4-((5-(sec-butyl)-6-chloropyridazin-3-yl)oxy)-3,5-dichloroaniline (32b)(80 mg, 230.79 umol) in HCl (3 mL) was added NaNO₂ (19.11 mg, 276.95umol) at 0° C., the mixture was stirred for 0.5 hours. Then the mixturewas added a solution of KI (76.62 mg, 461.58 umol) in H₂O (3 mL), themixture was stirred at 15° C. for another 1.5 hours. TLC and LCMSindicated 32b was consumed completely and the desired mass was detected.The mixture was extracted with ethyl acetate (20 mL*2) and H₂O 10 mL.The combined organic phase was washed with brine (10 mL*3), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by Prep-TLC (Petroleum ether: Ethyl acetate) to give 32c. MSmass calculated for [M+1]⁺ (C₁₄H₁₂Cl₃IN₂O) requires m/z 456.9, LCMSfound m/z 457.0.

¹H NMR (400 MHz, CDCl₃) δ 7.73 (s, 2H), 7.18 (s, 1H), 3.05-3.12 (m, 1H),1.59-1.83 (m, 2H), 1.32 (d, J=6.6 Hz, 3H), 0.97 (t, J=7.4 Hz, 3H).

4-(sec-butyl)-3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-oxy)pyridazine(32d). To a solution of4-(sec-butyl)-3-chloro-6-(2,6-dichloro-4-iodophenoxy)pyridazine (32c)(60 mg, 131.14 umol) and4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(99.91 mg, 393.43 umol) in dioxane (4 mL) was added KOAc (64.35 mg,655.71 umol) and Pd(dppf)C₁₂ (9.60 mg, 13.11 umol). The mixture wasdegassed and purged with N₂ for 3 times and stirred at 90° C. for 16hours. TLC and LCMS showed 32c was consumed completely and the desiredmass was detected. The mixture was extracted with ethyl acetate (20mL*2) and H₂O (10 mL). The combined organic phase was washed with brine(10 mL*3), dried with anhydrous Na₂SO₄, filtered and concentrated invacuum. The residue was purified by Prep-TLC (Petroleum ether: Ethylacetate) to give 32d. MS mass calculated for [M+1]⁺ (C₂₀H₂₄BCl₃N₂O₃)requires m/z 457.1, LCMS found m/z 457.2.

¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 2H), 7.17 (s, 1H), 3.04-3.12 (m, 1H),1.59-1.81 (m, 3H), 1.27 (s, 102H), 0.94-1.00 (m, 1H), 0.97 (t, J=7.4 Hz,3H).

6-(4-((5-(sec-butyl)-6-chloropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(32e). To a mixture of4-(sec-butyl)-3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridazine(32d) (60 mg, 131.12 umol) and6-bromo-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione (3a) (40.52 mg, 196.68umol) in THF (4 mL) and H₂O (1 mL) was addedditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (8.55 mg,13.11 umol) and K₃PO₄ (55.67 mg, 262.25 umol) was degassed and purgedwith N₂ for 3 times, and then the mixture was stirred at 90° C. for 16hours under N₂ atmosphere. TLC and LCMS showed 32d was consumedcompletely and the desired MS was detected. The reaction mixture wasdissolved in water and the pH was adjusted to 4 with HCl (1M, 1 mL).Then the mixture was extracted with ethyl acetate (15 mL*2). Thecombined organic phase was washed with brine (10 mL*3), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by Prep-TLC (Petroleum ether: Ethyl acetate) to give 32e. MSmass calculated for [M+1]⁺ (C₁₈H₁₆Cl₃N₅O₃) requires m/z 456.0, LCMSfound m/z 455.8.

¹H NMR (400 MHz, MeOH-d₄) δ 8.23-8.27 (m, 2H), 7.60 (s, 1H), 3.68 (s,3H), 3.09-3.18 (m, 1H), 1.65-1.88 (m, 2H), 1.35 (d, J=6.8 Hz, 3H), 0.97(t, J=7.4 Hz, 3H).

6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(32). To a solution of6-(4-((5-(sec-butyl)-6-chloropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione(32e) (40 mg, 87.58 umol) in AcOH (3 mL) was added NaOAc (35.92 mg,437.91 umol) at 15° C. Then the mixture was stirred at 120° C. for 16hours. LCMS and HPLC showed 32e was consumed completely and desired MSwas detected. The reaction mixture was concentrated under reducedpressure. The residue was purified by Prep-HPLC (column: Luna C18 100*305u; mobile phase: [water (0.225% FA)-ACN]) to give 32. MS masscalculated for [M+1]⁺ (C₁₈H₁₇Cl₂N₅O₄) requires m/z 438.1, LCMS found m/z438.0.

¹H NMR (400 MHz, DMSO-d₆) δ 12.45 (br s, 1H), 12.20 (s, 1H), 8.10 (s,2H), 7.43 (s, 1H), 3.58 (s, 3H), 2.85-2.94 (m, 1H), 1.46-1.76 (m, 2H),1.18 (d, J=7.0 Hz, 3H), 0.86 (t, J=7.4 Hz, 3H).

Example S33 P1 and P2:(R)-6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dioneand(S)-6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compounds 33 P1 and 33 P2)

6-(4-((5-(sec-butyl)-6-chloropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dione(33a). To a mixture of4-(sec-butyl)-3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridazine(32d) (280 mg, 611.91 umol) and 6-bromo-1,2,4-triazine-3,5(2H,4H)-dione(3a) (176.20 mg, 917.86 umol) in THF (4 mL) and H₂O (1 mL) was addedPd(dppf)C₁₂ (39.88 mg, 61.19 umol) and K₃PO₄ (259.78 mg, 1.22 mmol). Themixture was degassed and purged with N₂ for 3 times, and then themixture was stirred at 90° C. for 2 hours under N₂ atmosphere. TLC andLCMS showed 32d were consumed completely and desired MS was detected.The mixture was extracted with ethyl acetate (50 mL*2) and H₂O (15 mL).The combined organic phase was washed with brine (15 mL*3), dried withanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by Prep-TLC (Petroleum ether: Ethyl acetate) to give 33a. MSmass calculated for [M+1]⁺ (C₂₀H₂₄BCl₃N₂O₃) requires m/z 457.1, LCMSfound m/z 457.2.

¹H NMR (400 MHz, MeOH-d₄) δ 8.21-8.24 (m, 1H), 7.60 (s, 1H), 3.10-3.16(m, 1H), 1.66-1.86 (m, 2H), 1.35 (d, J=6.84 Hz, 3H), 0.97 (t, J=7.39 Hz,3H).

6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazi-ne-3,5(2H,4H)-dione(33b). To a solution of6-(4-((5-(sec-butyl)-6-chloropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dione(33a) (175 mg, 395.32 umol) in AcOH (8 mL) was added NaOAc (162.14 mg,1.98 mmol) at 15° C. Then the mixture was stirred at 120° C. for 16hours. HPLC and LCMS showed 33a was consumed completely and desired MSwas detected. The reaction mixture was concentrated under reducedpressure to remove AcOH. The residue was diluted with water (5 mL). Thesuspension was extracted with ethyl acetate (30 mL*3), the combinedorganic layers were dried over anhydrous Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified byPrep-HPLC (column: Luna C18 100*30 5u; mobile phase: [water (0.2%FA)-ACN]) to give 33b. MS mass calculated for [M+1]⁺ (C₁₇H₁₅Cl₂N₅O₄)requires m/z 424.1, LCMS found m/z 424.2.

¹H NMR (400 MHz, DMSO-d₆) δ 8.16 (s, 1H), 7.34 (s, 1H), 2.97-3.04 (m,1H), 1.55-1.82 (m, 2H), 1.26 (d, J=7.0 Hz, 3H), 0.96 (t, J=7.4 Hz, 3H).

(R)-6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dioneand(S)-6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compounds 33 P1 and 33 P2).6-(4-((5-(sec-butyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazi-ne-3,5(2H,4H)-dione(33b) (28 mg, 66.00 umol) was separated by SFC separation (column:DAICEL CHIRALPAK AD (250 mm*30 mm, 10 um); mobile phase: [0.1% NH₃H₂OIPA]; B %: 45%-45%) to give 33 P1 (11.36 mg, 26.78 umol, 40.57% yield):MS mass calculated for [M+1]⁺ (C₁₇H₁₅Cl₂N₅O₄) requires m/z 424.1, LCMSfound m/z 424.0;

¹H NMR (400 MHz, MeOH-d₄) δ 8.15 (s, 2H), 7.33 (s, 1H), 3.35 (s, 1H),2.97-3.04 (m, 1H), 1.54-1.82 (m, 2H), 1.26 (d, J=7.0 Hz, 3H), 0.95 (t,J=7.4 Hz, 3H); and 33 P2 (11.17 mg, 26.33 umol, 39.89% yield): MS masscalculated for [M+1]⁺ (C₁₇H₁₅Cl₂N₅O₄) requires m/z 424.1, LCMS found m/z424.0;

¹H NMR (400 MHz, MeOH-d₄) δ 8.16 (s, 2H), 7.33 (s, 1H), 2.97-3.04 (m,1H), 1.54-1.83 (m, 2H), 1.26 (d, J=7.0 Hz, 3H), 0.95 (t, J=7.4 Hz,3H).). In this Example, the isomers 33 P1 and 33 P2 were separated bychiral chromatography, but the absolute chirality of each isomer was notdetermined. Elution order was used to track the individual isomers.

Example S34:(6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 34)

1-(3,6-dichloropyridazin-4-yl)ethanol (34a). To a solution of3,6-dichloro-1,2,4,5-tetrazine (500 mg, 3.31 mmol) in Tol. (3 mL) wasadded but-3-yn-2-ol (278.59 mg, 3.97 mmol, 311.62 uL). The reactionmixture was sealed tube and stirred at 110° C. for 16 hours. TLCindicated starting material was consumed completely. The reactionmixture was concentrated under reduced pressure. The residue waspurified by Prep-TLC (SiO₂, Petroleum ether: Ethyl acetate) to give 34a.

¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J=1.0 Hz, 1H), 5.14 (dq, J=4.2, 6.3Hz, 1H), 2.38 (d, J=3.4 Hz, 1H), 1.56 (d, J=6.4 Hz, 3H).

3,6-dichloro-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazine (34b).To a solution of 1-(3,6-dichloropyridazin-4-yl)ethanol (34a) (300 mg,1.55 mmol) and DHP (653.68 mg, 7.77 mmol, 710.52 uL) in DCM (10 mL) wasadded TsOH (13.38 mg, 77.71 umol). The mixture was stirred at 20° C. for1 hour. TLC showed reactant was consumed completely and many new spotwas formed. The reaction mixture was concentrated under reducedpressure. The residue was purified by Prep-TLC (SiO₂, Petroleum ether:Ethyl acetate) to give 34b.

¹H NMR (400 MHz, CDCl₃) δ 7.77 (s, 1H), 7.63 (s, 1H), 5.10 (q, J=6.4 Hz,1H), 4.98 (q, J=6.6 Hz, 1H), 4.81 (br d, J=4.6 Hz, 1H), 4.47 (br s, 1H),3.99-3.90 (m, 1H), 3.67-3.53 (m, 2H), 3.47-3.40 (m, 1H), 1.95-1.55 (m,12H), 1.53 (d, J=6.4 Hz, 3H), 1.46 (d, J=6.4 Hz, 3H).

3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazin-3-yl)oxy)aniline(34c). To a solution of3,6-dichloro-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazine (34b)(167.00 mg, 938.13 umol) and 4-amino-2,6-dichlorophenol (200 mg, 721.64umol) in DMSO (5 mL) was added K₂CO₃ (299.21 mg, 2.16 mmol) and CuI(82.46 mg, 432.98 umol). Then the reaction mixture was degassed andpurged with N₂ for 3 times. The mixture was stirred at 90° C. for 2hours under N₂ atmosphere. TLC and LCMS showed 34b was consumedcompletely. The reaction mixture was diluted with H₂O (5 mL) andextracted with ethyl acetate (10 mL*3). The combined organic layers werewashed with brine (10 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified byPrep-TLC (SiO₂, Petroleum ether: Ethyl acetate) to give 34c.

¹H NMR (400 MHz, CDCl₃) δ 7.55 (s, 1H), 7.37 (s, 1H), 6.68 (s, 4H), 5.10(q, J=6.6 Hz, 1H), 5.00 (q, J=6.4 Hz, 1H), 4.90-4.85 (m, 1H), 4.52 (t,J=3.6 Hz, 1H), 3.96 (ddd, J=3.8, 7.5, 11.2 Hz, 1H), 3.81 (br d, J=2.4Hz, 4H), 3.65 (ddd, J=3.2, 8.0, 11.3 Hz, 1H), 3.61-3.54 (m, 1H),3.47-3.40 (m, 1H), 1.96-1.60 (m, 12H), 1.55 (d, J=6.4 Hz, 3H), 1.49 (d,J=6.4 Hz, 3H).

3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazine(34d). To a solution of3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazin-3-yl)oxy)aniline(34c) (165 mg, 394.08 umol) in ACN (5 mL) was added t-BuONO (609.56 mg,5.91 mmol, 703.06 uL) and KI (130.83 mg, 788.15 umol) at 0° C. And thenthe mixture was stirred at 20° C. for 1 hour. TLC and LCMS showed 34dwas consumed completely and many new spots were formed. The reactionmixture was concentrated under reduced pressure. The residue was dilutedwith water (10 mL) and extracted with ethyl acetate (10 mL*3). Thecombined organic layers were washed with brine (10 mL), dried overanhydrous Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by Prep-TLC (SiO₂, Petroleum ether: Ethyl acetate)to give 34d. MS mass calculated for [M+1]⁺ (C₁₇H₁₆Cl₃IN₂O₃) requires m/z528.9, LCMS found m/z 528.9.

3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazine(34e). A mixture of3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazine(34d) (53 mg, 100.08 umol), BPD (76.24 mg, 300.24 umol), AcOK (49.11 mg,500.39 umol) and Pd(dppf)C₁₂ (7.32 mg, 10.01 umol) in dioxane (3 mL).The mixture was degassed and purged with N₂ for 3 times, and then themixture was stirred at 90° C. for 16 hours under N₂ atmosphere. TLC andLCMS showed 34d was consumed completely. The reaction mixture wasconcentrated under reduced pressure. The residue was diluted with H₂O(10 mL) and extracted with ethyl acetate (10 mL*3). The combined organiclayers were washed with brine (10 mL), dried over anhydrous Na₂SO₄,filtered and concentrated under reduced pressure to give 34e (75 mg,crude). The crude used directly in next step. MS mass calculated for[M+1]⁺ (C₂₃H₂₈BCl₃N₂O₅) requires m/z 529.1, LCMS found m/z 447.0.

6-(3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(34f). To a solution of3-chloro-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazine(34e) (75 mg, 141.60 umol), 6-bromo-1,2,4-triazine-3,5(2H,4H)-dione(32.62 mg, 169.92 umol) in THF (2.4 mL) and H₂O (0.6 mL) was added K₃PO₄(60.12 mg, 283.21 umol) and Pd(dppf)C₁₂ (9.23 mg, 14.16 umol). Themixture was degassed and purged with N₂ for 3 times, and then themixture was stirred at 80° C. for 16 hours under N₂ atmosphere. TLC andLCMS showed reactant 34e was consumed completely. The reaction mixturewas concentrated under reduced pressure, and the residue was dilutedwith water (10 mL) and extracted with ethyl acetate (10 mL*3). Thecombined organic layers were washed with brine (10 mL), dried overanhydrous Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by Prep-TLC (SiO₂, DCM: MeOH) to give 34f. MS masscalculated for [M+1]⁺ (C₂₀H₁₈Cl₃N₅O₅) requires m/z 514.0, LCMS found m/z514.0.

6-(3,5-dichloro-4-((5-(1-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(34). To a solution of6-(3,5-dichloro-4-((6-chloro-5-(1-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(34f) (43 mg, 66.83 umol) in dioxane (1 mL) was added HCl (4 M, 835.36uL). The mixture was stirred at 80° C. for 16 hours. LCMS showed thereaction was completed, and desired MS was detected. The reactionmixture was concentrated under reduced pressure. The residue was dilutedwith water (10 mL) and extracted with ethyl acetate (10 mL*3). Thecombined organic layers were washed with brine (10 mL), dried overanhydrous Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by Prep-HPLC (column: Welch Ultimate AQ-C18 150*30mm*5 um; mobile phase: [water (0.1% TFA)-ACN]) to give 34. MS masscalculated for [M+1]⁺ (C₁₅H₁Cl₂N₅O₅) requires m/z 412.0, LCMS found m/z412.0.

¹H NMR (400 MHz, MeOH-d4) δ 8.19-8.13 (m, 2H), 7.52 (d, J=1.2 Hz, 1H),4.93-4.88 (m, 1H), 1.46 (d, J=6.6 Hz, 3H).

Example S35:6-(4-((5-acetyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 35)

6-(2,6-dichloro-4-iodophenoxy)-4-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3(2H)-one(35a). To a solution of3-chloro-6-(2,6-dichloro-4-iodophenoxy)-4-(2-methyl-1,3-dioxolan-2-yl)pyridazine(31c) (150 mg, 307.69 umol) in AcOH (3 mL) was added NaOAc (126.20 mg,1.54 mmol). The mixture was stirred at 120° C. for 16 hours. LCMS showed31c was consumed completely and the desired mass was detected. Thereaction mixture was concentrated under reduced pressure to remove AcOH.The crude product was triturated with H₂O (5 mL) at 20° C. for 15minutes, then the crude product was triturated with Petroleum ether:Ethyl acetate=20:1 (5 mL) at 20° C. for 30 minutes to give 35a, whichwas obtained as a white solid. MS mass calculated for [M+1]⁺(C₁₄H₁₁C₂IN₂O₄) requires m/z 468.9, LCMS found m/z 468.9.

6-(2,6-dichloro-4-iodophenoxy)-2-methyl-4-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3(2H)-one(35b). A mixture of6-(2,6-dichloro-4-iodophenoxy)-4-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3(2H)-one(35a) (80 mg, 170.55 umol), K₂CO₃ (47.14 mg, 341.11 umol), CH₃I (29.05mg, 204.67 umol, 12.74 uL) in ACN (5 mL) was degassed and purged with N₂for 3 times, and then the mixture was stirred at 25° C. for 1 hour underN₂ atmosphere. LCMS showed 35a was consumed completely and the desiredmass was detected. The reaction mixture was concentrated under reducedpressure. The residue was triturated with H₂O (5 mL) and stirred at 20°C. for 1 hour. Then the mixture was filtered to collect solid. The solidwas triturated with a solution of Petroleum ether: Ethyl acetate=5:1 (5mL) and filtered to give 35b. MS mass calculated for [M+1]⁺(C₁₅H₁₃Cl₂IN₂O₄) requires m/z 482.9, LCMS found m/z 483.0.

4-acetyl-6-(2,6-dichloro-4-iodophenoxy)-2-methylpyridazin-3(2H)-one(35c). To a solution of6-(2,6-dichloro-4-iodophenoxy)-2-methyl-4-(2-methyl-1,3-dioxolan-2-yl)pyridazin-3(2H)-one(35b) (70 mg, 144.90 umol) in dioxane (2 mL) was added HCl (4 M, 2 mL).The mixture was stirred at 80° C. for 16 hours. LCMS indicated 35b wasconsumed completely and the desired mass was detected. The reactionmixture was concentrated under reduced pressure. The residue wastriturated with a solution of Petroleum ether: Ethyl acetate and stirredat 20° C. for 1 hour. The mixture was filtered to give 35c. MS masscalculated for [M+1]⁺ (C₁₃H₉Cl₂IN₂O₃) requires m/z 438.9, LCMS found m/z438.9;

¹H NMR (400 MHz, MeOH-d₄) δ 7.89 (s, 2H), 7.78 (s, 1H), 3.54 (s, 3H),2.66 (s, 3H).

4-acetyl-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2-methylpyridazin-3(2H)-one(35d). To a solution of4-acetyl-6-(2,6-dichloro-4-iodophenoxy)-2-methylpyridazin-3(2H)-one(35c) (60 mg, 136.66 umol) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (104.11 mg,409.99 umol) in dioxane (3 mL) was added Pd(dppf)C₁₂ (10.00 mg, 13.67umol) and KOAc (67.06 mg, 683.32 umol) under N₂. The mixture was stirredat 90° C. for 16 hours under N₂ atmosphere. LCMS indicated ˜40% of 35cwas remained and the desired mass was detected. The suspension wasfiltered through a pad of Celite and the pad cake was washed with ethylacetate (10 mL*3). The combined organic layers were washed with H₂O (10mL), dried over Na₂SO₄, filtered and concentrated under reducedpressure. The residue was purified by Prep-TLC (SiO₂, Petroleum ether:Ethyl acetate) to give 35d. MS mass calculated for [M+1]⁺(C₁₉H₂₁BCl₂N₂O₅) requires m/z 439.1, LCMS found m/z 439.1.

¹H NMR (400 MHz, CDCl₃) δ 7.80 (s, 2H), 7.71 (s, 1H), 3.56-3.60 (m, 3H),2.75-2.77 (m, 3H), 1.34-1.39 (m, 12H).

6-(4-((5-acetyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dione(35). To a solution of4-acetyl-6-(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2-methylpyridazin-3(2H)-one(35d) (40 mg, 91.10 umol) and 6-bromo-2H-1,2,4-triazine-3,5-dione (34.98mg, 182.19 umol) in THF (2 mL) and H₂O (0.5 mL) was added Pd(dppf)C₁₂(5.94 mg, 9.11 umol) and K₃PO₄ (38.67 mg, 182.19 umol) under N₂. Themixture was stirred at 80° C. for 5 hours under N₂ atmosphere. LCMSindicated 35d was consumed completely and the desired mass was detected.The suspension was filtered through a pad of Celite and the pad cake waswashed with ethyl acetate (10 mL*3). The combined filtrates wereconcentrated in vacuum. The residue was purified by Prep-HPLC (column:Xtimate C18 100*30 mm*3 um; mobile phase: [water (0.225% FA)-ACN]) togive 35. MS mass calculated for [M+1]⁺ (C₁₆H₁₁C₂N₅O₅) requires m/z424.0, LCMS found m/z 424.0;

¹H NMR (400 MHz, MeOH-d₄) δ 8.18-8.21 (m, 2H), 7.79 (s, 1H), 3.54 (s,3H), 3.50-3.51 (m, 1H), 2.67 (s, 3H).

Biological Examples: Biological Screening Example B1: Time-ResolvedFluorescence Resonance Energy Transfer (TR-FRET) Assay for ThyroidHormone Receptor Agonist Screening

LanthaScreen™ TR-FRET Thyroid Receptor alpha Coactivator Assay kit(ThermoFisher) and LanthaScreen™ TR-FRET Thyroid Receptor betaCoactivator Assay kit (ThermoFisher) were used for agonist compoundscreening. Compounds in DMSO were diluted using ECHO Liquid Handler(Labcyte Inc.) into 384 plates in 10-point 3-fold series in duplicate (5micro M final top concentration). Buffer C (ThermoFisher) was added toeach well before the 4× mixture of fluorescein-SCR2-2 coactivator (200nM final concentration), Terbium-labeled anti-GST antibody (2 nM finalconcentration), and THR alpha-LBD (0.4 nM final concentration) or THRbeta-LBD (1.0 nM final concentration) was added. After 2 hoursincubation at room temperature in the dark, the TR-FRET signal wasmeasured on an EnVision plate reader (PerkinElmer) with excitation at340 nm and dual emission readout at 495 and 520 nm with the delay timeof 100 micro second and the integration time of 200 micro second. Theratio of emission signal at 520 and at 495 was used to calculate EC₅₀using GraphPad Prism (GraphPad Software). In every batch of compoundscreening, T3 (L-3,3′,5-Triiodothyronine sodium salt, >95%) (Calbiochem)was used as reference compound. The EC₅₀ of T3 measured were within3-fold of the reference value provided by the assay kit manufacturer(ThermoFisher Scientific). The Z′ factors measured in every batch ofscreening using T3 as high percent effect (HPE) control and 0.5% DMSO aszero percent effect (ZPE) control were in the range of 0.5 to 0.8.Compounds' THR-beta selectivity values in Table 2 are derived fromT3-selectivity normalized data. Data obtained using the TR-FRET assayfor certain compounds disclosed herein is listed in Table 2.

TABLE 2 Compound EC₅₀ THRβ- EC₅₀ THRα- THRβ- No. FRET [nM] ^(a) FRET[nM] ^(a) Selectivity  1 24.7 79.2 17  2 141.1 681 27.7  3 114.3 1234.469.8  4 * >5000 >5000 >3.0  5 98.6 62.6 2.3  6 196.2 981.4 23.6  7 136.2434.6 15.3  8 1448.1 3672.3 9.5  9 23.9 160.9 25.5 10 524.1 3322.5 22.713 750.4 >5000 >27.4 15 380.7 3342 31.2 16 162.9 1213.5 28.3 17 34.699.6 11.1 19 1415 >5000 13.9 20 1933 1328 2.7 21 2883 >5000 >9.5 22 11703436 12.9 23 1381 3229 9.2 24 1189 1485 4.7 25 22.2 25 4.4 26 1421.54265 10.9 27 213.4 1746 33.9 28 669.7 3443.5 19.2 29 2074.5 4043 7.10530 214.2 1311.5 24.7 31 986.9 2673 14.4 31 P1 1196.4 >5000 >26.2 31 P2451.6 3076 21.7 32 230.9 1132.7 20.9 33 P1 696.4 2427.9 11.3 33 P2 65.7274.3 14.1 34 399.7 1161 8.6 35 664.8 1866 10.6 * Compound 4 does notfall within the scope of formula (I) and is provided for comparativepurposes only. ^(a) all compounds were run in duplicate multiple times,and the average data is reported.

All publications, including patents, patent applications, and scientificarticles, mentioned in this specification are herein incorporated byreference in their entirety for all purposes to the same extent as ifeach individual publication, including patent, patent application, orscientific article, were specifically and individually indicated to beincorporated by reference.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it is apparent to those skilled in the art that certainminor changes and modifications will be practiced in light of the aboveteaching. Therefore, the description and examples should not beconstrued as limiting the scope of the invention.

1. A compound of formula (I):

wherein: R₁ is substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈), —N(R₉)C(O)(R₁₀), or halo; R₂ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or unsubstituted C₃-C₆ cycloalkyl; R₃ is H or halo; R₄ is H, or substituted or unsubstituted linear C₁-C₃ alkyl; L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—; R₅ and R₆ are independently H, halo, —CN, or substituted or unsubstituted C₁-C₆ alkyl, or R₅ and R₆ are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted C₃-C₆ cycloalkyl; R₇ and R₈ are independently H, or substituted or unsubstituted C₁-C₆ alkyl, or R₇ and R₈ are taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted 3- to 7-membered heterocycloalkyl; R₉ is H, substituted or unsubstituted C₁-C₆ alkyl, or substituted or unsubstituted C₃-C₆ cycloalkyl; R₁₀ is substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁); R₁₁ is substituted or unsubstituted C₁-C₆ alkyl, or substituted or unsubstituted C₃-C₆ cycloalkyl; M₁ and M₂ are independently halo, or substituted or unsubstituted C₁-C₆ alkyl; and M₃ is H, halo, or substituted or unsubstituted C₁-C₆ alkyl, or M₃ is taken together with M₂ and the carbon atoms to which they are attached to form a 5- to 7-membered ring containing 0, 1, or 2 heteroatoms selected from the group consisting of N, O, and S, or a pharmaceutically acceptable salt thereof.
 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —C(O)N(R₇)(R₈), —N(R₉)C(O)(R₁₀), or halo, wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents selected from the group consisting of —OH, oxo, —CN, and halo; R₂ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo; R₃ is H or halo; R₄ is H or linear C₁-C₃ alkyl optionally substituted by 1-5 substituents selected from the group consisting of —OH, oxo, —CN, halo, and —O(C₁-C₂ alkyl); L is —O—, —S—, —S(O)—, —S(O)₂—, —C(O)—, or —C(R₅)(R₆)—; R₅ and R₆ are independently H, halo, —CN, or C₁-C₆ alkyl, or R₅ and R₆ are taken together with the carbon atom to which they are attached to form a C₃-C₆ cycloalkyl, wherein each C₁-C₆ alkyl or C₃-C₆ cycloalkyl is optionally independently substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo; R₇ and R₈ are independently H or C₁-C₆ alkyl, or R₇ and R₈ are taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocycloalkyl, wherein each C₁-C₆ alkyl or 3- to 7-membered heterocycloalkyl is optionally independently substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo; R₉ is H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo; R₁₀ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, —N(R₇)(R₈), or —O(R₁₁), wherein C₁-C₆ alkyl and C₃-C₆ cycloalkyl are optionally substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo; R₁₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each of which is optionally substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo; M₁ and M₂ are independently halo or C₁-C₆ alkyl optionally substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo; and M₃ is H, halo, or C₁-C₆ alkyl optionally substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo, or M₃ is taken together with M₂ and the carbon atoms to which they are attached to form a 5- to 7-membered ring containing 0, 1, or 2 heteroatoms selected from the group consisting of N, O, and S.
 3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, each of which is optionally substituted by 1-5 substituents selected from the group consisting of —OH, oxo, —CN, and halo;
 4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein: R₁ is cyclopropyl, isopropyl, ethyl, —CH(CH₂CH₃)₂, —CH(CH₃)(CH₂OH), —CH(OH)(CH₂CH₃), —CH(OH)(CH₃), —CH(CH₃)(CH₂CH₃), or —C(O)(CH₃).
 5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R₂ is H or C₁-C₆ alkyl optionally substituted by 1-5 substituents selected from the group consisting of —OH, —CN, and halo.
 6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein: R₂ is H or methyl.
 7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R₃ is H.
 8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R₄ is H or linear C₁-C₃ alkyl optionally substituted by 1-3 substituents selected from the group consisting of —OH, oxo, —CN, halo, and —O(C₁-C₂ alkyl).
 9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein: R₄ is H, methyl, ethyl, —CH₂C(O)OCH₂CH₃, —CH₂CF₃, —CH₂CN, or —CH₂CHF₂.
 10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: L is —O—, —C(O)—, or —CH₂—.
 11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: M₁ and M₂ are independently halo or C₁-C₃ alkyl optionally substituted by 1-3 substituents selected from the group consisting of —OH, —CN, and halo.
 12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein: M₁ and M₂ are independently halo or methyl.
 13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein: M₁ and M₂ are each chloro.
 14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein: M₁ and M₂ are each methyl.
 15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, M₃ is H, halo, or C₁-C₃ alkyl optionally substituted by 1-3 substituents selected from the group consisting of —OH, —CN, and halo.
 16. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein: M₃ is H, F, or methyl.
 17. A compound selected from Compounds 1-3 and 5-35, or a pharmaceutically acceptable salt thereof.
 18. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
 19. A method of agonizing thyroid hormone receptor beta (THR beta) comprising contacting an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, with the THR beta.
 20. A method of treating a disorder which is mediated by THR beta in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.
 21. The method of claim 20, wherein the disorder is non-alcoholic steatohepatitis (NASH). 